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The Saccharomyces cerevisiae STE6 gene product mediates the export of the peptide mating
pheromone a-factor. The Ste6 polypeptide belong to the ABC transporter superfamily whose
members include many proteins of medical significance. The Ste6p is a short lived,
transmembrane protein which is produced in low levels in wild-type yeast. This thesis describes
the construction, expression and partial purification of a recombinant Ste6p from S. cerevisiae.
In the absence of a functional assay for Ste6p, its presence was detected by Western blot analysis
using polyclonal antibodies raised in this study. The antibodies were produced in rabbits in
response to a recombinant Ste6p-ProteinA fusion protein. Purification studies on wild-type Ste6p
were hindered due to the very low levels at which the protein was being produced. As an
alternative to conventional purification techniques the Ste6p was affinity tagged at its extreme N-
terminus with a hexa-histidine tail (N(His)6Ste6p) so that it could be "pulled" out of a dilute
solution by its high affinity to Ni-NTA (nickel-Nitrilo-Tri-Acetic-acid) resin. The chimaeric
protein was expressed under the control of the GAL promoter in aMATa, pep4 strain of S
cerevisiae against a background ofwild-type protein. Purification ofN(His)6Ste6p failed due to
an apparent inability to bind the chimaeric protein to the resin. Extracts of cells expressing
N(His)r,Stc6p were Western blotted and probed with an anti-histidine-tag monoclonal antibody.
The antibody failed to detect any protein of the correct size for the Ste6p chimaera. These results
suggested that the N-terminus ofN(His)6Ste6p had been removed during posttranslational
modification of the protein.
The third approach to the purification of Ste6p involved tagging the C-terminus of the protein
with an octa-histidine tag to produce C(His)gStc6p. As with the N-terminally tagged Ste6p this
chimaera was expressed under the control of the GAL promoter however in this case the protein
was expressed in aMATa.pep4 strain of S.cerevisae. This protein could be detected by the anti-
histidine tag monoclonal antibody and was able to bind to the Ni-NTA resin. The protein was
partially purified and was clearly identifiable on silver stained polyacrylamide gels. It was hoped
that the enigma surrounding the N-terminus of Ste6p would be resolved by sequencing the
partially purified C(His)gSte6p, however only a small amount of protein was produced in this
study and attempts at sequencing it were unsuccessful.
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The selective transport of specific molecules across biological membranes is essential
for cell survival as it provides a mechanism by which a cell may acquire nutrients,
excrete waste products and communicate with other cells in its environment. Selective
transmembrane transport is mediated by specific transporter and channel proteins
associated with cellular membranes. Molecular characterisation of these proteins has
revealed that they can be grouped into discrete superfamilies. The largest of these
groups is the ATP Binding Cassette (ABC); (Higgins, 1992) or Traffic ATPase (Ames
et al., 1992) superfamily of transport proteins which comprises ofmore than 100
members, with examples discovered in many organisms from simple prokaryotes to
man. Family members are characterised by their highly-conserved ATP binding
domain (Walker et al., 1982) with which they are thought to couple the hydrolysis of
ATP with the movement of substrate across biological membranes. ABC-transporters
are thought to be relatively substrate-specific and transporters specific for the
transport of amino-acids, sugars, inorganic ions, polysaccharides, peptides and
proteins have been identified (Higgins, 1992).
The ABC transporter superfamily includes many proteins ofmedical significance. In
humans, mutations in genes encoding ABC transporters cause genetic diseases such as
cystic fibrosis (Riordan et al., 1989), Zellweger syndrome (Kamijo, 1990; Gartner et
al., 1992), infantile hyperinsulinaemic hypoglycaemia (Aguilar-Bryan, 1995; Thomas,
1995) and adrenoleukodystrophy (Mosser et al., 1994). Other ABC transporters of
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medical significance include the human P-glycoprotein (Chen et al., 1986), which is
involved with the development ofmultidrug resistance in the treatment of cancer, the
Pghl protein of the malarial parasite Plasmodium falciparum, which contributes to
antimalarial drug (chloroquine) resistance (reviewed in Rubio and Cowman, 1996)
and the human TAP1 and TAP2 genes which are involved in the processing of antigen
by MHC class 1 molecules (Deverson et al., 1990). The significance of this family of
proteins has prompted research into elucidating the mechanism by which the substrate
molecules are recognised and transported.
The yeast Saccharomyces cerevisiae has been used as an experimental eukaryotic
organism for decades and to date twenty nine ABC-transport proteins have been
assigned to it (Michaelis and Berkower, 1995; Decottignies and Goffeau, 1997). The
STE6-encoded ABC-transporter of S. cerevisiae transports the oligopeptide mating
pheromone, a-factor, into the extracellular environment and is essential for the sexual
life cycle (McGrath and Varshavsky, 1989; Kuchler et al., 1989). The pheromonal
control of the life-cycle of S. cerevisiae has been of interest since 1956, when Levi
first reported that the mating process might be hormonally regulated. Decades of
intensive study centred on the production of and response to the mating pheromones
of S. cerevisiae have provided researchers with a model system on which to base
various eukaryotic cellular processes such as peptide secretion and signal
transduction. Unlike many eukaryotic ABC transporter proteins the substrate of
Ste6p, a-factor, has been unequivocally identified and many of the cellular processes
involved in the biosynthesis of a-factor and the mating process are understood. This,
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taken in addition with the ability to manipulate yeast genetically makes Ste6p an ideal
candidate for the study of eukaryotic ABC-transporter proteins.
Part 1
The ABC-transporter superfamily
1.1 The ABC-transporter superfamily of transport proteins
The ABC-transporters form one of the largest and most diverse superfamilies of
proteins known to date. They are present in many organisms providing a means of
transportation for a vast number of compounds ranging from inorganic ions to large
polypeptides. The majority ofABC proteins are active transporters, utilising the
energy of ATP hydrolysis to pump solute across biological membranes. However
recent findings have shown that some ABC proteins may function in the regulation of
other membrane proteins in addition to their own transport activities. P-glycoprotein
and the cystic fibrosis transmembrane conductance regulator (CFTR) are examples of
mammalian ABC-transporter proteins which have been shown to regulate the activity
of heterologous channels (reviewed in Higgins, 1995). The following section provides
a brief introduction to structure and cellular functions associated with this family of
transport proteins. This section deals mainly with the eukaryotic members of the ABC
transporter superfamily; reviews concerning the structure and function of the bacterial
permeases may be found in: Higgins, 1992; Ames et al., 1992.
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1.2 Structure
a) The four domain organisation ofABC-transporters
The ABC transporter superfamily is distinguished from other transport proteins by a
highly conserved nucleotide binding domain (ATP-binding cassette) and modular
structure. In general, ABC transporters are composed of homologous halves, each
containing multiple (usually six) highly hydrophobic membrane spanning domains
(MSD) and a nucleotide binding domain (NBD) (Figure 1.1A). The typical ABC
transporter therefore contains two membrane spanning domains (MSD1, MSD2) and
two nucleotide binding domains (NBD1, NBD2). The individual domains of an ABC
transporter are frequently expressed as separate polypeptides, particularly in
prokaryotic species (e.g. the oligopeptide transporter of S. typhimurium; Figure 1.1B,
i). In many other ABC transporter proteins the domains are fused into larger
multifunctional polypeptides, for example, the two ATP binding domains of the E.
coli ribose transporter are fused into a double sized protein and the two membrane-
spanning domains of the iron hydroxamate transporter, also from E. coli, are fused
into a single polypeptide (Figures 1.1B, ii and iii respectively). Certain members of the
ABC transporter superfamily consist of two separately encoded "half-molecules".
These include the haemolysin transporter ofE. coli (Figure 1.1B, iv) which is
composed of one MSD and one NBD thought to function by existing as a homodimer
and the mammalian TAP1 and TAP2 polypeptides (Figure 1.1B, v) which consist of
two separately encoded "half-molecules" which are thought to associate to form a
functional transporter molecule (Androlewicz et al., 1994; Momburg et al., 1994).
Finally, many eukaryotic transporters, such as the human multidrug resistance protein
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(Figure 1.1B, vi) the S. cerevisae Ste6p (Figure 1.1A, vii) and the cystic fibrosis gene
product (Figure 1.1A, viii), have all four domains fused into a single polypeptide in
the order MSD1 -NBD1-MSD2-NBD2. A small subset of these "full-length" ABC
transporters, for example CFTR, contain an additional domain, designated the R
(regulatory) domain which lies between NBD1 and MSD2 and is the site of
phosphorylation events that regulate its activity (Reviewed in Kuchler and Thorner,
1990; Ames et al., 1992; Fliggins, 1992; Michaelis and Berkower, 1995; Fliggins
1995).
b) The Nucleotide Binding Domains
The ATP-binding domains of the ABC transporters are their most characteristic
feature. Each domain is approximately 200 residues in length and contains two highly
conserved motifs, the Walker A and Walker B motifs (Walker et al., 1982; Hyde et
al., 1990) associated with many nucleotide binding proteins. The sequence identity
between ABC-transporters extends over the entire nucleotide binding domain and is
not restricted solely to the Walker motifs. Both ABC and non-ABC nucleotide
binding proteins contain Walker A and B motifs. The ATP-binding domains are highly
hydrophilic, contain no potential membrane spanning segments and are thought to be
tightly associated with the cytoplasmic face of the membrane as detailed in Figure 1.1
(reviewed in Higgins, 1992). The sequence motifs found within the NBDs of the
ABC-transporter superfamily are indicated in Figure 1.2. In addition to the Walker A
and B motifs the NBD contains a highly diagnostic "signature" or C motif which lies
5
Figure 1.1 Domain organisation of typical ABC-transport proteins






















Figure 1.1A A schematic representation of the typical arrangement of the four
domains that make up a ABC transporter in the membrane. The nucleotide binding
domain (NBD) is shown as a yellow sphere and the membrane spanning domain
(MSD), usually composed of six predicted transmembrane spans, as a blue cylinder.
Figure 1.1 B A schematic representation of the domain organisation of some
members of the ABC transporter superfamily. The transporter's source and organism
are indicated. Each transporter consists of four domains as described in (A). Certain
transporters, such as CFTR, have additional domains that are not part of the core
transmembrane translocation mechanism. The regulatory, R, domain of CFTR is
indicated.
Taken from: Kuchler and Thorner, 1990; Higgins, 1992; Michaelis and Berkower,
1995; Higgins 1995.
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upstream of the Walker B motif and has the consensus LSGGQ. This motif generally
distinguishes ABC-transporter proteins from other ATP binding proteins (Hyde
al.,1990; Ames et al.,1992;reviewed in Michaelis and Berkower, 1995). The final
motif found within the NBD is the so called "centre region" which lies between the
Walker A and B motifs and is found in many ABC-transporter proteins.
Figure 1.2 Consensus sequences within the NBD of an ABC protein
Walker A Centre Signature Walker B
GxxGxGKS/T LSGGQ
90-120
A schematised NBD (-200 residues in length) is shown with the conserved regions
represented by green boxes. The Walker A, Walker B, signature and centre motifs
are shown and the distance (in amino acids) between the Walker A and Walker B
motifs are indicated. The consensus sequence corresponding to each region is
represented below the box by the single letter amino-acid code, with (j) denoting a
hydrophobic residue. The centre region is only conserved between certain groups of
ABC-transporters and as a consequence no consensus sequence is shown.
Taken from: Michaelis and Berkower, 1995.
c) The membrane spanning domains
The two MSDs of the ABC transporters are very hydrophobic and each is predicted,
from its sequence, to consist ofmultiple a-helical segments. Hydropathy analysis
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predicts that each MSD has six (or five) membrane spanning segments per domain. In
general the ABC-transporter proteins do not appear to contain a high degree of
sequence homology within their MSD. Certain transporters do however contain the
"EEA" loop which is found in the region joining transmembrane segments IV and V
of the MSDs of bacterial ABC permeases, in the yeast PXA1 and YKL741 gene
products and in humanMDR1 (reviewed in Higgins, 1992; Michaelis and Berkower
1995; Decottignes and Goffeau, 1997).
The modular design of the ABC-superfamily of transport proteins has led to the
suggestion that eukaryotic members arose from the fusion ofMSDs and NBDs of
prokaryotic ancestors. Duplication of the fused domains followed by a further fusion
event would result in the formation of a "full-size" ABC- transporter protein
(reviewed in Ames et al., 1992). The duplication of the initial fusion product,
resulting in two MSD-NBD peptides, is consistent with the basic structure of bacterial
ABC-proteins such as the haemolysin transporter ofE. coli (Figure 1.1B, iv). The
evolution of ABC-transporter proteins in vertebrates is further discussed in Hughes,
1994.
1.3 Yeast ABC transporters
Within seven years of the discovery of the first yeast ABC-transporter protein, Ste6p
(McGrath and Varshavsky, 1989; Kuchler et al., 1989) the entire sequence of the
genome ofS. cerevisiae was determined uncovering a further 28 family members
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(Decottignes and GofFeau, 1997; Michaelis and Berkower, 1995). Sequence
comparisons of yeast family members using various techniques has enabled the
classification of the yeast ABC proteins into six clusters (family groups) which may in
turn be broken down into ten distinguished sub-clusters of distinct predicted topology
and presumed distinct function (Decottignes and GofFeau, 1997). The yeast ABC
proteins range from 289-1,661 residues in length and are thought to reside in a variety
of cellular locations both as membrane proteins (associated with the plasma,
mitochondrial and ER membranes) and as soluble proteins (within the nucleus).
Family members include both half size and full size proteins which may be categorised
into one of six main topological units (Figure 1.3). Figures 1.3 a and d represent full
size ABC-transporter proteins, examples ofwhich include the a-factor transporter
encoded by STE6 and the protein encoded for by PDR5 which is involved in
cycloheximide and multidrug resistance respectively. Figures 1.3 b and e represent
half size molecules which include the gene products encoded for by ATM1 (involved
with the maintenance ofmitochondrial DNA) and PXA1 (involved with the (3-
oxidation of very long chain fatty acids). Figures 1.3 c and f represent soluble
members of the yeast ABC transporter superfamily. The protein encoded for by YEF3
is expected to be a soluble protein with a NBD-NBD topology (Figure 1.3 c) and a
nuclear localisation (as determined by PSORT analysis, Nakai and Kanehisa, 1992)
where it is thought to be involved with the stimulation of amino-acyl-tRNA binding to
the ribosome. The protein encoded by YFL028 is predicted to contain one NBD
(Figure 1.3 e) and is predicted, by PSORT analysis, to have a mitochondrial location,
its function however remains to be determined (reviewed in Decottignies & GofFeau,
1997).




Schematic representation of the domain organisation and topology of the principal yeast
ABC transporters. The nucleotide binding domains (NBD) are represented by a yellow
sphere. The membrane spanning domains (MSD) consist of six predicted
transmembrane spans. Figures a and d represent full size transporter proteins with
Figures b and e representing half-size molecules.
Taken from: Decottignies & Goffeau, 1997.
Similarities between yeast and human ABC-transporter proteins have been revealed by
BLAST analysis (Basic Local Alignment Search Tool, Altschul et 1990;
Decottignes and Goffeau, 1997) which scores proteins on their degree of relatedness
with a low BLAST score indicating a high degree of relatedness. All human ABC-
proteins identified so far, except ABC1 and ABC2, may be included in the sub-clusters
defined by the yeast ABC proteins as they have extremely low BLAST scores
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with at least one yeast protein. A comparison ofABC-proteins implicated with human
disease and their closest yeast homologues are shown in Table 1.1.
Examples of the sequence and functional relatedness between yeast ABC proteins and
those which have an impact on human health (both human and non-human ABC
proteins) are discussed below. Detailed reviews on this subject may be found in
Decottignes and Goffeau, 1997; Michaelis and Berkower, (1995).
Human MDR1 and CDR1 and the yeast PDR5 subgroup
Members of the yeast PDR5 sub-cluster, which are involved in cycloheximide and
multidrug resistance in yeast, are functional homologues of the human multidrug
transporterMDR1 although their modules are arranged in a "reverse" order, and the
sequence identity is relatively low. Members of the PDR5 subgroup also have a high
degree of homology with the CDR1 gene of Candida albicans which is responsible
for drug resistant candidosis (Table 1.1; Prasad et al., 1995).
Human CFTR and yeast YCF1
The yeast YCF1 gene product confers resistance to high levels of Cd++ when
overexpressed (Szczypka et al., 1994; reviewed in Decottignes and Goffeau, 1997;
Michaelis and Berkower, 1995). The Yeast YCF1 gene product and related proteins,
resemble those encoded for by mammalian CFTR andMRP1 (a multidrug resistance
protein distinct from that encoded byMDR1, Grant et al., 1994). The F508 and
11
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N1303 residues that are mutated in some cases of cystic fibrosis are conserved, as are
the intracellular loops, ICL2 and ICL4, which appear to be important for CFTR
function (reviewed in Decottignes and Goffeau, 1997; Michaelis and Berkower,
1995).
Human MDRl and CFTR with S. cerevisiae STE6
The STE6 gene product of S. cerevisiae is one of the best characterised members of
the ABC superfamily in yeast. Ste6p exports a-factor, a hydrophobic lipopeptide, into
the extracellular environment providing functional similarities to MDR proteins which
are thought to be involved in the expulsion of hydrophobic compounds from the cell
(reviewed in Gottesman and Pastan, 1993). In addition Ste6p activity can be partially
complemented by human P-glycoprotein (Mdrlp) and its murine homologue Mdr3p
(Raymond et al., 1992; Kuchler et al., 1993) further compounding the functional
relatedness between these proteins.
It has been anticipated that the study of yeast ABC-transporter proteins will increase
our understanding of human ABC-protein associated disease. The yeast S. cerevisiae
provides a convenient model for the study of ABC-proteins. The entire sequence of
the yeast genome is known providing a full catalogue of all yeast ABC-proteins. The
yeast is relatively easy to manipulate genetically providing a straightforward means by
which protein function and location may be determined by creating a null mutation of
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the gene of interest. The following sections introduce the yeast as an experimental
organism and discuss the current understanding of the yeast a-factor export protein
encoded by STE6.
Part 2
Yeast pheromones and control of the life cycle of S. cerevisiae
1.4 An overview of the life-cycle of S. cerevisiae
The budding yeast S. cerevisae is a unicellular organism which can exist as any of
three distinct cell types. There are two haploid cell types, a-cells and a-cells, which
are able to conjugate (mate) to form a/a diploids. All three cell types are capable of
reproduction by mitotic division. When haploid cells of the opposite mating type are
mixed together a series of behavioural and morphological changes occur which can be
viewed through a light microscope (reviewed by Thorner 1981, Herskowitz 1988,
Sprague and Thorner 1992). When haploid a and a cells first come in contact, they
detect each others' presence by responding to the pheromone (a or a factor,
respectively) produced by cells of the opposite mating type, a-type cells produce a-
factor (a-pheromone) which elicits its effects through the STEi-encoded cell surface
receptor of a-cells. In turn a-cells secrete a-factor (a-pheromone) which interacts
with the STE2-&ncoded a-factor receptor of a-type cells. The binding of pheromone
to the cell-type specific receptors activates a heterotrimeric G-protein linked protein
kinase cascade mechanism which is common to both cell types. The signal
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transduction cascade activates the STE12-encoded DNA-binding protein which acts
as a transcriptional activator bringing about the changes in gene expression required
for sexual conjugation. Pheromone-inducible genes include those required for cell
recognition, agglutination, cell-cycle arrest, cell polarity and morphology changes,
plasmogamy, karyogamy and those whose gene products are involved in the adaption
and recovery processes. The pheromone-induced signal transduction pathway has
been reviewed in Fields, 1990; Kurjan, 1992; Sprague and Thorner, 1992; Bardwell et
cil., 1994 and Flerskowitz, 1995.
Within 30-60 min ofmixing cells of the opposite mating types together they begin to
aggregate into a multicellular mass. This aggregation is mediated by the production of
cell-type specific sexual agglutinins which mediate cell-cell contact during the mating
process (Lipke and Kurjan 1992). About 90-120 min (one doubling time) after the
haploid cells first come in contact with each other they synchronise their cell-cycles by
arresting growth at the G1 phase of their cell division cycle. Cultures which have gone
into G1 arrest may be identified by the virtual absence ofbudding cells (Pringle and
Hartwell 1981). Once cell-cell contact and synchronous growth have been established
(about 180 min) the mating cells undergo morphological changes in which they
project towards each other forming pear-shaped cells known as "Shmoos". It was the
observation of such morphological changes which resulted in Levi's (1956)
suggestion that the yeast mating process was under hormonal control. Once the
respective projections of the mating cells have come in contact, autolytic enzymes
remove, and others restructure, the cell walls and plasma membranes that originally
separated the two cells resulting in cell fusion and plasmogamy, the formation of a
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continuous cytoplasm. (Shimoda 1972). Zygote formation is completed when the
nuclei from the mating pair fuse (karyogamy) to form a single diploid nucleus. The
a/a diploid cell may then continue to reproduce by mitotic division but is unable to
mate with either a or a cells. If the diploid cell is exposed to nutritional deprivation it
is capable of undergoing meiosis and sporulation to produce an ascus containing four
haploid meiotic progeny. A schematic representation of the life-cycle of S. cerevisiae
is given in Figure 1.4.
1.5 An overview of the genetic control of mating
The three different cell types of S. cerevisiae differ in their ability to express certain
cell-type specific genes: for example a-cells produce only a-factor and respond to a-
factor whereas a-cells produce only a-factor and respond to a-factor, while a/a
diploids neither make nor respond to either pheromone. The cell-type specific
expression of genes encoding proteins required for cell-type-specific functions, such
as those required in the mating process, is controlled by the composition of the
genetic material contained at theMA T locus. Haploid cells that carry the MA 7a allele
are a-type cells and haploid cells that carry [he MATa allele are a-type cells. Diploid
cells contain both the MATa andMATa alleles. The MAT alleles encode three
polypeptides, Matalp and Mata2p are expressed by [heMATa allele and Matalp is
expressed from [heMATa allele. Together these polypeptide products
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A schematic representation of the life cycle of A. cerevisiae reproduced from Sprague
and Thorner, 1992.
form three transcriptional regulatory products, Matalp, Mata2p and Matalp-
Mata2p, which control the expression of a, a and a/a specific gene products.
MATalp activates the expression of a-specific genes in a-cells, Mata2p represses
the transcription of a-specific genes in a-cells and Matalp-Mata2p represses the
transcription of haploid specific genes in diploid cells. In an a-type cell the Matalp
has no regulatory function: a-cells are such because they do not express the a-specific
activator protein Matalp, or the a-specific repressor protein Mata2p. The regulation
of the transcription of cell-type specific genes of S. cerevisiae has been reviewed in
Herskowitz, 1988, Dolan and Fields, 1991 and Herskowitz et al., 1992.
18
Many genes whose products are required for the mating process have been identified
by isolating mutants which were either unable to mate or unable to respond to the
mating pheromones. A large number of yeast genes necessary for mating but distinct
from theM4T locus have been identified (MacKay and Manney, 1974a; 1974b;
Hartwell, 1980). These genes were termed Sterile (STE) genes as mutations in them
conferred a sterile phenotype on affected cells. Since then other genes necessary for
mating have been identified and include for example those encoding the precursors to
the mating factors, which were not isolated in the original screens because they are
both encoded by two genes (Kurjan and Herskowitz, 1982; Singh et al., 1983;
Gething, 1985) and STE24 which is involved in an NH2-terminal processing event in
the production ofmature a-factor (Chen et al., 1997). To date some genes known to
be involved in the mating process have yet to be identified and include the genes
whose products are essential for a-factor processing and degradation (Caldwell et al.,
1995). The isolation of genes essential for the production and response to the mating
pheromones has allowed elucidation of the mechanisms involved in these cellular
events (reviewed in Sprague and Thorner, 1992).
1.6 The expression, biosynthesis and secretion of the mating pheromones
The mating pheromones ofA cerevisiae are oligopeptides with similar functions but
which differ greatly in their structure, biosynthesis and secretion, a-factor is an
unmodified tridecapeptide which is secreted through the "classic" yeast secretory
pathway which involves the endoplasmic reticulum (ER), Golgi and secretory vesicles.
In contrast a-factor is a prenylated and methylated dodecapeptide whose export from
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the cell is mediated by the activity of the STE6 gene product. For the purpose of this
project a brief overview of a-factor production and secretion is given with more
consideration being given to the production and export of a-factor. Review articles on
yeast pheromone processing include Fuller et al., 1988; Sprague and Thorner, 1992
and Kurjan, 1992.
a) An overview of the biosynthesis and secretion of a-factor: the secretion of a
peptide by the "classic" yeast secretory pathway
Mature extracellular a-factor is an unmodified tridecapeptide which is coded for by
two a-cell-type-specific, functionally redundant genesMFal andMFa2 (Kurjan and
Herskowitz, 1982; Singh et al., 1983). These genes encode polypeptide precursors
that contain tandem repeats of the a-factor peptide. TheMFal gene product is a
165-amino-acid polypeptide which contains four a-factor repeats whereas theMFa2
gene product is a 120-amino-acid polypeptide which contains two a-factor repeats.
Both gene products contain an amino-terminal hydrophobic signal peptide leader
sequence for transit into the ER (Julius et al., 1984; Waters et al., 1988; reviewed in
Rapoport, 1992 and Walter and Jackson, 1994); a hydrophilic domain (pro-region)
which contains three consensus sites for asparagine-linked glycosylation; and a C-
terminal segment containing the tandem repeats of the mature a-factor sequence.
These precursor molecules are targeted to the ER by the presence of the hydrophobic
signal sequence which is removed by signal peptidase (Dev and Ray, 1990). The pro-
region is glycosylated upon entry to the ER by the addition of three N-linked core
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oligosaccharides (Julius et al., 1984; Fuller et al., 1992). On entry to the Golgi
apparatus the core oligosaccharides are elongated and the pro-a-factor is
proteolytically processed to form mature a-factor. The mature a-factor then exits the
cell by exocytosis in a constitutive manner.MFal andMFa2 expression is induced
when cells are exposed to a-factor (Achstetter, 1989; Jarvis et al., 1988). The
processing and secretion of a-factor is an example of the classic protein secretory
pathway of yeast. Mutations in genes encoding proteins required for secretion (SEC
genes) prevent mature a-factor from being secreted into the extracellular environment
(Novick et al., 1980 and Novick et al., 1981).
b) a-factor
i) Introduction
Mature extracellular a-factor is a farnesylated and methylated dodecapepeptide which
is encoded by two a-specific functionally redundant genesMFal and MFa2 (Brake et
al, 1985; Michaelis and Herskowitz, 1988). The MFal and MFa2 genes encode a-
factor precursor molecules of 36 or 38 amino-acid residues respectively which are
composed of three main functional segments 1) the mature portion which is eventually
secreted: b) the NH2 terminal extension: and 3) a COOH-terminal portion which
contains the signal sequence for farnesylation and methyl-esterification known as the
CAAX motif (Figure 1.5). Maturation of the precursor molecules includes both NH2
and COOH terminal cleavage events and COOH-terminal modification to yield mature
a-factor molecules YIIKGLFWDPAC(Farnesyl)-OCH3 and
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YIIKGVFWDPAC(Farnesyl)-0CH3 fromMFa1 and MFa2 respectively (divergent
residues emboldened). Unlike the a-factor precursor molecules these polypeptides
contain neither a hydrophobic signal sequence nor sites for asparagine-linked
glycosylation and encode only one copy of the a-factor sequence. The precursor
molecules are produced in equal quantities in the cell and are induced by the presence
of a-factor (Dolan et al., 1989; Davis et al., 1992).
The differences in the structures ofa and a-factor precursor molecules indicate that
the maturation and secretion of a-factor may occur in a manner distinct from that
occurring in the classic secretory pathway. Indeed the secretion of a-factor occurs
when temperature-sensitive sec mutants are shifted to a non-permissive temperature
(Sterne and Thorner, 1986; McGrath and Varshavsky, 1989). In addition mutations in
genes essential for a-factor processing, for example kex2 and sie 13, have no effect on
the maturation of a-factor (Julius et al., 1983, 1984) indicating that another
mechanism for the secretion of the a-factor peptide must be present. Studies on
strains ofS. cerevisiae that were unable to mate because of a lack of a-factor
production has led to the identification of several genes required for a-factor
biogenesis and secretion (Chen et al., 1997; reviewed in Caldwell et al., 1995).
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Figure 1.5 Structure of precursors and mature forms of a-factor encoded by
MQPSTATAAPKEKTSSEKKDN|Y11KGVFWDPAC|VIA Precursor
N-tTmjml extension C A A X
/"vk/\A/\A
|YI IKG VF WPP AC Mature a-factor
O-CH3
The a-factor precursor encoded byMFal is shown with the NH2-terminal extension,
COOH-terminal CAAX motif and mature portion (shaded) indicated. The mature a-
factor molecule derived from this precursor molecule is shown modified at the
COOH-terminal with a farnesyl moiety and a carboxyl methyl group.
Taken from Chen el al.,1997.
ii) The biogenesis of a-factor
The C-terminus of a-factor contains a CAAX motif (C is cysteine, A is aliphatic and
X is one ofmany residues) which is CVIA in the case of a-factor. The CAAX motif
is common to all known prenylated proteins including small GTP-binding proteins
such as the ras proteins (plasma membrane-localised molecules which regulate cell
differentiation and proliferation), lipopeptide pheromones, nuclear lamins and
trimeric G-proteins. The CAAX motif signals a triplet of post-translational
modifications which include prenylation of the cysteine residue, proteolysis of the
COOH terminal AAX residues and methylation of the newly exposed cysteine
carboxyl group (Clarke, 1992; Schafer and Rine, 1992; Zhang and Casey, 1996).
Protein prenylation is thought to enhance membrane association and direct the
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polypeptide to its correct intracellular location. Farnesylation of a-factor is carried
out in the cytosol by the heterodimeric farnesyltransferase encoded by 11AM1 and
RAM2. The RAMgenes were initially identified by the discovery ofmutants of S.
cerevisiae which were deficient in both a-factor and Ras function suggesting that
there was a maturation pathway common to both proteins. These ram (Ras and a-
factor modification) mutants accumulate a-factor precursors intracellularly and
contain ras proteins which are non-functional due their inability to localise at the
plasma membrane (Fujiyama et al., 1987; He et al., 1991; Powers et al., 1986;
Schafer et al., 1990; Goodman et al., 1990). Following farnesylation the a-factor
precursor polypeptide is thought to become membrane-associated by virtue of the
hydrophobic interactions promoted by the lipid attachment. The a-factor precursor
molecule then undergoes a series of membrane-associated processing events to yield
mature a-factor. The three carboxy-terminal amino-acids distal to the farnesylated
cysteine (AAX) are removed by an endoprotease whose activity has been detected
and shown to be membrane-associated but whose gene(s) have yet to be identified
(Ashby et al., 1992; Hrycyna and Clarke, 1992). The a-factor precursor is then
methylated by the STEl4-encoded prenylcysteine-dependent carboxyl methyl
transferase (Hrycyna and Clarke, 1990; Hrycyna et al., 1991). The a-factor precursor
is then further matured by proteolytic removal, in two stages, of the N-terminal
extension by the proteins encoded by STE24 and AXL1 (Chen et al., 1997; Michaelis,
1997) to yield mature a-factor.
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iii) Secretion of a-factor is dependent on the STE6 gene product
In 1989 two groups (McGrath and Varshavsky 1989; Kuchler et al1989) reported
the importance of the STE6 gene product for the export of a-factor from a-cells.
McGrath and Varshavsky discovered the previously-mapped STE6 gene whilst
working on genes involved in the yeast ubiquitin pathway. They demonstrated that
deletion of the STE6 gene in an a-type strain resulted in a loss of a-factor secretion
whereas the same deletion had no effect on a-factor secretion from a-cells, further
compounding the evidence that a-factor is secreted in a manner distinct from the
classic secretory pathway. The STE6 and the human multiple drug resistance P-
glycoprotein gene, MDR1, were found to be 57% identical or highly conserved at the
amino acid level. The involvement of theMDR1 gene product in the energy dependent
export of cytotoxic drugs out of the cell implied that the function of the STE6 gene
product was in the export of a-factor into the extracellular environment. Kuchler et
al. demonstrated that the STE6 gene product is required for, and is the rate-limiting
step in, the secretion of a-factor. They demonstrated, by the use of antibodies directed
against a-factor, that ste6 mutants affected a-cells by preventing a-factor secretion.
The maturation of a-factor is completed prior to secretion as the mature form of a-
factor is found intracellularly mMATn ste6 mutants. These results showed that the
phenotype seen mMATn ste6 mutants was due to the inability to secrete a-factor
rather than to the secretion of biologically inactive a-factor. The transportation of the
a-factor mating peptide by Ste6p highlighted a novel mechanism for the transport
across cell membranes of peptides that lack the classic hydrophobic signal sequence.
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Figure 1.6 shows a schematic representation of the biogenesis and secretion of a-
factor.
iv) Localisation of a-factor biogenesis
In Figure 1.6 the biogenesis of a-factor following prenylation is shown to be localised
on the plasma membrane. However although the biogenesis of a-factor is intimately
associated with cell membranes, as determined by the localisation of all the maturation
enzymes apart from the soluble farnesyl transferase encoded by RAMHRAM2, the
precise location of a-factor maturation has yet to be fully clarified. The PhD thesis of
Sterne, (1989 referred to by Kuchler and Thorner, 1990; Sprague and Thorner, 1992)
describes subcellular fractionation and protease accessibility studies which suggest
that a-factor precursor molecules do not enter any intracellular membrane-bound
compartment. Caldwell et al., (1995) point out that enzymes involved in the
maturation of prenylated proteins and peptides in animal cells have been found in
microsomal membranes, for example a STEM functional analogue of isoprenyl
cysteine methyltransferase is found to cofractionate with an endoplasmic reticulum
marker in mammalian cells (Stephenson and Clarke, 1990; 1992) suggesting that such
peptides and proteins pass through a microsomal membrane compartment on their
way to their final destination. Microsomal membrane involvement in the maturation of
a-factor has not been ruled out and the Michaelis group (Chen et al, 1997) are
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Figure 1.6 Maturation and export of a-factor
1. Preitvlation ofCAAX cysteine
2. Proteolysis ofAAX




Model for a-factor synthesis and secretion. During a-factor biogenesis, the
unmodified a-factor precursor undergoes COOH-terminal processing (prenylation,
proteolytic trimming ofAAX, and carboxyl methylation) to yield the fully modified
membrane-associated species. The N-terminal proteolytic processing events occur in
two stages to generate mature a-factor. The CAAX processing machinery includes
the Ramlp/Ram2p farnesyltransferase, the genetically unidentified AAX protease
and the Stel4p methyltransferase. The N-terminal processing events are carried out
by the STE24 and AXL1 gene products. The export ofa-factor is mediated by ABC
transporter Ste6p. The presumed localisation of a-factor biogenesis is as indicated.
















currently conducting detailed fractionation analysis in order to determine the precise
cellular location of a-factor intermediates. The cellular locations of the final stages of
a-factor biogenesis are important in understanding the interaction of a-factor and
Ste6p and are further discussed in relation to Ste6p in 1.11.
Part 3
The ^STEYj-encoded a-factor transporter of the yeast S. cerevisiae
1.7 The iSTis6-encoded a-factor transporter
The original ste6 mutant was isolated in a screen for mutants ofS. cerevisiae which
were defective in mating (Rine, 1979 Ph.D. thesis, referred to in Wilson and
Herskowitz, 1984 and subsequent papers related to STE6). Wilson and Herskowitz
(1984) cloned the STE6 gene and demonstrated that production of stable STE6
mRNA is limited toMATa cells and is under negative regulation by MATa2p. The
sequence of 469 nucleotides from the 5' flanking region ofSTE6 was determined by
Wilson and Herskowitz (1986). The STE6 gene is located on chromosome XI
(McGrath and Varshavsky, 1989) and has an open reading frame (ORF) of 3870
nucleotides which would encode a protein of 1290 amino acids with a calculated
molecular weight of 144,774 (McGrath and Varshavsky, 1989; Kuchler ei al., 1989).
Sequence analysis of STE6 revealed that it was a member of the ABC-transporter
superfamily with the topological arrangement MSD1-NBD1-MSD2-NBD2. The
sequence similarities between Ste6p and Mdrlp are continuous throughout the length
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of the polypeptides. In addition their hydropathy profiles are virtually superimposible
suggesting that they share a common membrane topology with both the amino and
carboxyl termini being located on the cytosolic face of the plasma membrane as
indicated in Figure 1.7 (McGrath and Varshavsky, 1989; Kuchler 1989;
Gottesman and Pastan, 1993).
Figure 1.7 Predicted topology of Ste6p in the plasma membrane
Schematic representation of Ste6p in the plasma membrane. The two predicted
nucleotide binding domains (NBD) are shown as loops. The appropriate location of
the Walker A, Walker B and Centre regions within the NBD are indicated in red. The
membrane spanning domains (MSD) are represented as cylinders with each cylinder
representing a membrane spanning segment. The arrow indicates the site used for the
in vivo severing experiments discussed in section 1.10. See text for details.
Taken from: Michaelis, 1993; Browne et al., 1996.
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a) Ste6p is an integral membrane protein
Studies carried out on epitope-tagged versions of the STE6 gene product have shown
that Ste6p is an integral membrane protein which may be solubilised from cell
membranes by the addition of the non-ionic detergent Triton X-100. In contrast
treatments used for the removal of peripherally-bound proteins from cell membranes
(0.1M Na2C03 at pHl 1 and 3M urea) were unable to release detectable amounts of
Ste6p (Kuchler et a/., 1993).
b) Ste6p is not a glycoprotein
The STE6 sequence contains 14 consensus sites for the addition ofAsn-linked
carbohydrate (Kuchler et al., 1989). As one of the potential glycosylation sites lies
within the first putative hydrophilic loop of the protein, in an almost identical position
to a single Asn-linked chain found in theMDR1 gene product, it was reasonable to
expect that Ste6p would be a glycoprotein. However the molecular weight of Ste6p
has been shown to be unaffected by expression of the protein in the presence of
tunicamycin (an inhibitor ofN-linked glycosylation) suggesting that Ste6p does not
contain any N-linked oligosaccharide. In addition Ste6p, solubilised from yeast
membranes with Triton X-100, has been shown to be unable to bind to concanavalin
A, a lectin that recognised both O- and N-linked sugars. Thus, native Ste6p appears
not to contain any O- or N-linked oligosaccharide chains (Kuchler et al., 1993).
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c) Ste6p is an ATP-binding protein
Ste6p is predicted, from its sequence, to contain two discrete ATP-binding domains
with which it is thought to couple the hydrolysis ofATP with the movement of a-
factor across the plasma membrane. Ste6p solubilised from membranes with Triton X-
100 and partially purified by immunoprecipitation has been shown to be capable of
interacting with the photoactivatable ATP analogue, 8-azido-ATP (Kuchler et al.,
1993; reviewed in Kuchler et al., 1994). The crosslinking was shown to be specific for
Ste6p by the fact that appearance of the photolabelled 145kDa product was only
detectable in cells expressing Ste6p which had been exposed to the required UV
irradiation. In addition the labelling was effectively competed by the presence of
unlabelled 8-azido ATP.
d) Ste6p is a phosphoprotein
Several of the gene products involved in the mating signal transduction pathway
including Ste2p, Ste5p and Stel2p are phosphoproteins. In each case the level of
phosphorylation is stimulated by the presence ofmating pheromone. Ste6p was shown
to exist in a phosphorylated state by immunoprecipitation of Ste6p which had been
radiolabelled with 32P043~ in the presence or absence of a-factor. Ste6p was shown to
be phosphorylated in the absence of a-factor. On addition ofa-factor the level of
radioactivity incorporated into Ste6p significantly increased. However the increase in
phosphate incorporation was shown to be proportional to the increase in Ste6p
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concentration indicating that although Ste6p is phosphorylated the level of
phosphorylatoin is unlikely to be linked to the presence ofa-factor.
1.8 Structure-function analysis of Ste6p
Structure-function studies of Ste6p can be conducted by quantifying Ste6p activity
either by measuring the mating efficiency ofmutant cells or by quantifying a-factor
immunoprecipitated from the culture fluid of mutated cells. The following section
discusses mutagenic studies that have been carried out on Ste6p in order to determine
which structural components are necessary for the protein's function.
a) Both halves of Ste6p are essential for activity
The relative importance of the two halves of the Ste6p transporter has been analysed
by severing the STE6 coding sequence (as indicated in Figure 1.7) and expressing the
different halves of the molecule as two separate peptides, MSD1-NBD1 (N-half) and
MSD2-NBD2 (C-half). Neither peptide, when expressed alone, was capable of
complementing a ste6 null mutation indicating that both halves of the molecule are
critical for full activity and are therefore not functionally redundant. Co-expression of
the different halves of Ste6p results in the formation of a functional Ste6p transporter
suggesting that transport function is dependent on the formation of heterodimers
(Berkower and Michaelis, 1991; Michaelis and Berkower, 1995).
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The interactions between the domains of the human MDR1 gene product, P-
glycoprotein, have been examined by expressing each domain as a separate
polypeptide and testing for association by coimmunoprecipitation (Loo and Clarke,
1995). It was shown that interactions between the different halves of the molecule are
mediated by association between both the MSDs and the NBDs. These findings
coupled with the ability of the separated halves of Ste6p to associate and reconstitute
a functional transporter appear to reflect the modular architecture characteristic of
this family of transport proteins. Interactions between the domains of bacterial ABC-
transporters, which are composed of separate polypeptides, have been shown to be
critical for their function (Kerppola et al., 1991). The human TAP (transporter
associated with antigen) transporter protein is an example of a eukaryotic
heterodimeric ABC-transporter which is composed of the products of two separate
genes, in this case TAP1 and TAP2 (Figure 1.1B, v).
b) The effect of mutations in the Walker A, Walker B, LSGGQ signature
sequence and Centre region on Ste6p activity
The most highly conserved regions of the ABC-transport superfamily include the
Walker A, Walker B, LSGGQ signature and centre regions (Figure 1.2). The high
degree of conservation between these regions suggests that they may be essential for
ABC-transporter function. This notion is supported by the observation that mutations
in each of these four regions in the CFTR gene have been associated with the disease
cystic fibrosis. The introduction ofmutants into the conserved residues in the Walker
A and LSGGQ signature regions of Ste6p have been demonstrated to cause a
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dramatic loss of Ste6p function (Berkower and Michaelis, 1991; Browne et al., 1996).
This supports the suggestion that these residues play an vital role in ATP utilisation by
Ste6p and other ABC transporters (reviewed in Michaelis and Berkower, 1995). In
contrast mutations in the centre region of the NBDs of Ste6p have little effect on
Ste6p activity.
i) Mutagenesis of the Walker A motif of Ste6p
Many of the mutations ofCFTR associated with the cystic fibrosis phenotype are
found within the NBDs. An alteration of the first glycine residue of the Walker A
motif in either NBD ofCFTR results in cystic fibrosis (DeVoto et al., 1991).
Mutagenesis of the corresponding glycine residues in Ste6p (G392 and G1087) results
in a dramatic reduction in the level of a-factor secretion. In addition the mutagenesis
of a conserved lysine residue within the Walker A motif (K398 and K1093), which
leads to a loss of drug resistance when both halves of murine Mdrlp are affected,
results in a reduction of a-factor secretion of affected Ste6p (Berkower and Michaelis,
1991).
ii) Mutagenesis of the Walker B and LSGGQ motifs of Ste6p
The LSGGQ or "signature motif' of the ABC-proteins is located just N-terminal to
the Walker B motif (Figure 1.2). Several mutations of the CFTR protein associated
with cystic fibrosis are clustered in or near the LSGGQ motifs. The introduction of
cystic fibrosis-associated missense mutations into or near the LSGGQ motif of the
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first NBD of Ste6p has been shown to result in a broad-range of a-factor transport
defects with those mutations introduced directly within the LSGGQ motif causing the
most severe defects (Browne et al., 1996). Mutations of residues within the LSGGQ
signature region had no effect on either the steady-state level or intracellular location
of Ste6p indicating that this region of the protein may have a direct involvement in
Ste6p transporter function.
iii) Mutagenesis of the Central region of Ste6p
The ABC-transporters show only limited homology over the Centre Region (Figure
1.2). Nevertheless this region is of interest as the most prevalent cystic fibrosis
mutation, AF508, occurs in this region of the CFTR transporter. This phenylalanine
residue is not conserved amongst ABC proteins however Ste6p and P-glycoprotein
each contain a hydrophobic residue at an analogous position. Corresponding
mutagenesis in each of the domains of Ste6p (AL455 in the N-terminal NBD and
AY1150 in the C-terminal NBD) has been shown to have no effect on the activity of
the Ste6p in the export of a-factor. This and other mutagenic alterations to the central
region of Ste6p failed to exhibit any effect on the activity of the protein. This is in
marked contrast to the dramatic reduction in Ste6p activity associated with
mutagenesis of residues within the Walker A, Walker B and Signature regions of the
protein. It would appear that the centre region of Ste6p does not play an active role in
the transportation of a-factor (Berkower and Michaelis, 1991).
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1.9 Expression of mammalian ABC transporters in S. cerevisiae
The successful expression of mammalian ABC-transporters in yeast provides a
mechanism by which these proteins might be genetically manipulated and studied in an
environment free from the inherent difficulties ofworking with mammalian cells. The
extent of the structural and functional similarities between Ste6p and mammalian
ABC-transporters has been demonstrated by functional complementation of Ste6p
activity by the expression of heterologous ABC-proteins in a tsste6 strain of yeast.
The following section discusses some of the insights that have been obtained into the
function of mammalian ABC-proteins by their expression in S. cerevisiae.
The extensive homology between Ste6p and mammalian P-glycoproteins has led to
the suggestion that the P-glycoproteins might function to catalyse the transport of
peptides or proteins under normal physiological conditions (Kuchler et al., 1989;
Kuchler and Thorner 1990a; 1990b). The murine homologue of human Mdrlp,
Mdr3p, has been shown to partially complement a ste6 deletion, allowing yeast to
mate at low but significant frequency (Raymond et al., 1992). Mdr3p behaves as a
fully-functional drug transporter when expressed in yeast, conferring cellular
resistance to the immunosuppressive and antifungal drug FK520, a known MDR
substrate (Raymond et al., 1994). A mutation in the 11 transmembrane domain of
Mdr3p decreases activity and changes the substrate specificity of the protein in
mammalian cells. This mutant form ofMdr3p is unable to complement a Aste6
mutation in S. cerevisiae suggesting that the Mdr3p functions in a similar way in yeast
and mammalian cells (Raymond et al., 1992). Similar studies have been conducted on
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the expression of humanMDlll in S.cerevisiae (Kuchler and Thorner, 1992). These
studies indicated that Mdrlp is capable of both complementing a Aste6 mutation and
conferring increased resistance toward valinomycin when expressed in S. cerevisiae.
However other groups have been unable to repeat these expression studies and as a
result doubt their authenticity (unpublished observations of S. Michaelis, reported in
Michaelis and Berkower, 1995).
The pfmdrl gene ofPlasmodium falciparum encodes the protein Pghl (P-
glycoprotein homologue) which is associated with chloroquine-resistance in the
parasite. Pfmdrl, like murineMDR3, is capable of the functional complementation of
a Aste6 mutation in yeast (Volkman et al., 1995). The functional complementation is
abolished by the presence, in Pghl, of two naturally occurring polymorphisms which
are associated with chloroquine resistance (Volkman et al., 1995). The expression of
wild-type Pghlp in S. cerevisiae confers cellular resistance to four quinoline-
containing antimalarial drugs. This drug-resistant phenotype is abolished by the
introduction ofPghl carrying the genetic polymorphisms discussed above (Ruetz et al
, 1996b). The heterologous expression ofPghl in S. cerevisiae has therefore not only
implicated Pghl in anti-malarial drug resistance, but has also provided a means by
which the structure-function relationships in this protein may be studied by genetic
analysis in yeast.
Other heterologous ABC-proteins which have been shown to complement a Aste6
mutation include the human MRP encoded multidrug resistance-associated protein
(Ruetz et al., 1996a) and the HST6 gene product from Candida albicans (Raymond
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et al., 1995). Ste6p-CFTR chimaeric proteins have been shown to complement a
Aste6 mutation and have consequently been used as tools for the study of certain
properties of mammalian CFTR (Teem et al., 1993).
It should be noted that not all of the mammalian ABC-transporters expressed in
S.cerevisiae are able to complement a Aste6 mutation. For example the expression of
human TAP1 and TAP2 in S. cerevisiae results in the formation of a stable, ER
located, TAP heterodimer which is fully functional in terms of selective peptide
binding, ATP-dependent transport and specific inhibition of herpes simplex virus
ICP47, but is unable to complement a Aste6 mutation. (Urlinger et al., 1996).
1.10 Intracellular trafficking, localisation and degradation of Ste6p
As Ste6p appears to be an integral membrane protein and functions to transport a-
factor to the extracellular environment, it would be expected to reside primarily in the
plasma membrane. This section discusses experimental evidence that indicates that
Ste6p is a metabolically unstable protein that is found primarily in intracellular vesicles
and is only transiently associated with the plasma membrane. It also discusses the
experimental data that suggests that Ste6p is degraded by two independent pathways,
one vacuolar and the other a cytosolic, ubiquitin-dependent mechanism.
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a) The cellular location of Ste6p
The cellular location of Ste6p has been investigated by comparing the equilibrium
distribution of Ste6p with marker proteins following fractionation of crude-cell lysates
by differential centrifugation (Kuchler et al., 1993; Kolling and Hollenberg 1994a).
Kuchler zt al. (1993) found that the bulk of cellular (c-myc-epitope) tagged Ste6p co-
fractionated with the plasma membrane marker protein, Pmalp (plasma membrane-
associated H+-translocating ATPase). No cytosolic marker protein (phosphoglycerate
kinase) was detected in this fraction indicating that Ste6p was primarily located in the
plasma membrane. Additional information on the association of Ste6p with the plasma
membrane was obtained by examining the distribution of Ste6p through a sucrose
density gradient. It was found that the distribution of Ste6p matched exactly that of
Pmalp again indicating that Ste6p is a plasma membrane protein (Kuchler et al.,
1993; Kuchler et al., 1994). In contrast Kolling and Hollenberg (1994a) carried out
sucrose density gradient fractionation of crude cell extracts and found that only a
minor portion of the total Ste6p localised with Pmalp. Instead they found that the
majority of Ste6p followed a distribution pattern virtually identical to that of the Golgi
marker protein dipeptidyl aminopeptidase A, indicating that Ste6p is predominantly
associated with internal membranes and not the plasma membrane. The apparent
discrepancy between these results might be explained by a plasma membrane
enrichment step carried out by Kuchler et al. (1993) prior to sucrose density gradient
analysis.
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Further information regarding the cellular localisation of Ste6p has been obtained by
the use of indirect immuno-fluorescence using overexpressed Ste6p which had been
epitope-tagged either with c-myc (Kuchler et al., 1993; Rolling and Hollenberg,
1994a) or with the influenza virus hemagglutanin epitope, HA1 (Berkower et al.,
1994). Both epitope-tagged variants of Ste6p were capable of complementing a ste6
deletion and were detected in immunofluorescence experiments by anti-epitope
antibodies. Kuchler et al. (1993) noted that the Ste6p had a patchy rim-like staining
pattern and appeared in vesicular bodies associated with the plasma membrane. They
concluded that this staining pattern was consistent for a plasma membrane protein and
suggested that the vesicular bodies might represent a) newly-synthesised Ste6p within
compartments of the secretory pathway en route to the cell surface or b) a reservoir
of Ste6p-containing secretory vesicles awaiting delivery to the plasma membrane in a
(perhaps) regulated manner.
The punctate staining pattern of Ste6p was observed by the other groups (Berkower
et al., 1994; Rolling and Hollenberg 1994a) who, however, concluded that the
staining pattern was more consistent with an intracellular localisation of Ste6p.
Berkower et al. (1994) analysed the staining pattern of the plasma membrane marker
protein, Pmalp, and found that it gave a characteristic rim-staining pattern which was
quite different to that seen for Ste6p. These observations were surprising considering
the supposed role of Ste6p in the export of a-factor into the extracellular
environment. The results could be interpreted in two ways; either Ste6p is an
intracellular protein, which queries its role in a-factor export, or Ste6p is transported
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to the plasma membrane but resides there for a short period of time before being
internalised by endocytosis. In order to ascertain whether or not Ste6p is plasma
membrane associated its distribution was examined in end3 and end4 strains of yeast
which carry temperature-sensitive defects in genes required for endocytosis (Raths et
al., 1993). Any Ste6p localised in the plasma membrane of either an end3 or an end4
mutant would become trapped at the membrane on shifting the cells to a non-
permissive temperature. Ste6p trapped at the plasma membrane would be expected to
produce an intracellular distribution pattern more consistent to that observed for
Pmalp. It was found that Ste6p exhibited a rim-staining pattern when expressed in
both end3 and end4 mutant strains at the non-permissive temperature indicating that it
had accumulated in the plasma membrane (Berkower et al., 1994; Rolling and
Hollenberg 1994a). In addition, sucrose gradient fractionation of crude cell lysates
obtained from the end4 mutant strain indicated that Ste6p fractionated with Pmalp
when the cells were grown at their non-permissive temperature (Rolling and
Hollenberg 1994a). Thus it would appear that when endocytosis is blocked, Ste6p
appears at the plasma membrane, exposing its normally transient residency in this site.
The immuno-fluorescent studies carried out on epitope-tagged Ste6p in wild-type and
on end3 and end4 mutant strains of yeast suggest that, at any given point in time, the
majority of Ste6p is found in intracellular vesicles and is either en route to or en route
from the plasma membrane.
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b) Trafficking and degradation of Ste6p
Pulse chase analysis of Ste6p has shown that is a metabolically unstable protein with a
half-life of 13 min (Rolling and Hollenberg 1994a) or 37 min (Berkower et al., 1994)
in wild-type strains of S. cerevisiae grown on minimal medium at 30°C. The half-life
of Ste6p is increased to greater than 2 hours in a pep4 mutant strain of yeast which is
deficient in several vacuolar ATPase functions (Ammerer et al., 1986; Woolford et
al., 1986) indicating that Ste6p is degraded in the vacuole (Berkower et al. 1994
Rolling and Hollenberg 1994a). Indirect immunofluorescence studies on the
intracellular localisation of epitope-tagged Ste6p in pep4 mutants indicate
Ste6p is localised in the vacuole (Berkower et al., 1994).
Plasma membrane proteins are transported from the ER to plasma membrane via the
Golgi apparatus and secretory vesicles. On reaching the plasma membrane the
proteins may exist either as stable resident proteins such as Pmalp, which has a half
life of over 5 hours (Berkower et al., 1994), or as tightly regulated protein such as the
pheromone receptors, Ste2p and Ste3p, which undergo rapid intracellular movement
and turnover via the endocytic pathway.
Evidence of the existence of a yeast endosomal pathway was not confirmed until
Riezman (1985) revealed that several yeast secretory mutants were in fact defective in
endocytosis. The internalisation of the yeast pheromone receptors has been used as a
model system for the study of endocytosis in yeast. Studies on the yeast a-factor
receptor, Ste3p, have shown that the formation of a pheromone-receptor complex
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initiates endocytosis and subsequent vacuolar degradation (reviewed in Riezman,
1993). Along with pheromone-induced endocytosis, the Ste3p receptor is subject to
constitutive endocytosis that occurs in the absence of pheromone (Davis et al.,
1993).The temperature-sensitive endocytosis mutants ends and end4 were isolated
through their inability to internalise a-factor or its receptor. The end4 mutant
specifically affects step(s) of the of the endocytic pathway prior to the formation of
the endosomal compartment (Raths et al., 1993). The ability of an end4 mutant strain
of yeast to "trap" Ste6p at the plasma membrane indicates that Ste6p is internalised
via the endocytic pathway. This, together with the dramatic instability of Ste6p
indicates that it is a tightly regulated protein. The following section discusses the
current models relating to the intracellular trafficking and degradation of Ste6p.
i) Endocytosis and vacuolar degradation of Ste6p
A model depicting the movement of Ste6p to and from the plasma membrane is
shown in Figure 1.8. Evidence in support of this model comes from cellular
fractionation and immunofluorescence studies, as discussed in the previous section,
combined with a series of experiments conducted both on mutants in the yeast
secretory pathway and on recombinant Ste6p molecules.
Mutations in genes essential for the trafficking of Ste6p have been identified by virtue
of their ability to increase the half-life of the protein by affecting its transport to the
vacuole. Ste6p is stabilised when temperature sensitive mutations in genes involved in
both ER to Golgi transport, (ste23) and in the fusion of post-Golgi secretory vesicles
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Figure 1.8 Endocytosis and vacuolar degradation of Ste6p
Intracellular trafficking and vacuolar degradation of Ste6p. The model depicts the
trafficking of Ste6p to the plasma membrane via the ER, Golgi and post-Golgi
secretory vesicles. From the plasma membrane, Ste6p undergoes endocytosis into an
endosome, which is delivered to the vacuole. In the vacuole, Ste6p is degraded by
proteases (yellow "pacmen") activated by Pep4p. The products of the SEC1, SEC4,
SEC6, SEC23, END3 and END4 genes act at the indicated steps. The dotted lines
represent purely hypothetical processes: direct trafficking of Ste6p to the vacuole and
a compartment for the recycling of Ste6p between the endosomes and the plasma
membrane.
Taken from Berkower et al 1994; Rolling and Hollenberg, 1994a.
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with the plasma membrane {seel, sec4 and sec6) are grown at a non-permissive
temperature (Berkower et al., 1994; Rolling and Hollenberg, 1994a). Likewise, in
addition to "trapping" Ste6p at the plasma membrane, mutations in gene products
essential for endocytosis (end3 and end.4) stabilise Ste6p.
Recombinant Ste6p molecules have been used in attempt to determine which physical
elements of the protein are required for recognition by the cells transportation
machinery. Rolling and Hollenberg (1994b) conducted studies on a chimaeric protein
produced by the fusion of the first hydrophobic segment of Ste6p (amino-acids 1-78)
to the secreted protein invertase which was lacking its ER signal sequence. The
results of the study indicated that the first hydrophobic segment of Ste6p was capable
of directing invertase to the ER membrane indicating that this region of Ste6p
functions as a signal sequence. In addition a quarter molecule of Ste6p encoding the
six N-terminal transmembrane domains has been shown to contain sufficient
information to enable internalisation by endocytosis at a rate comparable to that of the
full length molecule (Berkower et al., 1994). The signal sequences required for
recognition by both the endocytic machinery and the endoplasmic reticulum
recognition machinery remain to be determined.
In general the results of these studies indicate that Ste6p is a highly unstable protein
that is transported to the plasma membrane through the secretory pathway where it
resides for a transient period before being internalised and transported to the vacuole
by way of the endocytic pathway. The detection of Ste6p by indirect
immunofluorescence has shown that Ste6p is only visible at the plasma membrane
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when it is "trapped" there by end 4 and end3 mutant cells which are unable to carry
out the early stages of endocytosis. This, taken in the light of the results obtained
from the stability of Ste6p in various mutant strains, implies that Ste6p spends much
of its short lifetime in transit to or from the plasma membrane. Kolling and Hollenberg
(1994a) suggest that if there was an accumulation of Ste6p within the cell it would be
likely to occur at some stage prior to reaching the plasma membrane. Berkower et al,
(1994) suggest that the vesicular staining pattern for Ste6p could represent Ste6p in
endocytic or exocytic vesicles which might function as a recycling compartment
between endosomes and the plasma membrane. They suggest also that Ste6p may
never reach the plasma membrane by moving directly from the secretory pathway to
the vacuole. Both of the later hypotheses are represented in Figure 1.8.
It has been suggested that Ste6p may reside in a novel intracellular compartment that
fuses with the plasma membrane following induction by a-factor (Kuchler et al.,
1993). Sucrose gradient fractionation studies on a-factor-stimulatedM4Ja cells have
indicated that the presence of a-factor does not lead to a relocalisation of Ste6p to the
plasma membrane (Kolling and Hollenberg 1994a). In addition exogenous treatment
ofMA 7a cells with a-factor does not effect the half-life of Ste6p (Berkower et al.,
1994). Preliminary experiments therefore indicate that a-factor has no affect on the
localisation and half life of Ste6p.
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ii) Ste6p is multiubiquitinylated in endocytosis mutants
Ubiquitin is a small protein found in eukaryotic cells either free or covalently joined to
cellular proteins. It functions as a regulatory protein and often appears to serve as a
marker that targets a protein for degradation. Stable proteins are usually mono-
ubiquitinylated whereas substrates targeted for degradation are often modified by the
addition of a branched multiubiquitin chain. The degradation of multiubiquitinylated
proteins may occur in a cytosolic ubiquitin-dependent pathway defined by the
multisubunit protease yscE. yscE is structurally homologous to the so-called
proteasome particle, which is a component of the 26S proteolytic complex that has
been shown to specifically degrade ubiquitin-protein conjugates in reticulocyte
extracts. Selective degradation of proteins by ubiquitinylation allows tight regulation
and selective turn-over. Mata2p is an example of a regulatory protein which is known
to exist in a multiubiquitinylated form. Mata2p activity must be limited to a single cell
cycle and selective degradation would allow the concentration of the protein to be
tightly monitored so that this haploid-specific protein could be removed rapidly from
the cell with the onset ofmating or mating type interconversion. The yeast ubiquitin
system is reviewed in Finley (1992).
The dramatic stabilisation and vacuolar localisation of Ste6p in apep4 mutant
indicates that the majority of Ste6p is degraded in the vacuole. However none of the
secretory mutants examined in the previous section were capable of completely
blocking the degradation of Ste6p suggesting that it can be degraded by an alternative
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pathway. The accumulation of a low-mobility form of Ste6p in the plasma membrane
fraction of endocytosis mutants led to the suggestion that Ste6p was being
ubiquitinylated (Rolling and Hollenberg, 1994a). Studies have shown that Ste6p
expressed in an end4 mutant, grown at a non-restrictive temperature, is capable of
being both immuno-precipitated and detected on Western blots by an antibody
specific to ubiquitin. The appearance of this Ste6p species indicated that Ste6p most
likely exists as a multiubiquitinylated protein. In addition Ste6p was found to be
stabilised approximately 3-fold in a strain of yeast deficient in two ubiquitin
conjugating enzymes, Ubc4p and Ubc5p. These enzymes have been implicated in the
turnover of short lived and abnormal proteins (Seufert and Jentsch, 1990; Rolling and
Hollenberg, 1994a). Thus it would appear that Ste6p can exist in a ubiquitinylated
form and that the ubiquitinylation of Ste6p acts as a degradation signal.
It is possible that Ste6p is degraded by two independent pathways, both by the
vacuole and by a cytosolic ubiquitin-dependent pathway. In this case the majority of
Ste6p would be degraded in the vacuole, with the Ubc4p and Ubc5p-dependent
pathway being utilised in a situation where the vacuole is overloaded or blocked.
Alternatively the ubiquitinylation of Ste6p may be acting as a signal to direct Ste6p
into the vacuolar degradation pathway. Recent research (Rolling, 1996) has indicated
that Ste6p is stabilised by the removal of a putative ubiquitin binding domain.
Removal of this domain prevented the Ubiquitinylation of Ste6p and resulted in a shift
in the cellular distribution of Ste6p towards the plasma membrane. The
ubiquitinylation of Ste6p may therefore play an important role in the endocytosis of
Ste6p by labelling the protein for internalisation and transfer to the vacuole. Findings
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from studies conducted on the ligand stimulated endocytosis of Ste2p-a-factor
complexes from the plasma membrane support this notion. The ubiquitinylation of
Ste2p is stimulated by the binding of a-factor to the receptor and has been shown to
be required for the endocytosis of the receptor ligand complexes (Hicke and Riezman,
1996). Hicke and Riezman (1996) propose that the ubiquitinylation of Ste2p mediates
the degradation of the receptor-ligand complexes, not via the proteasome, but by
acting as a signal for endocytosis leading to subsequent degradation in the vacuole. A
schematic representation of the ubiquitin-mediated degradation of Ste6p is given in
Figure 1.9.
c) Possible roles for the rapid turnover of Ste6p
Since Ste6p is an a-type specific protein it must be capable of being rapidly cleared
from the cell surface immediately following mating. In addition S. cerevisiae is
capable of switching mating-type via interconversion of theM4riocus, necessitating
the rapid removal of cell-type specific proteins. Thus the continuous turn-over of
Ste6p provides a mechanism by which the cell can constantly monitor and modulate
the protein level as required. The pheromone receptors Ste2p and Ste3p are rapidly
endocytosed from the plasma membrane inferring that this might be a common feature
of cell-type specific proteins involved in the mating process (Davis et al., 1993).
As previously discussed the yeast endocytic pathway is thought to be responsible for
the internalisation of Ste6p. Endocytosis may also play a role in the courtship phase of
the mating of S. cerevisiae by concentrating Ste6p, and therefore a-factor, at the
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projection tip. The role of Ste6p in the courtship behaviour of S. cerevisiae is further
discussed in 1.12.
Figure 1.9 The Ubiquitinylation and degradation of Ste6p
Ubiquitinylation of Ste6p acts as a degradation signal. Ubiquitin is represented by
the small green box. Details of the trafficking of Ste6p are as indicated in Figure 1.8.
The model depicts Ste6p becoming ubiquitinylated in a UBC4, UBC5 dependent
manner. The ubiquitinylated Ste6p is internalised from the membrane in an END4
dependent manner and enters the endocytic pathway. The ubiquitinylated Ste6p is
then targeted for degradation either in the vacuole or in an ATP-dependent protease
complex, the proteasome.
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1.11 Ste6p and a-factor export
The experiments discussed in 1.10 indicate that Ste6p is located at the plasma
membrane for a transient period only with the majority of Ste6p being localised in
intracellular vesicles. This is surprising considering the supposed role of Ste6p in the
export of a-factor which is generally thought to occur when a-factor molecules,
partitioned in the plasma membrane by virtue of their hydrophobic modifications,
encounter Ste6p which exports them into the extracellular environment. (McGrath
and Varshavsky, 1989).
It has been suggested (Rolling and Hollenberg, 1994a) that Ste6p may function in the
intracellular accumulation of a-factor rather than in the direct transportation of a-
factor across the plasma membrane. In this scenario Ste6p would function to
sequester mature a-factor into intracellular vesicles. The contents of the vesicles
would be released on fusion with the plasma membrane leaving Ste6p in a position to
be internalised and transported to the vacuole. This model would provide a
mechanism without the requirement for Ste6p to be resident largely at the plasma
membrane. It would also explain why Ste6p appears to accumulate in intracellular
compartment before it becomes associated with the plasma membrane. However this
model does not provide a mechanism by which the, presumably plasma membrane
associated, a-factor molecules would be trafficked to the Ste6p vesicular
compartment. In addition the export of a-factor is not thought to involve vesicular
intermediates as its secretion occurs despite blocks imposed by various secretory
mutants (McGrath and Varshavsky, 1989). Studies have shown that pro-a-factor is
not sequestered into vesicles as it is not protected from degradation by proteases
(Kuchler et al., 1989; Sprague and Thorner, 1992) however a large fraction of a-
factor is degraded in the vacuole ofMATn cells suggesting that mature a-factor is
actually capable of entering the endosomal pathway (Rolling and Hollenberg, 1994a).
Figure 1.10 proposes a model for the maturation and secretion of a-factor in which
the a-factor maturation machinery and Ste6p are located within the same vesicular
compartment. In this model immature a-factor becomes associated with the membrane
located maturation machinery following COOH-terminal processing in the cytosol. On
maturation the a-factor is transported into the vesicle by the action of Ste6p where it
is accumulated until it is released by the fusion of the vesicle with the plasma
membrane. The requirement for components of the yeast secretory pathway could be
removed if a-factor is secreted by a different type of vesicular transport than normal
secretory proteins. If, for example, the intracellular vesicular compartment were
derived from the plasma membrane by endocytosis the homotypic fusion necessary for
a-factor release could occur without the involvement of the yeast secretory pathway.
Both of the models described above provide a mechanism by which the requirement of
Ste6p at the plasma membrane is minimal, thus providing an explanation as to how
Ste6p can function effectively in the export of a-factor during its transient visit to this
site. Further work is required to determine the precise cellular location of Ste6p and
a-factor interaction and a-factor maturation. This could prove problematical due to
the unstable nature and poor detectablility of both Ste6p and a-factor.
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The intracellular accumulation of a-factor by Ste6p. The trafficking and
representation of Ste6p are as previously indicated, a-factor molecules are shown in
pink. In this model immature a-factor associates with membrane associated
maturation machinery (green sphere) following COOH-terminal processing in the
cytosol. Mature a-factor is sequestered into intracellular vesicles by the action of
Ste6p. The vesicles dock at the plasma membrane releasing a-factor into the
extracellular environment. Ste6p is rapidly internalised from the plasma membrane
via the endocytic pathway.
1.12 Ste6p, partner discrimination and cell fusion in S. cerevisiae
Mating between the two haploid cell types of S. cerevisiae is dependent upon the
efficient secretion and delivery of a and a-pheromones to their respective target cells.
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It is thought that the level of a and a factor secreted by M4 7a and MATa cells,
respectively, acts as the primary determinant of each haploid cell's identification as an
appropriate mating partner by the target cell. This section discusses how both the
pheromones and their representative receptors are thought to mediate partner choice
in S. cerevisiae. It also discusses the evidence that indicates that Ste6p is directly
involved in both partner selection and in the final stages of diploid cell formation
a) Pheromones, pheromone receptors and courtship in S. cerevisiae
In addition to stimulating the signal transduction pathway the pheromones and their
receptors play an important role in mate selection in yeast. Cells which are unable to
produce pheromone are sterile (Kurjan 1985, Michaelis 1988) as are those cells
deficient in the cell-type specific receptors encoded by STE2 and STE3 (MacKay and
Manney 1974a; 1974b; Hagen et al., 1986). Immediately prior to sexual conjugation
haploid cells of S. cerevisiae preferentially choose their sexual partners following the
production and response to each others pheromone in a process termed "courtship"
(Jackson and Hartwell 1990a; 1990b). Jackson and Hartwell demonstrated that, when
faced with a choice of partner, both haploid cell types preferentially choose a partner
which is producing the highest level of pheromone. This observation implicates the
involvement of the pheromone receptors in partner discrimination and is in agreement
with the observation ofBender and Sprague (1989) and Jackson et al, (1991).
Browne et al, (1996) produced a series of Ste6p mutant molecules which differed
from wild-type molecules only in their ability to transport a-factor. They found that
there was a positive correlation between the level of transported a-factor and the
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efficiency of mating. They also showed that, under conditions in which the level of a-
factor is limiting for yeast mating, small changes in the amount of pheromone
transported caused large changes in the mating efficiency. These observations are in
agreement with the studies of Jackson and Hartwell (1990a; 1990b) and indicate that
MATcl cells can efficiently discriminate between small differences in the level of a-
factor presented byMATu cells.
b) Ste6p and mate choice in S.cerevisiae
The sterile phenotype ofMATst cells containing null mutations in bothMFal and
MFal can be relieved, in part, by the addition of exogenous a-factor. In contrast the
addition of exogenous a-factor is unable to restore mating mMATu cells which
contain a ste6 null mutation. This suggests that Ste6p can interact with the exogenous
a-factor and that this interaction is required for recognition byMATol cells (Marcus et
al, 1991). It is plausible therefore that a Ste6p-a-factor interaction occurs at the cell
surface and that this interaction is necessary for recognition by the iSTFi-encoded a-
factor receptors on the surface ofMATa cells (Nahon et al., 1995).
c) Ste6p localisation and a-factor transportation during mating ofS.cerevisiae
Stimulation of S. cerevisiae by high levels of the appropriate mating pheromone
results in asymmetric growth and the formation of a projection or shmoo. (1.4;
Sprague and Thorner, 1992). The orientation of cell growth responds to the gradient
of pheromone such that the mating projection points to the nearby partner (Jackson
55
and Hartwell 1990a and 1990b). The tip of the projection is the actual site of
conjugation where the two haploid cells fuse to form a zygote. Indirect
immunofluorescence studies onMA Ta cells exposed to a-factor cells has shown that
the majority of cellular Ste6p becomes located at the tip of the projection (Kuchler et
al., 1993; reviewed in Kuchler et al., 1992). The localisation of Ste6p at the
projection tip may be a result of constitutive endocytosis of older Ste6p molecules,
combined with a pheromone-induced increase in the synthesis of new Ste6p, all of
which goes to the projection tip (Berkower et al., 1994). a-factor induced expression
ofSTE6, MFal andMFa2 coupled with the localisation of Ste6p at the projection tip
would be expected to result in a dramatic increase in a-factor concentration at this
site. The high concentration of a-factor at the tip of the projection may be maintained
by the hydrophobicity and poor diffusibility of the molecule. As the tip of the
projection is the actual site of cell fusion it is possible that the localised secretion of a-
factor at this site is required for effective courtship and partner selection. Ste6p may
be critical for the establishment and/or maintenance of the polarity in a-factor
secretion that is required for effective courtship and partner selection. This would
explain why the presence of Ste6p is essential for mating even when its role as an a-
factor transporter has been removed by the addition of exogenous pheromone. The
pheromone receptors, like Ste6p, become concentrated at the projection tip during
mating (Davis et al., 1993). The projection tips can therefore be considered as
specialised organelles that would be highly enriched for signalling and signal
reception. The close contact between two mating cells should therefore create an
environment of very high concentration of pheromone and pheromone receptors. It
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can be envisioned that this would create the very environment necessary for courtship
and partner discrimination to occur.
d) Ste6p, a-factor and cell fusion
Studies onMATu cell specific mutants which are deficient in the ability to carry out
cell fusion have shown that both high levels of a-factor and Ste6p are required for this
final phase ofmating to occur (Elia and Marsh, 1996; Brizzio et al., 1996). Two
MATu specific cell fusion mutants, fus5 and fus8 were shown to produce less a-factor
than an isogenic wild-type strain, and the mutations were found to be allelic with two
genes known to be required for a-factor biogenesis, namely AXL1 and RAMI. Several
experiments have demonstrated that it is the partial defect in a-factor production,
created by mutations in these genes, that causes the fusion defective (Fus") phenotype.
First the overexpression of a-factor was found to be capable of suppressing the Fus"
phenotype. Second, slMATcl sst2A. strain that is more sensitive to a-factor suppressed
the Fus" phenotype in trans. Finally, reduced levels of wild-type a-factor from a
repressible promoter were shown to produce a cell fusion defect identical to that
observed in the fus5 and fus8 mutants. It would appear that thefns5 and fns8 mutant
strains are capable of producing enough a-factor to trigger the early stages of the
mating process (cell cycle arrest, shmoo/ projection formation and mating pair
formation) but cannot reach the levels required to elicit the cell fusion response in
partner a cells. Similar experiments conducted onMATa cells have shown that cells
secreting lower levels of a-factor have appreciable cell fusion defects. Thus it would
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appear that high levels of pheromone are required as one component of the signal for
prezygotes to initiate cell fusion (Brizzio et al., 1996).
Screens for mutants of S. cerevisiae that were defective in cell fusion (Cef)
uncovered three partial-function alleles ofSTE6 which elicited a substantial mating
defect (Elia and Marsh, 1996). The ste6(cefl-l) allele was recovered, sequenced and
found to contain an amber stop codon which was predicted to truncate Ste6p at
amino acid residue 862. It was unclear however whether the phenotype was the result
of underexpression of Ste6p, or of the expression of a mixture of truncated and
functional forms of the transporter. The ste6(cefl-l) mutant was found to be capable
of secreting a-factor and inducing many mating responses in uMATa strain. Electron
microscopy ofMA 7 a ste6(cefl-l) and MA 7a wild-type mating pairs revealed that the
mating process had become arrested at a late stage of conjugation in which the fusion
wall remained intact. Close examination of the mating pairs revealed that many of the
early mating functions remained intact, indicating that there had been adequate
pheromone present to stimulate the pheromone response pathway. Mating the
ste6(cefl-l) with &MATa sst2 strain had no effect on alleviating the defect in fusion
wall degradation indicating that the ste6(cefl-l) defect was not due simply to a lack
of pheromone secretion. In addition the overexpression of a-factor in the ste6(cefl-l)
strain resulted in an increase in the level of a-factor secretion but did not suppress the
mating fusion defect. The results of this study would suggest that Ste6p may be
playing a role in cell fusion distinct from its role in a-factor transport. It is conceivable
that Ste6p has an additional role as a regulatory protein that functions, either directly
or indirectly, in the activation of the cell fusion machinery. Other members of the
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ABC-transporter superfamily have been found to have additional roles in the
regulation of heterologous channels, and other membrane proteins as well as carrying
out their own transporter/ channel activities (reviewed in Higgins, 1995).
The findings discussed above indicate that Ste6p may be instrumental to the processes
of partner selection and cell fusion in addition to its role as the a-factor transporter. A
model providing a mechanism for the actions of Ste6p in partner discrimination is
discussed in Nahon et al., 1995. They propose that Ste6p and a-factor interact at the
cell surface and that it is this a-factor-Ste6p complex which interacts with Ste3p
receptors on the a-cell surface. This would provide direct cellular contact for
courtship. They also propose a role for a-propeptide in the mating process by
suggesting that exhibition of the molecule at the cell surface could act as a signal to
signify cell quality during courtship. Like the a-factor-Ste6p conjugate, the a-
propeptide would interact with Ste3p receptors on the surface ofMATn cells. In both
scenarios the cells would be brought into close contact by the interaction of the
receptor on one cell surface binding with the pheromone attached to the opposite cell
surface. This model might explain in part why the presence of Ste6p is required in the
final stages of the mating process.
1.13 Structural requirements for a-factor bio-activity and recognition by Ste6p
The mature form of a-factor consists of three structural components, the methyl
moiety, the lipid moiety and the amino-acid backbone (Figure 1.5) all of which are
candidates for the recognition of a-factor by Ste6p and Ste3p. Studies on the
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significance of the C-terminal modifications of a-factor have shown that both the
farnesyl and methyl ester groups are required for export and biological activity
(Schafer et al., 1989; Schafer et al., 1990; Marcus et al 1990). The removal of either
the farnesyl or methyl group leads to a 100 times reduction in a-factor bioactivity,
when compared to correctly modified pheromone, indicating that the methylation and
farnesylation of a-factor are essential for its interaction with Ste3p (Marcus et al.,
1991). Likewise yeast defective in farnesyltransferase and methyltransferase activity,
encoded by RAMHRAM2 and STEM respectively, are unable to produce extracellular
a-factor indicating that these a-factor modifications are essential for the interaction
with Ste6p (Schafer et al., 1989; Schafer et al., 1990; Sapperstein et al 1994). It is
presumed that the lack of the farnesyl moiety prevents a-factor from associating with
cell membranes thus impeding its interaction with either the Ste6p transporter or the
Ste3p receptor. The methyl-moiety is thought to promote protein-protein interactions
between a-factor and Ste3p/Ste6p. (Sapperstein et al., 1994). The contribution made
by the amino-acid backbone to the recognition of a-factor by Ste3p/Ste6p is thought
to be minimal and is further discussed in Chapter 6.
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Part 4
Outline of the project
1.16 Study of the interaction of Ste6p
The aim of this project was to study the interactions between Ste6p and a-factor by a
combination of biochemical and genetic techniques. The biochemical approach was
centred on the purification of Ste6p from an over-expressing strain ofS.cerevisiae. In
the absence of a functional assay for Ste6p a polyclonal antibody was to be raised
against the C-terminal domain of Ste6p to allow detection.
Further initial aims included the reconstitution of Ste6p into phospholipid vesicles in
order to allow the kinetics of its interaction with a-factor to be determined.
A genetic, or in vivo, approach to studying the interaction between Ste6p and a-factor
was to be undertaken in which a-factor molecules, mutagenised at random over their
amino-acid backbone, would be screened for their ability to interact with and block
the Ste6p pump. The isolation of such a-factor molecules would allow the





2.1 Chemicals, antibodies and enzymes
Chemicals were generally obtained from either BDH Chemicals, Sigma
Chemical Co., or Fisons Ltd. The Sequenase II DNA sequencing kit and
[a-^SJATP (>600Ci/mmol) were obtained from Amersham International pic.
The majority ofDNA manipulation enzymes e.g. restriction endonucleases,
ligase, and VENT polymerase were obtained from New England Biolabs. Taq
polymerase was purchased from Promega. Gel solutions for DNA sequencing
were purchased from Hybaid. DNA purification kits for the preparation of high
quality DNA (plasmid or M13) were purchased from Qiagen. Oligonucleotides
were purchased from Oswell. The NiNTA resin for nickel affinity
chromatography was also purchased from Qiagen. IgG Sepharose was from
Pharmacia. Hybond C-extra for Western Blotting and the Enhanced
Chemiluminescent (ECL) detection kit were supplied by Amersham. HRP
antibody conjugates were gifted by the Scottish Antibody Production Unit
(SAPU). Poly prep columns were from Bio Rad. Polaroid and X-ray film were
obtained from Genetic Research Instrumentation. Media components were from
Difco Laboratories. Protein sequence analysis was carried out by the Welmet
Protein Characterisation Facility, University of Edinburgh. The Bead-beater was
from Stratech Scientific LTD.
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Subunit M39 of the bovine adrenal chromaffin granulae ATPase, N-terminally
tagged with 10 histidine residues was gifted by D.K Apps (Edinburgh). The
gene encoding this protein was originally cloned by Wang et al., (1988). The
histidine tagged variant was constructed by Leonora Cuifo and expressed and
purified by Lorna Webster in the Biochemistry Department at the University of
Edinburgh.
2.2 Bacterial and yeast strains
Strains ofif. coli and S. cerevisiae used in this study are listed in Tables Al and
A2 respectively.
2.3 Plasmids.
Plasmids used in this study are listed in Table A3.
2.4 Media
In general all E.coli cultures were grown in Luria Broth (LB) consisting of 1%
(w/v) Bacto Tryptone, 0.5% (w/v) Bacto yeast extract and 0.5% (w/v) NaCl.
Bacto agar was added at a concentration of (2% (w/v) to make plates and at
0.8%(w/v) for making top agar. Antibiotics were added to a final concentration
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of 15pg/ml as necessary. For blue/white colony selection the media were
supplemented with 15pM 1PTG and 0.005% X-gal.
For the preparation of uracil-containing single-stranded DNA the E.coli strain
CJ236 was grown in 2xYT media which contains 1.6% (w/v) Bacto Tryptone,
1% Bacto yeast extract and 0.5% NaCl. Bacto agar was added at a
concentration of 2%(w/v) to make plates and 0.8% (w/v) for top agar.
Bacterial strains NM522 and CJ236 were kept on M9 minimal plates to
maintain the F' genotype. The medium was made as follows: 2%w/v Bacto agar
and 0.4% glucose were autoclaved and left to cool to 40-50°C. 100X additive
(0.1M magnesium sulphate and 0.01M calcium chloride) and 10X M9 salts (7%
(w/v) sodium phosphate (dibasic), 3% (w/v) potassium phosphate (monobasic),
0.5% (w/v) NaCl, 1% (w/v) ammonium chloride) were added to a final
concentration of IX and this was supplemented with 0.0002% thiamine. For
maintenance ofCJ236, chloroamphenicol was added to the medium at a
concentration of 15p.g/ml
Yeast cultures were grown in either rich medium (YPD; containing 1% (w/v)
Bacto yeast extract, 2% (w/v) Bacto peptone and 2%(w/v) glucose) or minimal
(selective) medium (SD; containing 0.67% Bacto yeast nitrogen base without
amino acids and either 2% (w/v) glucose, 2% (w/v) mannose or 2% w/v
raffinose as a carbon source. Amino acids and bases were added as required to a
final concentration as follows; histidine (20pg/ml), leucine (30p.g/ml),
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tryptophan (20p.g/ml), uracil (20pg/ml) adenine (20pg/ml). Yeast strains
auxotrophic for tryptophan, due to the presence of plasmid DNA, were
maintained on SD medium containing 1% casamino acids and uracil (20jig/ml).




DNA manipulations such as restriction endonuclease digestion, ligation,
mutagenesis using the Kunkel method, purification from host organisms and
treatment with CIP were carried out as described in Sambrook et al., (1989).
DNA was separated by electrophoresis through 0.4-1% (w/v) agarose gels.
Fragment size was estimated by comparison with standard markers, typically
digests of phage X DNA withHindlll or BstEll or the commercially available
lKbp ladder (Gibco BRL).
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2.6 Purification of DNA
Double and single-stranded DNA was purified from host bacteria according to
either the methodology of Sambrook et cil, (1989) or by use of Qiagen kits for
mini preparations, midi preparations, Ml3 purification and band purification of
DNA from agarose gels. The production and purification of single-stranded
DNA from phagemid vectors is detailed below. Yeast genomic DNA was
purified either according to the method below or, by using a kit from Igl.
a) Production of single-stranded DNA from phagemid vectors using the
M13K07 helper phage
Single stranded DNA was isolated from E. coli transformed with a phagemid
vector pVT103-U (AmpR) containing the gene of interest (e.g. MFal). 50pi of
an overnight culture of transformed E. coli strain BW313 or CJ236 (Table Al)
was inoculated into 5 ml TBG (1.2% w/v tryptone, 2.4% w/v yeast extract,
0.4% v/v glycerol, 17mM KH2P04, 55mM K2HP04 and 20mM glucose)
supplemented with ampicillin. A 20pl aliquot ofM13K07 helper phage at 1011
plaque forming units (pfu)/ ml was added to the culture. The culture was then
incubated, with agitation, at 37°C and 275rpm for 2 hours. Kanamycin was then
added to the culture at a concentration of75pg/ml and the culture was
incubated, as before, for a further 22-24 hours. The culture supernatant was
harvested by centrifugation at 14krpm for 10 min at 4°C in a microfuge. This
centrifugation step was repeated and the single-stranded DNA was purified
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from the supernatant either by use of a Qiagen kit or by the methodology
detailed in Sambrook et al., 1989; Lin et al., 1992; Vernet et al., (1987).
2.7 DNA Sequencing
Double-stranded plasmid DNA for sequencing was prepared from the bacterial
strain DH5a using Qiagen mini or midi preparation kits. These gave very high
quality sequencing-grade DNA. The Sequenase version 2.0 kit (USB) was used
for all sequencing reactions. Double-stranded DNA was sequenced using either
the method ofHsiao (1991) or the method noted below:
1. To 8pi (5-1 Oug) DNA add: lpl primer (lOng/pl)
lp.1 lMNaOH
2. Incubate for lOmins at 68°C (during this interval it is convenient to thaw
termination mixes (ddNTPs) and to prepare the labelling mix).
3. Add: 4pl TDMN





dd H20 to 50ml
pH 1.6
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4. Incubate for 10 min at room temperature. The reaction mix may be stored on
ice until ready to use.
Add: 4pl labelling mix
1 pi DTT (In sequencing kit)
0.4pl 5x Sequenase labelling mix
2.1 pi TE (3mM Tris, pH7.5, 0.2mM EDTA)
0.5pi [a35S]ATP
2p T7 DNA polymerase (Sequenase) diluted 1:5 with enzyme
dilution buffer
6. Incubate for 5 min at room temperature. It is convenient to pre-warm the
termination mixes at this point (aliquot 2.5pl of each into separate
microfuge tubes and incubate at 37°C).
7. Add 4pl of the labelling reaction to each termination reaction
(A,C,G,T) pre-warmed for 5 min at 37°C.
8. Incubate for 10 min at 37°C.
9. Add 5pi of stop buffer to each reaction.
10. Boil reaction mixtures for 2 min before loading 3pi on to a 6%
polyacrylamide gel.
Ml3 single stranded DNA was purified from NM522 culture supernatants using
standard protocols (Sambrook et a/., 1989). Sequencing reactions were carried
out using the instructions supplied with the Sequenase Version 2.0 kit (USB).
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The products of the sequencing reactions were separated on either 0.2-0.7mm
wedge gels or 4mm standard 6% polyacrylamide gels using pre-made solutions
as detailed in 2.1.
2.8 Polymerase Chain reaction (PCR)
PCR extensions were carried out using a Techne thermal cycler. Both VENT
and Taq polymerases were used. VENT was preferred to Taq as Taq is prone to
making errors as it lacks VENT's proof-reading ability. The reactions were
carried out in lOOpl volumes with typically 20pmol of each primer, lng
template DNA and 50pM of each dNTP (VENT requires 200-400 pM of each
dNTP). The reactions were buffered using the buffers supplied with the enzyme.
The magnesium concentration was optimised for each reaction and was usually
in the region of 2-6mM. The reaction mixtures were overlaid with 50pl of
mineral oil. A typical programme would be as follows:
Denaturation 95°C for 1 min
Primer Annealing 5°C below the true Tm of the amplification primers
for 1 min
Primer extension 72°C extension time is calculated from the reaction
proceeding at lkb per min
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In general 30 cycles were performed followed by a final extension of 10 min at
72°C.
Typically 5pl of PCR product was analysed on an agarose gel before being
purified either by phenol/chloroform extraction and ethanol precipitation or by
use of the appropriate Qiagen kit.
2.9 Cloning PCR products
In general PCR products were cloned into the appropriate vector following
digestion with the appropriate restriction endonuclease. If this was not
successful the pGEM-T vector system from Promega was employed. Essentially
this utilises the fact that Taq-derived PCR products have overhangs consisting
of dATP that are added by the terminal transferase activity of Taq. The pGEM-
T vector has a T overhang which allows for the ligation of the A-overhang PCR
product. Unfortunately VENT polymerase does not add terminal adenosine,
however this can be overcome by treating a VENT-derived PCR product as
follows: Phenol/chloroform extract and precipitate the DNA with two volumes
of isopropanol. Resuspend in Taq buffer and add 1 unit of Taq DNA
polymerase and 200p.M dATP. Mix and incubate at 72°C for 20 min. The
pGEM-T cloning system can now be employed. The PCR fragment can be
subcloned into the appropriate vector as required.
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2.10 Oligonucleotide-directed mutagenesis
Oligonucleotide-directed mutagenesis was carried out according to the Kunkel
method as detailed in Sambrook et al., 1989. This methodology is discussed in
greater detail in Chapter 3.
2.11 Preparation of genomic DNA from yeast
Genomic DNA was prepared from BJ5465 as follows: 5ml of yeast was grown
up overnight in YEPD. The following day the cells were harvested in a
microfuge (20,000g, 30 sec) and resuspended in 200pl of the following: 2%
Triton X100, 1% SDS, lOOmM NaCl, 10mM Tris pH 8.0, ImM EDTA. To this
lOOp.1 phenol and lOOpl 24:1 chloroform: isoamyl alcohol was added along with
300mg of glass beads. The mixture was then vortexed for 2 min before
centrifugation for 5 min at 20,000g. The upper aqueous layer was removed and
the DNA precipitated by the addition of 2.5x volume of ethanol plus O.lx
volume 3M sodium acetate pH5.2. The precipitated DNA was harvested by
centrifugation at 20,000 for 20 min and resuspended in 20pl TE. The DNA
could now be used as a template for PCR amplification reactions.
In later experiments the Igl Yeast Genomic DNA kit was utilised. This enabled
high quality DNA to be purified in 30 min.
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2.12 Transformation of bacterial and yeast cells
Bacterial cells were made competent by treatment with CaCl2 and transformed
as detailed in Sambrook et al., 1989. Yeast were transformed following
treatment with LiOAc according to the method of Geitz et al., 1992.
Protein methods
2.13 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Proteins were separated by electrophoresis through a 5% acrylamide stacking
gel followed by a 7.5-12% acrylamide separating gels according to the basic
method of Laemmli (1970). For routine analysis the Hoefer "tall mighty small"
gel apparatus was used. A Bio-Rad "Protean II" apparatus was employed when
larger gels were required (e.g. for band purification of proteins). The following
reagents were used:
1. Separating gel buffer
0.75M Tris.HCl pH8.8, 0.2% (w/v) SDS
2. Stacking gel buffer
0.25M Tris.HCl pH6.8, 0.2% (w/v) SDS
3. Acrylamide solution
44% (w/v) acrylamide, 0.8% (w/v) N N'-methylene-bisacrylamide.
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4. Electrophoresis Buffer
0.125M Tris.HCl., 0.2M glycine, 0.1% (w/v) SDS. The pH is 8.3 without
adjustment.
5. SDS sample buffer
0.0625M Tris.HCl pH6.8, 20% glycerol, 4% (w/v) SDS, 5% (w/v) (3-
mercaptoethanol.
Separated proteins were visualised by staining with either Coomassie Blue R-
250 or by Silver staining as follows:
(a) Coomassie Blue staining
Gels were stained by soaking in a solution of 0.25% (w/v) Coomassie Brilliant
Blue dissolved in 50% (v/v) methanol, 7% (v/v) acetic acid for approximately
15 min. Excess stain was removed by rinsing the gel in distilled water. The gels
were then destained in a solution of 10% (v/v) methanol, 7% (v/v) acetic acid
until bands could be clearly visualised.
(b) Silver staining
This method is based on that ofWray et al., 1981. SDS-PAGE was carried out
as above. Gels were fixed in a 50% methanol, 10% acetic acid solution for 20
min or overnight. The gels were then soaked in 50% methanol for 1 hour and
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washed in water for 5 min. This step was repeated two more times. The
following solutions were then prepared:
A) 0.4g silver nitrate dissolved in 2ml H20.
B) 21ml of 0.36% NaOH, 1.4ml ammonia (14.8M)
C) add solution A drop-wise to B stirring constantly. The solution
should be clear. Make up to 100ml with H20.
D) mix 2.5ml of a 1% (w/v) citric acid solution with 0.25ml
Formaldehyde (38% stock). Make to 500ml with H20.
E) 50% (v/v) methanol, 10% (v/v) acetic acid.
F) 3.7g NaCl, 3.7g CuS04.5H20 in 85ml H20. Add ammonia until
solution becomes deep blue. Make up to 100ml with H20.
Gels were stained with solution C for 15 min and then washed in H20 for 5 min.
The gels were then soaked in solution D for 5-15 min until protein bands could
be seen. The development was stopped by adding solution E. If the gel was
over stained solution F was added to destain.
2.14 Transfer of proteins onto nitrocellulose
Proteins were transferred onto a nitrocellulose filter (Hybond C extra




Anode buffer 1: 0.3M Tris.HCl, 20% (v/v) methanol, 0.1% SDS
pH10.4
Anode buffer 2: 25mM Tris.HCl, 20% (v/v) methanol, 0.1% SDS
pH10.4
Cathode buffer: 25mM Tris.HCl, 20% (v/v) methanol, 0.1% SDS,
40mM 6-amino-N-hexanoic acid pH9.4.
The proteins were separated by SDS-PAGE as usual. Six pieces ofWhatman
3MM filter paper and one piece of nitrocellulose membrane were cut to the
same size as the gel. Two pieces of filter paper were soaked in buffer 1, one in
buffer 2 and three in the cathode buffer. The gel was soaked in cathode buffer
and the nitrocellulose in H20. The above components were then layered onto
the anode plate as follows: first the two pieces of anode 1-soaked paper, then
the piece of anode 2, then the nitrocellulose filter followed by the gel and finally
the three pieces of cathode buffer-soaked paper. The cathode plate was placed
on top and a current of 0.8mA X [area of geljcm^ was applied for one hour.
2.15 Detection of proteins by Western blot analysis
Proteins were transferred onto nitrocellulose as described in section 2.13. The
nitrocellulose strip was then incubated for at least one hour in blocking buffer
(TBST (lOrnM Tris.HCl pH7.4, 150mM NaCl,l% (v/v) Tween-20) plus 5%
(w/v) "Marvel" (non-fat dried milk powder) to block any non-specific sites to
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which antibody molecules might bind. The strip was then placed in fresh
blocking buffer and the primary antibody applied at the suitable dilution in
blocking buffer for the appropriate period of time (normally 20 min to
overnight). The blot was then washed four times (IX 10 min followed by 3X 5
min) in TBST to remove excess antibody. The strip was then placed in fresh
blocking solution with the secondary antibody. This was usually a donkey anti-
rabbit HRP conjugate applied at a dilution of 1: 5,000 for 20 min. The strip was
then washed as before, then developed with either the Enhanced
chemiluminescence (ECL) detection system (Amersham) according to
manufacturers directions, or latterly using the method detailed below which
essentially follows the same principles. All washes and incubations were carried
out with gentle agitation.
Stock solutions:
Luminol (Fluka) stock of 250 mM in DMSO. Stored in the dark at -20°C.
p-coumaric acid (Sigma) stock of 90mM in DMSO stored as above.
Solution 1: 1 ml luminol; 0.44ml coumaric acid; 10ml of 1M Tris pH 8.5
in 100 ml distilled E^O.
Solution 2: 64pl 30% H2O2; 10ml of 1M Tris pH 8.5 in 100 ml
distilled H2O.
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Solutions 1 and 2 were stored at 4°C. To develop a 50cm2 strip 2 ml of
solution 1 was mixed with 2 ml of solution 2 and applied to the blot for 1 min.
The blot was then removed from the solution and excess moisture removed by
blotting with a tissue. The strip was then placed between two pieces of Saran
Wrap (Dow) and exposed to a piece of blue sensitive X-ray film which was
subsequently developed in an automatic processor.
2.16 Lysis and fractionation of bacterial cultures
Cells were harvested by centrifugation (5 min at 5000rpm in a Hareus
Centrifuge), washed once in lOOmM Tris.HCl (pH7.4) and resuspended in an
appropriate volume (usually 5-10ml) of the same buffer. Lysozyme was then
added to a concentration of lmg.ml"! and the cells were incubated for 20 min.
Cell lysis was achieved by sonication for 4 bursts of 30 seconds interspersed
with 1 min cooling intervals on ice. The lysate was centrifuged at 3000rpm for 5
min to give the P3 (inclusion) body fraction, the supernatant was then further
centrifuged at 20,000rpm for 20 min to give a soluble fraction (S20) and an
insoluble fraction (P20)
2.17 Glass bead lysis and preparation of membranes from S. cerevisiae
Cells were harvested by centrifugation for 5 min at 5000rpm (in a Hareus
centrifuge) and washed once in 200mM Tris.HCl (pH8.5). The cell pellet was
then weighed and resuspended in 2X volume 200mM Tris.HCl (pH8.5)
77
(protease inhibitors were added at this stage if required). Glass beads (0.45-
0.6mm diameter) were added to the meniscus of the suspension and lysis was
achieved by vigorous vortexing for three 2 min intervals interspersed with 2 min
cooling on ice. The homogenate was then resuspended to 7.5X lysis volume
with 200mM Tris.HCl (pH8.5) and centrifuged for 5 min at l,000rpm
(centrifuge) to remove unbroken cells and glass beads. The supernatant was
recentrifiiged as above as a further clearing spin. The cell membranes were then
collected by centrifugation of the cleared lysate at 100,000 rpm for 20 min in a
Beckman TL100 using the TLA100.3 rotor. The soluble, S100, fraction was
then removed and pellet, PI00, was carefully resuspended in 100-300ml 200pM
Tris.HCl (pH8.5) and homogenised until a uniform solution was produced.
On occasion the breakage of large quantities of yeast cells was achieved by the
use of a Bead-Beater (Stratech Scientific LTD) according to manufacturers
instructions.
Preparation ofprotease inhibitors:
The 5X mix contained 20mM EDTA, 20mM EGTA, 20mM PMSF and
lOpg.ml'l each of pepstatin, leupeptin, chymostatin and antipain. The following
stocks and the 5X mix were aliquoted and stored at -20°C.
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perml 5X
PMSF 200mM in isopropanol
pepstatin lmg.ml in methanol
lOOpl
lOpil
antipain lmg.ml" in water lOpl
leupeptin ling.ml"1 in 3:1 MeOH:DMSO lOpl
chymostatin lmg.ml in 3:1 MeOH:DMSO 10p.l
2.18 Purification of a-factor on Amberlite XAD-2
The following purification method was taken from Strazdis and MacKay (1982)
and Proteau etal., 1990.
a) Preparation ofXAD-2.
Amberlite XAD2 resin was washed in several times in distilled H20. The resin
was then incubated with gentle agitation for 3 hours at 40°C in 6 volumes of
1.2 dichloropropane: 1-propanol (1:3). The resin was then further incubated for
3 hours with gentle agitation at 40°C in 6 volumes of 1-propanol. The resin
could then be stored at room temperature until needed or washed well in
distilled water and autoclaved. At no point was the resin allowed to go dry.
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b) Addition ofXAD-2 to growth media.
An appropriate yeast culture (in this case BJ5465(pAMB8)) was inoculated into
selective media and grown overnight shaking at 30°C. The following day the
overnight culture was diluted into fresh medium to give an Agoo of 0.1. At this
point 100ml of autoclaved XAD-2 was added per litre of culture. The culture
was then grown, shaking, at 30°C for 24 hours.
c) Removal ofa-factorfrom XAD-2.
The resin was retrieved by decanting off the growth medium and washing the
resin several times with distilled H20. The XAD-2 was then washed in 40%
methanol at 40°C for 2 hours. The methanol was then removed by aspiration
and the resin resuspended in 3 volumes of 1-propanol and incubated, shaking,
for 2 hours at 40°C. The propanol containing a-factor was then removed by
aspiration and rotary evaporated to dryness at 55-60°C. The resulting orange/
brown residue was then dissolved in a minimal quantity ofDMSO, aliquoted
and stored at -20°C until required. It was found that a-factor stored like this
will maintain its activity (as detected in a "Halo" assay) for several years.
80
2.19 Determination of protein concentration
Protein concentration was determined by the use of the BCA kit (Pierce)
following manufacturer's instructions. Bovine serum albumin (Sigma) was used
as a standard in all assays conducted.
2.20 Expression of Protein A fusion proteins from the lac promoter.
The E. coli strain NM522 was transformed with either pAX12 or pAMBl and
grown in 500ml ofLB plus kanamycin at 25°C until an Agog °f 0.6 was
obtained. Expression from the lac promoter was then induced by the addition of
1PTG to a final concentration of 0.25mM. The cells were then left to grow for a
further 2 hours before being harvested.
2.21 Expression of (3-gaIactosidase fusion proteins from thePr promoter.
The E. coli strain pop2136 was transformed with either pEX12 or pAMB3 and
grown in 100ml LB plus ampicillin at 30°C until an Aggg of 0.6 was obtained.
Protein expression from the.P^> promoter of bacteriophage X was then induced
by shifting the cells to 42°C where they were grown for a further 4 hours before
being harvested.
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2.22 Purification of Pgal-Ste6 fusion protein from inclusion bodies
The inclusion body (P3) fraction harvested from the E. coli strain
pop2136(pAMB3), induced as detailed in 2.21, was resuspended in 500ml
lOOmM Tris.HCl (pH7.4) and loaded onto a preparative 10% SDS-
polyacrylamide gel. The gel was stained briefly with Coomassie Blue and the
region of the gel corresponding to the .Pgal-Ste6 fusion protein excised. The
fusion protein was placed in dialysis tubing containing 5- 10ml electrophoresis
buffer and removed from the gel by electroelution (50V for 2-5 hours) in this
same buffer. The buffer containing the electroeluted protein was then placed in
fresh dialysis tubing and dialysed against distilled H20 overnight. The protein
was then concentrated by lyophilisation.
2.23 Immunisation of rabbits for antibody production and collection of
serum
Two New Zealand white rabbits were subcutaneously injected with 150pxg of
purified PrtA-Ste6p chimera which had been mixed with an equal volume of
Freund's complete adjuvant to form an emulsion. A second injection was
administered six weeks later, however in this, and all subsequent injections,
Freund's incomplete adjuvant was used in the emulsion. A 5 ml test bleed was
taken a week after the third injection. The blood was left at room temperature
for 10 min before being placed at 4°C overnight. The following day the serum
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was collected by centrifiigation (3,000rpm for 15 min in a MSE bench top
centrifuge) and filtered through a 0.22pm ultrafilter (Acrodisc). After the
addition of sodium azide to a final concentration of 0.1%, the serum was stored
at -20°C in aliquots. The rabbits were boosted and bled at regular intervals until
they were finally sacrificed and the serum stored at -20°C.
2.24 Affinity purification of antibodies using antigen immobilised on
nitrocellulose
A sample of antigen, in this case (3gal-Ste6 fusion protein (2.22), was subjected
to 10% SDS-PAGE then blotted onto nitrocellulose (2.14). The nitrocellulose
was then stained with 0.2% Ponceau S in 3% TCA for 5 min and then washed
in water to remove background staining. The band corresponding to the Pgal-
Ste6p was excised from the blot with a scalpel and marked to indicate which
side had protein bound. The Ponceau S was then removed by washing the strip
of nitrocellulose in TBST several times. The strip was then incubated in 5%
Marvel in TBST for at least 60 min to block any non-specific sites on the
nitrocellulose. The strip was then washed in TBST and placed, antigen side up,
on a piece ofNescofilm. As much serum that could be held in place by surface
tension (typically 0.5-lml) was then placed on top of the affinity strip. A lid was
placed over the strip to avoid evaporation and the strip was incubated like this
at room temperature for 2 hours. The excess serum was then removed from the
affinity strip and the strip was washed 4 times, for 5 min each wash, in TBST.
The antibody was eluted from the strip by incubating it for 20 min in the
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presence of as much 0.2M glycine (pH2.8) as could be held by surface tension.
The eluted antibody was removed from the strip and added to an equal volume
of 0.1M Tris.HCl (pH8.5), sodium azide was then added to a concentration of
0.1%. The affinity-purified antibodies were aliquoted and stored at -20°C until
required. The strip could be re-used by washing it in a copious amount of TBST
then storing it in the presence of 0.1% sodium azide.
2.25 Protein sequencing from Immobilon P
a) Preparation ofpolyacrylamide gels for separation ofproteinsprior to
protein sequence analysis.
The following method utilises a buffer exchange procedure to provide enhanced
resolution of polyacrylamide gels pre-run for protein sequencing in the presence
of a free radical scavenger, to prevent blockage of the N-terminus of the protein
and it is taken from Dunbar and Wilson (1993).
All solutions used in this procedure were made up fresh and filtered immediately
before use. The electrophoresis was carried out using either the Hoefer Tall
Mighty Small or Bio-Rad Protean II apparatus. The polyacrylamide gels were
produced according to 2.13 however in this case both the separating and
stacking gels were made using the separating gel buffer. The gel was loaded
with SDS-PAGE sample buffer containing tracker dye (2.13) and was pre-run
at 20mA in the buffers detailed below until the dye had reached the bottom.
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Top reservoir Stacking buffer (diluted 2X) containing 5pM reduced
glutathione.
Bottom reservoir Separating buffer (diluted 2X)
The sample, which had been resuspended in SDS-PAGE sample buffer and
heated at 37°C for 10 min, was then electrophoresed through the gel at 20mA
in the presence of elecrophoresis buffer (2.13) to which lOOpM thioglycollate
had been added.
b) Electrotransfer ofprotein onto Immobilon P.
The following method for the electotransfer of material from a polyacrylamide
gel to Immobilon P is taken from Matsudaira, (1987). Following electrophoresis
the gel was soaked in transfer buffer (lOmM CAPS, 10% methanol, pHl 1.0) for
5 min. During this time a piece of Immobilon P was cut to the same size as the
gel, soaked in 100% methanol and stored in the transfer buffer. The gel,
sandwiched between a sheet Immobilon P and several sheets of 3MM paper,
was assembled into a wet blotting apparatus and electroeluted for 16 hours at
0.2 amps in transfer buffer.
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c) Staining Immobilon P with Coomassie Blue R-250.
The staining method was taken from Matsudaira, (1987). The Immobilon P
membrane onto which protein had been transferred was washed in deionised
water for 5 min. The proteins were detected by staining the membrane with
0.1% Coomassie Blue R-250 in 50% methanol for 5 min then destaining in 50%
methanol, 10% acetic acid for 10 min at room temperature. The membrane was
then washed in deionised water. The band corresponding to the protein of
interest (C(His)8Ste6p in this case ) was then excised and retained for protein
sequence analysis.
d) Direct transfer ofprotein onto Immobilon P.
The following method was obtained from D.K. Apps (University ofEdinburgh).
The C(His)sSte6p was separated from contaminating proteins by
polyacrylamide gel electrophoresis as detailed in 2.25a. The gel was stained
with filtered Coomassie Blue staining solution (2.13a). The band corresponding
to C(His)8Ste6p was excised, weighed, crushed and added to 2X volume per
weight lOOmM NH4HCO3. SDS was added to a concentration of 0.1% and the
mixture was incubated for 24 hours at room temperature. The mixture was
diluted 2X with distilled water and a 100mm2 piece of Immobilon, which had
been wetted with methanol, was added to the mixture. The protein solution and
Immobilon membrane were incubated for several hours to allow binding to take
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place. The membrane was washed with water and dried and used for N-terminal
protein sequence analysis.
Miscellaneous methods
2.26 Detection of Ste6p activity, the "halo assay"
The a-factor supersensitive strain, RC757, was grown in YEPD until an A6qo
of 0.6 was obtained. A 1 ml aliquot of the cells was then added to 4ml of top
agar (YPD or YPG plus 0.8% Bacto agar which had been maintained at 45°C)
and poured immediately onto the required agar plate (YPD or YPG) to create a
lawn of sensitive cells. The plates were allowed to set and were dried by placing
them in a 30°C incubator for 30 min. Overnight cultures of the strains to be
tested for a-factor secretion were harvested by brief centrifugation (6,000 rpm
for 3 min in a bench top microfuge) and 3p.l of the cells, or purified a-factor,
were spotted onto the lawn. The plates were then incubated for 2-3 days at
30°C until the RC757 lawn had grown and halos of growth inhibition due to the
presence of a-factor could be seen. Halo size is indicative of how much a-factor
is present, the greater the halo the more a-factor present.
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Chapter 3
Production and affinity purification of rabbit antibodies
specific for the C-terminal region of Ste6p
3.1 Introduction
In the absence of a functional assay for Ste6p it was necessary to raise antibodies
against Ste6p to allow detection. In order to produce (Ste6p) specific antibodies in
rabbits an appropriate antigen had to be produced. One way of producing antigen
from a cloned gene is to create a fusion protein which can be overexpressed in E.coli
and affinity purified from bacterial extracts. A variety of suitable expression vectors
are available including one which permits fusing the gene of interest to the N-terminal
portion of protein A, consisting of two and a half IgG binding domains, by use of the
pAX vector system (Zueco and Boyd, 1992). Protein A, a polypeptide from the cell
wall ofS. aureus, is an ideal candidate for fusion protein production as it has a high
affinity for the Fc domain of immunoglobulins. This enables the fusion protein to be
readily affinity purified on commercially available IgG Sepharose. The IgG binding
capacity of protein A also allows for detection of chimaeric proteins with
commercially available rabbit anti-bovine IgG HRP conjugate (SAPU) following
Western Blot analysis. It is thought also that the repetitive structure of protein A
enhances the immunological response to the fusion protein (Lowenadler et al., 1986).
Antigen-specific antibodies may be purified from serum by immunoaffinity absorption.
This may be achieved by the production in E. coli of a second fusion protein by means
of the pEX vector system (Kusters et al., 1989). Here the gene is expressed from the
Pjl promoter as a cro-lacZ ((3-galactosidase) fusion protein under control of the
temperature-sensitive cI875 repressor protein giving a very high and consistent level
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of gene expression. The fusion protein is purified from inclusion bodies by preparative
SDS-PAGE and attached to a solid support as described in Chapter 2.
This Chapter describes the production and purification of a bacterially-expressed
Ste6p-proteinA fusion protein to use as an antigen for the production of anti Ste6p
antibodies. I also describe the production of a P-galactosidase-Ste6p fusion protein
and its use in the affinity-purification of Ste6p specific antibodies.
3.2 Construction of a protein A-tagged Ste6p chimaeric protein
Ste6p is thought to have f2 membrane-spanning domains (Kuchler et al., f989;
McGrath and Varshavsky, 1989) making it a fairly hydrophobic molecule. For this
reason it was decided to raise antibodies against the extreme C-terminal portion of
the protein. This region is thought to be exposed on the cytosolic face of the plasma
membrane. The solubility of the fusion protein was an important consideration as the
production of insoluble aggregates (inclusion bodies) would make purification of the
fusion protein on IgG Sepharose difficult. Another important consideration when
choosing the region of Ste6p to use in antibody production was the degree of
sequence similarity between domains of Ste6p and other members of the ABC
transporter family which may be present in yeast. The other major extramembrane
domains of the protein are thought to be mainly located on the cytosolic face of the
cell membrane and are thought to encode the conserved nucleotide binding-domains
associated with the ABC transporter family. At this time little was known about other
S. cerevisiae ABC transporter proteins. It was hoped that the C-terminal region of
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Ste6p would share little sequence homology with other family members so as to avoid
immunological cross reactivity which could render a polyclonal antibody useless.
A SaR fragment of approximately 6.6kb containing the entire STE6 gene and 600bp of
upstream sequence cloned into pUC7 was obtained from Benjamin Glick, University
ofBasel (originally supplied by Alexander Varshavsky MIT). A 1.2kbp fragment
corresponding to the extreme 3' end of the STE6 open reading frame was amplified by
PCR using as primers the oligonucleotides;
1) 5'-CGG AAT TCA GAT ACC CGA TAT AAG TAG AGG-3'
2) 5'-CGG GAT CCT TTC TTA TGG CGT TTC TCT TTA TGC CTC-31.
These two oligonucleotides contain the restriction sites .EcoRI and BamHI,
respectively which were used for sub-cloning. The PCR product was cloned into the
BamHl and EcoKl sites of pAX12 (Zueco and Boyd, 1992) to create an in-frame
fusion with IgG binding domains of protein A under control of the lac promoter.
Expression from the E. coli lac promoter can be induced by the presence of IPTG
(Chapter 2). This construct was called pAMBl and was predicted to encode a protein
of 56kDa (16.9kDa from the protein A and 39kDa from the Ste6p). This fusion
protein was called PrtA-Ste6p.
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3.3 Expression of PrtA-Ste6p in E. coli
The E.coli strain NM522 was transformed with either pAX12 or pAMBl to make
strains NM522(pAX12) and NM522(pAMBl) respectively. Expression ofPrtA-Ste6p
in the presence of IPTG was compared with IPTG-induced protein expression from
untransformed NM522 and NM522(pAX12) (Figure 3.1a). The blot indicates that no
protein was expressed from untransformed NM522 cells which was capable of
interacting with rabbit IgG (lane 1). In lane 2 a band of around 17kDa corresponding
to the protein A moiety from pAX12 was detected. Induced NM522(pAMBl) cells
produced a protein of approximately 56kDa (lane 3). This corresponds to the
expected molecular weight of the PrtA-Ste6p chimaera demonstrating that the fusion
protein is being expressed correctly. To examine further the expression ofPrA-Ste6p
in NM522, cell lysates of IPTG induced NM522(pAMBl) were subjected to
differential centrifugation and Western Blot analysis. The results shown in Figure 3.1b
indicate that the majority of the chimaera is found in the insoluble, P20, fraction in
cells grown at 37°C.
3.4 Expression of the PrtA-Ste6 fusion protein in cells grown at 25°C
For ease of purification it was important that the PrtA-Ste6p chimaera could be
isolated from a soluble extract of the cells. Early expression studies carried out at
37°C showed that the fusion protein was found predominantly in the insoluble P20
fraction (Figure 3.1b). In an attempt to prevent the formation of insoluble protein
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aggregates (inclusion bodies) cells were grown and expressed at 25°C. Figure 3.2
indicates that the majority of the fusion protein is found in the soluble S20 fraction in
NM522(pAMBl) grown at 25°C. In comparison, when grown at 37°C, nearly all of
the fusion protein is in the insoluble P20 fraction. There was a considerable amount of
protein degradation apparent in cells grown at 25°C. Subsequent experiments on the
PrtA-Ste6p were conducted at 25°C with an induction time of 2 hours.
3.5 RIPA buffer enhances binding of the PrtA-Ste6 fusion protein to IgG
Sepharose
Affinity purification of protein A fusion proteins is normally achieved by binding
soluble cell extract onto IgG Sepharose under suitable conditions (low salt
concentration) washing the Sepharose to remove non-specifically bound protein and
then eluting the fusion protein either by increasing the salt concentration or by
decreasing pH. Initial purification studies on the PrtA-Ste6 fusion protein indicated
that it failed to bind efficiently to the IgG Sepharose. In an attempt to increase binding
efficiency the S20 fraction of the cell lysate was treated with a complex detergent
mixture called RIPA buffer (added to give a final concentration of 150mM NaCl, 1%
Nonidet P-40, 0.1% sodium deoxycholate and 0.1% SDS). The results obtained using
RIPA-treated S20 extracts compared with those in a low salt solution are shown in
Figure 3.3. It can be seen that a far greater proportion of the fusion protein is bound
to IgG Sepharose when RIPA buffer is added to the S20 fraction prior to addition to
the IgG. Figure 3.3 also demonstrates that the temperature at which binding is carried
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out is unimportant. Subsequent purifications were carried out at 4°C in the presence
ofRIPA buffer.
3.6 Purification of the PrtA-Ste6 fusion protein and its use as an antigen for
production of Ste6p specific antibodies
The PrtA-Ste6p fusion protein was bound onto IgG Sepharose in the presence of
RIPA buffer as detailed in section 3.5. Contaminating proteins were removed by
washing the IgG Sepharose in wash buffer (150mM NaCl, 50mM Tris-HCl and
0.05% Tween 20 pH 8.0) until the wash buffer gave an A2go of less than 0.1. At this
point several attempts were made to elute the chimera from the IgG Sepharose. It was
found that neither high salt (1M NaCl, 50mM Tris.HCl, 0.05% Tween 20 pH8.0) nor
0.5M acetic acid were able to remove the majority of the chimera from the IgG
Sepharose (data not shown). To overcome this problem the fusion protein was
electroeluted from a preparative polyacrylamide gel loaded with IgG-Sepharose-
bound PrtA-Ste6p which had been dissociated in gel sample buffer. The eluate was
dialysed overnight against distilled water and concentrated by lyophilization.
Sufficient pure PrtA-Ste6p was obtained to use as antigen for antibody production in
two New Zealand White rabbits (as detailed in Chapter 2). At a later date it was
discovered that the fusion protein could be dissociated from the IgG Sepharose by
incubation in the presence of 0.1M Glycine pH 3, 1% CHAPS for 20 min (Figure
3.4). This method gave greater yields of fusion protein and was less time demanding
than elution from a preparative gel. Protein purified by this later method was used for
all subsequent booster inoculation of the rabbits.
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3.7 Construction and expression of a pgal-ste6 chimaeric protein for the affinity
purification of anti Ste6p antibodies
Antibodies specific to Ste6p protein were affinity-purified by the use of a second
fusion protein. This time a pgal-Ste6p fusion protein was produced by sub-cloning the
1.2kbp EcoRH BamHl fragment ofpAMBl corresponding to the extreme 3' end of
STE6 into pEX12 (Kusters et al., 1989) to create an in-frame fusion with p-
galactosidase. The resultant plasmid, pAMB3, was transformed in to the if coli strain
pop2136. Growth and expression from the Pr promoter was carried out as detailed in
Chapter 2 and was compared with pop2136 cells containing either no vector or the
parent pEX12 vector. The results are shown in Figure 3.5. The results indicate that
the pgal-Ste6p fusion protein is being correctly expressed in pop2136.
3.8 Detection of Ste6p in yeast with the affinity-purified anti-Ste6p antibody
Polyclonal antibodies specific for Ste6p were affinity purified from rabbit serum by the
method detailed in 2.24. The affinity purified antibodies were tested for their ability to
bind specifically to Ste6p expressed in yeast by use of the S. cerevisiae stains BJ5464
and WKK7 (Table A2). The BJ5464 strain has a wild-type STE6 gene whereas
WKK7 is a AZEd-deleted strain. As shown in Figure 3.6a the antibodies recognise a
protein of approximately 145kDa (the expected molecular weight of Ste6p) in a
membrane extract ofBJ5464 cells whereas no protein was detected in a membrane
fraction ofWKK7. To further demonstrate that the antibody was specific for Ste6p,
WKK7 was transformed with pAMB14 (Table A3) which contains the STE6 gene
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under the control of the powerful GAL promoter. When WKK7(pAMB14) was
grown on mannose no immunoreactive protein was detectable in the membrane
fraction, however when grown in the presence ofgalactose a protein of 145kDa was
detected (Figure 3.6b). Thus the affinity-purified antibody was specific for Ste6p and
was capable of detecting Ste6p in yeast cell membranes by Western blot analysis.
3.9 Discussion
In this Chapter the successful production, expression and purification of an affinity
purified anti-Ste6p antibody was described. The antibody was capable of detecting
Ste6p found in membrane fractions of glass bead-lysed yeast cells by Western Blot
analysis. The affinity-purified antibody was found to be quite unstable and tended to
be non-functional after 1-2 months even when stored in aliquots at -20°C. The
addition of 1-2% BSA appeared to help stabilise the antibody; however, it was still
necessary to re-purify antibody from rabbit serum at regular intervals.
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Figure 3.1 Expression of PrtA-Ste6p in E. coli
A. The E. coli strain NM522 was transformed with either pAX12 or pAMBl and
grown shaking at 37°C in LB plus ampicillin until an Agoo °f 0.6 was obtained. The
cultures were then induced by the addition of.0.25mM IPTG and grown at 37°C for a
further 4 hours. Cell pellets were weighed and resupended in an equal volume of 2x
SDS-PAGE sample buffer. The samples were then boiled for 10 min before analysis
by 12% SDS-PAGE. The proteins were visualised by Western blot analysis using a
rabbit anti-bovine IgG HRP conjugate at a 1:10,000 dilution for 20 min. The blot was
developed by use of enhanced chemiluminescence (ECL).
B. A culture ofNM522(pAMBl) was grown and induced as in 3.1a. The cells were
harvested then subjected to glass bead lysis and differential centrifugation as described
in Chapter 2. The cell fractions (P3, S20 and P20) were made up to an equ.al volume
and combined with 2x SDS-PAGE sample buffer. The samples were then subjected to
Western blot analysis as detailed in Figure 3.1a.
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Figure 3.2 The PrtA-Ste6p fusion protein is soluble in cells grown at 25°C
NM522(pAMBl) cells were grown at either 37°C or 25°C until an Aggo °f 0-6 was
reached. They were then induced by the addition of 0.25mM IPTG and grown for a
further 4 hours. Samples were taken at hourly intervals. The cells were lysed and then
subjected to differential centrifugation to give S20 and P20 fractions as described in
materials and methods. The samples were then run on 12% SDS-PAGE and the
presence of the fusion protein detected by Western blot analysis using a rabbit anti-
bovine IgG HRP conjugate at a 1:10,000 dilution for 20 min. The blot was developed
by use ofECL.
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a) NM522(pAMBl) grown at 37»C
b) NM522(pAMBl) grown at 25°C
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Figure 3.3 Solubilisation of the PrtA-Ste6p chimera with RIPA buffer aids
binding to IgG Sepharose
Overnight cultures ofNM522(pAMBl) were inoculated into LB with ampicillin and
grown shaking at 25°C until an AggO °f 0.6 was obtained then induced by the
addition of 0.25mM IPTG and grown for a further 2 hours. The cells were lysed and
the S20 fraction collected as detailed in Chapter 2. The S20 fraction was then either
left untreated or treated with RIPA buffer (final concentration 150mM NaCl, 1%
Nonidet P-40, 0 .1% sodium deoxycholate and 0.1% SDS) and applied to 1ml of IgG
Sepharose previously equilibrated with wash buffer (150mM NaCl, 50mM Tris-HCl
and 0.05% Tween 20 pH8.0). Binding of the fusion protein occurred during gentle
rotation at either room temperature or at 4°C for 1 hour. The IgG Sepharose was
then pelleted by centrifugation (30 seconds at 3,000g) and the supernatant fraction
("unbound") collected for analysis by SDS-PAGE. The IgG Sepharose was then
washed with wash buffer until an A28O of less than 0.01 was obtained, then
resuspended in 2X SDS-PAGE sample buffer (Chapter 2). Samples of unbound and
bound chimaeric protein were analysed by 12% SDS-PAGE and Western blot analysis
as described in Figure 3.1. In the following blot B signifies Chimaeric protein Bound
to the IgG Sepharose with UB indicating material which remained UnBound
following incubation with IgG Sepharose.
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Figure 3.4 Purification of the PrtA-Ste6p fusion protein on IgG Sepharose
The S20 fraction from a 500ml culture ofNM522(pAMBl), grown and expressed as
detailed earlier in this Chapter, was treated with RIPA buffer before being applied to
lml of IgG Sepharose previously equilibrated in wash buffer. Binding was carried out
for 1 hour at 4°C with constant gentle agitation. The IgG Sepharose was then washed
with wash buffer until an A280 of less than 0.01 was obtained. The chimaera was
removed from the IgG Sepharose by incubation in the presence of 0.1M glycine pH3,
1% CHAPS for 20 min with gentle agitation. The eluate was then dialysed and
concentrated by lyophilization. The purified fusion protein was analysed by 12% SDS-
PAGE and either stained with Coomassie Blue or transferred onto nitrocellulose and
visualised with ECL following probing with rabbit anti-bovine IgG HRP conjugate at
a 1:10,000 dilution for 20 min.
A) SDS-PAGE: a 12% polyacrylamide gel stained with Coomassie Blue.
Lane 1 Molecular Weight markers
Lane 2 PrtA-Ste6p




Figure 3.5 Expression of a (3gaI-Ste6 fusion protein in pop2136 cells
Untransformed pop2136, pop2136(pEX12) and pop2136(pAMB3) cells were grown,
shaking, in 100ml LB plus ampicillin at 30°C until an Aggo of 0.6 was obtained. Half
the culture from each was then shifted to 42°C, the remainder staying at 30°C, and
grown for a further 2 hours. The cells were then lysed and the P3 (inclusion body
containing) fraction collected as detailed in Chapter 2. The inclusion body fraction
from each culture was resupended in 5ml lysis buffer, mixed with 2X sample buffer
and analysed by SDS-PAGE (Chapter 2).
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Figure 3.6 Detection of yeast Ste6p with affinity purified antibodies
Figure 3.6a single colonies of yeast strains BJ5464 and WKK7 were grown overnight
in selective media containing glucose as a carbon source (SD). The following day the
cultures were inoculated into 50ml of SD and grown until an A^oo of 0.6 was
obtained. The cells were harvested then subjected to glass bead lysis and differential
centrifugation to yield a membrane, PI00, fraction as described in Chapter 2. The
PI00 fractions were then subjected to SDS-PAGE and Western blot analysis. The blot
was probed with affinity-purified anti-Ste6p antibody at a 1:100 dilution for 16 hours
followed by a 1: 1,000 dilution ofDonkey anti-rabbit HRP conjugate for 20 min. The
blot was then developed by use ofECL.
Figure 3,6b single colonies of yeast strains WKK7 and WKK7(pAMB14) were grown
in selective medium containing mannose as a carbon source (SM). The following day
the cultures were inoculated into 50ml of either SM or SG (selective media containing
galactose) and grown until an A<;oo of 0.6 was obtained. The cells were then lysed and








The attempted purification of a recombinant Ste6p tagged
at the amino terminus with six histidine residues
4.1 Introduction
In order to carry out biochemical analysis of the Ste6p and a-factor substrate it was
essential that the Ste6p could be purified and reconstituted into phospholipid vesicles.
It was intended that the wild-type Ste6p would be isolated from a membrane enriched
fraction of lysed yeast cells that were overexpressing the protein. The first stage of the
purification would be to determine which detergents were capable of solubilising the
Ste6p. Once solubilised it was hoped that the protein could be purified using standard
techniques such as ion-exchange chromatography and exclusion chromatography.
As an alternative to traditional purification techniques there are various methods
available that enable a protein of interest to be tagged to allow rapid affinity
purification. One example of this is tagging a protein with a domain ofProtein A to
allow purification on IgG Sepharose as detailed in Chapter 3. Another, now widely
used technique exploits metal chelate chromatography. For this the protein of interest
is tagged at either the amino or carboxyl terminus with six or more consecutive
histidine residues. These histidine residues have a high affinity for the metal nickel that
may in turn be bound to a solid matrix. The commercially available Ni-NTA (nitrilo-
tri-acetic-acid) resin (Qiagen) is capable of binding hexa-histidine tags with a Kd=10"13
M at pH8. The high binding efficiency permits the removal of contaminating protein
either by competition with imidazole or by lowering the pH and theoretically leads to
a one-step purification procedure. The tag is very small and is therefore unlikely to
interfere with protein structure. Another advantage of using this type of affinity tag is
that the resin does not require any functional protein structure and can therefore bind
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tagged protein in the presence of 8M Urea, lOmM {3-mercaptoethanol, up to 1% non-
ionic detergent and salt concentrations of 1M. All of the above considerations are
important in the purification of a large membrane protein which has a low level of
expression and a relatively short half life.
Initial purification studies were centred around the constitutive expression ofwild-
type protein from a yeast episomal vector. The protein was found to be easily
solubilised with a wide variety of detergents and was detectable by Western blot
analysis. However, the level of protein expression, even when expressed in a strain in
which the vacuolar ATPase encoded by the PEP4 gene had been deleted, was poor
and it was envisioned that it would be virtually impossible to purify by conventional
means.
As an alternative to conventional purification procedures the amino terminus of Ste6p
was tagged with a hexa-histidine tail. It was hoped that resultant recombinant protein
(N(His)<5Ste6p) could be easily purified from the membranes of yeast expressing the
protein. Several different purification procedures were attempted using both native
and denaturing conditions, however, none appeared to enable binding of
N(His)gSte6p to the Ni-NTA resin. It was proposed that the N(His)gSte6p failed to
bind to the Ni-NTA resin because the hexa-histidine tail had been removed during
posttranslational processing of the protein.
This Chapter describes the attempts made to purify from S. cerevisiae both wild-type
Ste6p and an N-terminally hexa-histidine tagged variant.
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4.2 Production of a Ste6p-overexpressing strain of S. cerevisiae
For the purification ofwild-type Ste6p to be successful it was essential that its
expression in S. cerevisiae could be optimised to give high protein yields. As
discussed in Chapter 2 Ste6p is a metabolically unstable protein which is stabilised by
yeast containing a defect in the vacuolar protease A gene PEP4 (Rolling et al., 1994;
Berkower et al., 1994). With this in mind it was decided that BJ5465 apep4MAT&
strain of S. cerevisiae (Table A2) would be used for the expression studies.
An expression vector for wild-type Ste6p was produced by cloning the Sail fragment
of pSTE6, which contains the entire STE6 gene, into the Sail site of the yeast
episomal vector YEplacl81 (Geitz and Sugind., 1988) to make pAMB7. This plasmid
was transformed into the yeast BJ5465 to create BJ5465(pAMB7). Expression of
Ste6p from BJ5465 and BJ5465(pAMB7) was compared by Western blot analysis of
crude cell lysates as detailed in Figure 4.1. As can be seen from Figure 4.1 there was a
large increase in the amount of Ste6p expression from BJ5465(pAMB7) when
compared to wild-type BJ5465. All subsequent experiments on the purification of
wild-type Ste6p utilised the BJ5465(pAMB7) strain. A control experiment was
carried out in which pAMB7 was transformed into the MATa strain JRY188.
Expression of Ste6p from JRY188 and JRY188(pAMB7) was carried out as detailed
in Figure 4.1. As expected no Ste6p expression was detected in either strain (data not
shown) in agreement with Wilson and Flerskowitz (1984) who observed that STE6
expression is cell type specific and negatively regulated by theM47a2 product.
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The Ste6p detected by Western blot analysis appears as a diffuse band. The
appearance of the band would correspond with that of a glycoprotein; however Ste6p
is not thought to be glycosylated (Kuchler et al., 1993). Attempts were made at
improving the resolution of the band by altering the conditions of protein treatment
prior to and during analysis by SDS-PAGE. The most favourable conditions found are
those detailed in Figure 4.1.
4.3 Localisation of Ste6p by differential centrifugation
In order to optimise the purification conditions it was first necessary to determine
which cell fraction contained the greatest quantity of Ste6p. Crude cell lysates of
growing BJ5465(pAMB7) were subjected to differential centrifugation and analysed
by SDS-PAGE and Western blot analysis (Figure 4.2). As can be seen from Figure
4.2b the greatest quantity of Ste6p was found in the membrane fraction (PI00). A
large quantity of Ste6p was also found in the P3 and P12 fractions. The most likely
cause of this is incomplete cell lysis. Figure 4.2a indicates that there are a great many
contaminating proteins in the PI00 fraction. It also shows that Ste6p is not a major
protein and is not identifiable as a distinct protein in a crude cell lysate such as this.
All further experiments on the isolation of Ste6p were conducted on the PI00 fraction
from BJ5465(pAMB7) cells lysed with glass beads.
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4.4 Ste6p is solubilised by a wide range of detergents
When determining which detergent to use for the purification it was necessary to take
into account its critical micelle concentration (CMC). A detergent with a high CMC is
preferable for the reconstitution of protein into proteoliposomes and a CMC of ImM
or greater is preferable for detergent removal by dialysis (Neugebauer, 1990).
Preliminary experiments conducted on the solubilisation of Ste6p with a range of non-
ionic detergents indicated that Ste6p was readily solubilised by 1% Thesit, CHAPS,
Triton X-100 and Zwittergents 3-8 to 3-14. Of the detergents tested only LDAO and
MEGA-8 were inefficient at solubilising Ste6p. The Zwittergent 3-10 was picked for
the solubilisation of Ste6p, due to its favourable CMC and its relative cost efficiency.
At this point it became clear that it was going to be very difficult to purify wild-type
Ste6p from S. cerevisiae. The main problem envisioned was the very low level at
which the protein was being produced. This could have been overcome if large culture
volumes had been utilised, however this was deemed impractical due to the
constraints of handling large cell quantities. The expression of the protein might also
have been improved had it been put under the inducible control of the powerful GAL
promoter. Another alternative was to affinity-tag the protein with a oligo-histidine tail
so that it could be "pulled" out of a dilute solution by its high affinity to Ni-NTA resin
(Qiagen). It was decided that the Ste6p should be tagged with six consecutive
histidine residues at its amino terminus and be put under control of the GAL promoter
to produce N(His)gSte6p. The amino terminus was chosen for several
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reasons. First the anti-ste6p antibody is directed against the C-terminus of the Ste6p
and there were worries that a tag here would interfere with some antibody
recognition. The C-terminus is thought to contain a large non-membrane associated
domain on the cytosolic face whereas the N-terminus is thought to be part of a short,
non-membrane associated domain on the cytosolic face of the plasma membrane.
Thus it was reasoned that the larger C-terminal domain was more likely to have an
integral role in the function of the Ste6p than the rather shorter N terminal region. As
a consequence it was decided not to place the oligo-histidine tag on the C-terminus in
case it affected the activity of the protein.
4.5 Production of a recombinant Ste6p by attaching six consecutive histidine
residues on the amino terminus to produce N(His)6Ste6p
The addition of six consecutive histidine residues to the extreme N-terminus of Ste6p
was carried out by the use ofPCR using the following primers:
1) 5' primer
Start 5'end ofSTE6
5-CGCC AAG CTT ATG CAT CAC CAT CAC CAT CAC AAC TTT TTA AGT TTT AAG TA C-3'
Hindlll 6 consecutive histidine residues
2) 3' primer:
3'end ofSTE6
5-CGC CAA OCT TTT ACC ATT CCA TCT ATG AGT AAC-3'
Hindlll
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The PCR reaction was carried out using VENT polymerase with pSTE6 as the
template as detailed in Chapter 2. The 4.3kb product was digested with Hindlll and
cloned into the Hindlll site of pK19, a standard laboratory general purpose vector, to
produce pAMBlO. The Hindlll fragment containing the tagged STE6 gene was then
subcloned into the Hindlll site of the yeast episomal vector YEpGAL thus placing the
tagged STE6 gene under the control of the inducible GAL promoter. The resultant
vector was called pAMB 11. It was possible that the PCR process could introduce an
error into the STE6 gene that would render it useless. It was decided therefore to
sequence to the first EcoRl site (lkb down stream of the extreme 5'-end of the tagged
STE6 gene) so that, if necessary, the tagged region of the gene could be sub-cloned
into the wild type sequence using a simple HindlllJEcdRl digest of both pAMBl 1
and pSTE6 to produce a "wild-type" gene. A high quality sample of pAMBlO was
produced by the Qiagen midi-preparation kit from the E .coli strain DH5a. The DNA
was then subjected to double stranded DNA sequencing (method 1) as detailed in
Chapter 2 with the M13 forward sequencing primer and primers N1384-5'-AGC
GGC ATT CAT CGA CCA-3' and N2710-5'-CAT CAA GGT TTG TAT TCC-3'.
This enabled the first 1 kb ofDNA corresponding to the extreme 5' end of the
histidine tagged STE6 gene to the first EcoRl site be read. The sequence was checked
by two non-biased readers and was found to contain no mistakes.
A cartoon ofN(His)gSte6p spanning the plasma membrane is shown below. The
boxed "His" motif at the N-terminus indicates the position of the six consecutive
histidine residues and NBD stands for Nucleotide Binding Domain.
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4.6 N(His)6Ste6p complements a ste6 strain of A. cerevisiae
It was essential that N(His)gSte6p could act as a functional a-factor transporter. In
order to test this an a-factor supersensitive strain of S. cerevisiae, RC757 (MATasst2
Table A2), was utilised. Mutations in sst2 cause both a and a cells to display both
hypersensitivity and greatly prolonged responses (especially to division arrest) to
pheromone (Chan and Otte, 1982a,b; reviewed in Sprague and Thorner, 1992). As the
sst2 mutation in RC757 renders it hypersensitive to a-factor, the secretion of a-factor
can be semi-quantitatively monitored by the production of an area of growth
inhibition, or "halo", around an a-factor producing patch of cells on a lawn ofRC757
cells. To test whether N(His)gSte6p was capable of producing active Ste6p, pAMBl 1
was transformed into the S. cerevisiae strain WKK7 which has aMA 7a Aste6::HIS3
genotype (Table A2). The expression ofN(His)gSte6p and its ability to complement
the WKK7 Aste6::HIS3 genotype is detailed in Figure 4.3. Wild-type WKK7 was
unable to secrete a-factor in the presence of either glucose or galactose. As expected
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the control strains, BJ5465 and WKK7(pAMB7), were capable of secreting a-factor
on both carbon sources. No halo was produced from WKK7(pAMBl 1) grown on
glucose however a-factor secretion was apparent when the cells were grown on
galactose. The N(His)gSte6p was thus capable of complementing a ste6 strain of
yeast and was produced in the presence of galactose and not glucose.
4.7 Expression ofN(His)gSte6p in BJ5465
N(His)gSte6p was expressed in BJ5465 in order to stabilise the protein by virtue of
the strain'spep4 genotype. As a consequence the N(His)gSte6p would be expressed
in a STE6 wild-type background producing a protein mix that would be
indistinguishable by Western blot analysis unless the addition of the histidine residues
greatly altered the molecular weight ofN(His)gSte6p in comparison to Ste6p. This
mixture of anti-Ste6p antibody reactive proteins will be referred to simply as Ste6p
immunoreactive material.
The expression ofN(His)gSte6p was checked by comparing the amount of Ste6p
produced in BJ5465 cells with anti-Ste6p antibody immunoreactive protein produced
by BJ5465(pAMBl 1) cells. The cells were grown and induced with galactose as
detailed in Figure 4.4. As can be seen from Figure 4.4 the membrane fraction of
BJ5465(pAMBl 1) cells appeared to contain more Ste6p immunoreactive material
than wild-type BJ5465 membranes isolated under identical conditions. The protein
detected by the anti-Ste6p antibody appears as a distorted, or smudgy, band. This
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banding pattern had been observed previously and did not appear to be due to the
N(His)6Ste6p.
The DNA sequence data, halo assay and Western blot ofN(His)6Ste6p expression
gave the clear impression that an active, galactose induced N-terminal hexa-histidine
tagged variant of Ste6p was being produced from the pAMBl 1 vector. From these
data we decided to continue the purification studies in the knowledge that the protein
was active and correctly tagged at the N-terminus. In addition the solubilisation of
N(His)6Ste6p protein with the range of detergents detailed in section 4.4 gave
comparable results to the those obtained from the wild-type protein (data not shown).
4.8 Attempted purification of N(His)6Ste6p solubilised from BJ5465(pAMBll)
membranes
It was hoped that the N(His)6Ste6p could be purified from the membranes of
galactose-induced BJ5465(pAMBl 1) cells under relatively mild conditions. Initial
purification studies were centred on solubilising the protein from a glass bead lysate
using the Zwittergent 3-10. The results shown in Figure 4.5 indicate that a large
amount of Ste6p immunoreactive material was present in the cell lysate suggesting
successful induction ofN(His)6Ste6p expression. Comparison of the amounts of
protein in the S20 and P20 fractions indicates that the protein was at best only 50%
soluble. The disappointing solubilisation of anti-Ste6p antibody reactive protein may
have been due partially to incomplete cell lysis. The lysis could have been monitored
by measuring the absorbance due to the release of DNA from lysed cells at 260nm
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until it reached a constant level. The blot also indicates that there was a large amount
of Ste6p immunoreactive material in the unbound fraction suggesting that very little, if
any, soluble N(His)gSte6p applied to the Ni-NTA resin actually bound to it. There
was no Ste6p immunoreactive protein found in either of the washes nor the eluate.
The results shown in Figure 4.5 indicate that the N(His)eSte6p was unable to bind to
the Ni-NTA resin under these conditions.
An identical experiment to that described in Figure 4.5 was carried out using Triton
X-100 instead ofZwittergent 3-10. The Triton X-100 was marginally better at
releasing anti-Ste6p antibody reactive protein from membranes of induced
BJ5465(pAMBl 1) cells and was an economical detergent to use while initial protein
binding experiments were being conducted. Virtually identical results were obtained
when Triton X-100 was used (data not shown) indicating that no anti-Ste6p antibody
reactive protein was being bound to the Ni-NTA resin. Further experiments in which
the concentration ofTX-100 for both protein solubilisation and binding were varied
were also carried out. No Ste6p immunoreactive material was found to have been
bound to or eluted from the Ni-NTA resin under any of the detergent concentrations
attempted (data not shown).
It was possible that the protein was being solubilised with Zwittergent 3-10 and
Triton X-100 but had somehow folded and as a result the histidine "tail" was
inaccessible to the Ni-NTA resin. In an attempt to overcome this problem both the
solubilisation and binding of the protein to the Ni-NTA resin were carried out in the
presence of 8M Urea (Figure 4.6). As demonstrated in Figure 4.6 there was no
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binding of Ste6p immunoreactive material to the Ni-NTA resin in the presence of 8M
urea and 1% Triton X-100.
4.9 Discussion
This Chapter described preliminary experiments relating to the purification ofwild-
type Ste6p and the production and expression of a N-terminally-hexa-histidine tagged
variant of the protein, N(His)6Ste6p. N(His)6Ste6p was expressed as an active protein
as shown by its ability to complement a ste6 null mutation in the yeast strain WKK7
and was detectable as an increase in Ste6p immunoreactive material when expressed
against a wild-type background in BJ5465.
Attempts made at purifying N(His)6Ste6p on Ni-NTA resin were unsuccessful due to
the inability to detect any N(His)6Ste6p binding to the Ni-NTA resin. This may have
been due to a low concentration ofN(His)eSte6p leading to poor visualisation on
Western blots. The blots themselves might have been misleading as the Ste6p
immunoreactive material visualised on the blots might have consisted mainly of the
wild-type Ste6p. Ideally the N(His)6Ste6p would have been expressed in apep4 strain
in which the STE6 gene had been deleted to remove contaminating wild-type protein.
This was attempted following the protocol detailed in the appendix to this Chapter.
Numerous attempts at making this ste6::URA3 strain failed due to inability to ligate
the blunt ended, filled-in URA3 fragment into the parent vector.
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It was possible that the binding ofN(His)6Ste6p to the Ni-NTA resin failed because
the tagged N-terminus was in some way unavailable for binding to the resin. As there
was no binding evident in the presence of 8M urea is would seem unlikely that this
was due to any residual protein structure which may have "hidden" the oligo-histidine
"tail". Alternatively it was conceivable that the N-terminus of the N(His)6Ste6p was
being cleaved during a posttranslational event and was therefore not available to bind
to the Ni-NTA resin. At this time Rolling and Hollenberg (1994b) conducted studies
on a chimaeric protein produced by the fusion of the 1st hydrophobic segment of
Ste6p (amino-acids 1-78) to the gene of the secreted protein invertase (SUC2) which
was lacking its ER signal sequence. The results of the study showed that the first
hydrophobic segment of Ste6p was capable of directing invertase to the ER membrane
indicating that this region of Ste6p functions as a signal sequence. During the course
of their experiments they observed that, when deglycosylated, the chimaeric protein
had the same mobility on SDS-gels as wild-type invertase. This was unexpected as the
chimaeric protein had a calculated molecular weight of 8.8 kDa larger than wild-type
invertase. It was concluded that this discrepancy was due to the removal of the N-
terminal Ste6p sequences by signal peptidase upon transition into the lumen of the
ER. Analysis of the Ste6p sequence by the rules set up by von Heijne (1986) predicted
that there would be a potential signal cleavage site at Gly62^Ser63.
In order to determine whether or not the extreme N-terminus was being removed
during some posttranslational event it was decided that the C-terminus of Ste6p
should be tagged with a oligo-histidine tail and tested for its ability to bind to Ni-NTA
resin. At this time monoclonal antibodies specific for an oligo-histidine sequence were
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becoming commercially available. It was hoped that such antibodies could be used to
determine whether or not the extreme N-terminus of Ste6p was present in the mature
protein. The results on the study of a C-terminally-oligo-histidine tagged variant of
Ste6p are detailed in Chapter 5.
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Figure 4.1 Overexpression of Ste6p from BJ5465(pAMB7)
Overnight cultures ofBJ5465 and BJ5465(pAMB7) were inoculated into 50ml of
glucose-containing selective medium (SD) supplemented with the necessary amino
acids and uracil. The cultures were grown, shaking, at 30°C until an A^oo of 1.0 was
obtained. The cells were then harvested, lysed with glass beads as detailed in Chapter
2. The crude cell lysate was diluted in 2X SDS-PAGE sample buffer and subjected to
electrophoresis on a 7.5% polyacrylamide gel. The electrophoresed protein was
transferred onto nitrocellulose. The blot was probed with a 1:100 dilution of anti-
Ste6p serum for 2 hours followed by a 1:5,000 dilution of donkey anti-rabbit HRP





Figure 4.2 Localisation of Ste6p by differential centrifugation of
BJ5465(pAMB7) cell lysate
An overnight culture of BJ5465(pAMB7) was inoculated into 50ml of selective
medium with glucose as a carbon source. The culture was grown shaking at 30°C
until an A^oo of 1.0 was obtained. The cells were then harvested and subjected to glass
bead lysis and differential centrifugation as detailed in Chapter 2. The cell fractions
were resuspended to an equal volume in lysis buffer and diluted in an equal volume of
2X SDS-PAGE sample buffer (Chapter 2). The samples were then heated at 37°C for
10 min and subjected to electrophoresis on a 7.5% polyacrylamide gel. Gels were
either stained with Coomassie Blue or transferred onto nitrocellulose. The Western
blot was probed with a 1:100 dilution of anti-Ste6p serum for 2 hours and a 1:5,000
dilution ofDonkey anti-rabbit conjugate for 20 min. The blot was developed with
ECL.
A. SDS-PAGE: a 7.5% polyacrylamide gel stained with Coomassie Blue.




Figure 4.3 Expression of N(His)6Ste6p in WKK7; the Halo Assay
Agar plates containing either glucose or galactose as a carbon source were seeded
with RC757 cells as detailed in Chapter 2. Single colonies ofWKK7,
WKK7(pAMB7), WKK7(pAMBl 1) and BJ5465 were inoculated into 5 ml of
selective medium containing mannose as a carbon source and supplemented with
necessary amino-acids and uracil (SM). The cultures were grown for 16 hours until
they appeared turbid to the eye. The cells from a 1.5 ml aliquot of each culture were
harvested by centrifugation (3g for 5 min). The pellets were gently resuspended by
pipetting until a uniform cell solution was obtained. A 3 pi aliquot of each cell
suspension was then carefully pipetted on to the lawn ofRC757 cells. The plates were




Figure 4.4 Expression of N(His)6Ste6p in BJ5465
Overnight cultures ofBJ5465 and BJ5465(pAMBl 1) were inoculated into 50ml of
selective medium containing mannose as a carbon source and supplemented with the
necessary amino-acids and uracil. The cultures were grown, shaking, at 30°C until an
A^oo of 0.6 was obtained. The growth medium was then supplemented by the addition
of galactose to a concentration of 2%. The cultures were then grown, shaking, at 30°
C for a further 12 hours. The cells were then harvested and subjected to glass bead
lysis and differential centrifugation to yield S100 and PI00 fractions as detailed in
Chapter 2. The cell fractions were made up to an equal volume in cell lysis buffer and
diluted in 2X SDS-PAGE sample buffer. The samples were then heated at 37°C
before being separated by electrophoresis through a 7.5% polyacrylamide gel. The
gel was then blotted onto nitrocellulose and probed for the presence of
immunoreactive Ste6p with a 1:100 dilution of anti-Ste6p serum for 2 hours and a




Figure 4.5 Attempted purification of N(His)6Ste6p solubilised from
BJ5465(pAMBll) membranes with Zwittergent 3-10
Overnight cultures ofBJ5465(pAMBl 1) were inoculated into 1 litre of selective
medium containing 2% mannose as a carbon source and supplemented with the
necessary amino acids and uracil (SM). The cultures were grown, shaking, at 30°C
until an A^oo of 0.6 was obtained. The cells were then harvested and resuspended in 1
litre of SG (as SM but using galactose as a carbon source). The cultures were
incubated as before for a further 16 hours. The cells were harvested and washed in
50mM Tris.HCl pH 7.5, then weighed and resuspended in an equal volume of lysis
buffer (50mM Tris.HCl, 300mM NaCl plus protease inhibitors). The cell suspension
was placed in the small chamber of the Bead Beater (Chapter 2), which had been half
filled with glass beads. The cells were lysed by 4 bursts of 1 min on the bead beater
interspersed with 1 min cooling intervals on ice. The cell lysate was separated from
the beads by centrifugation at 6,000g for 5 min (centrifuge) and solubilised by the
addition ofZwittergent 3-10 to a concentration of 1%. The lysate was incubated with
gentle agitation for 1 hour at 4°C then centrifuged to yield an S20 fraction (Chapter
2) which was added to 1ml ofNi-NTA resin that had been previously equilibrated in
Solubilisation buffer (lysis buffer plus protease inhibitors and 1% Zwittergent 3-10).
The Ni-NTA resin/cell lysate mixture was incubated, with gentle agitation, for 1 hour
at 4°C. The unbound material was removed from the resin by centrifugation (l,200g
for 3 min). The resin was washed in 10 volumes of solubilisation buffer (Wash 1) and
then in 10 volumes of wash buffer 2 (solubilisation buffer plus 10% glycerol pH6.0)
until the A2go of the wash buffer was less than 0.01. Oligo-histidine containing
proteins were competed off the resin by the addition of a high concentration of
imidazole in the final elutant wash (wash buffer 2 plus 500mM imidazole). Samples of
the cell lysate, unbound material, washes 1 and 2 and eluate were diluted with 2x
sample buffer and subjected to 7.5% SDS-PAGE and Western blot analysis. The blot
was probed with a 1:100 dilution of anti-Ste6p serum for 2 hours and a 1:5,000
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Figure 4.6 Attempted purification of N(His)6Ste6p solubilised from
BJ5465(pAMBll) membranes with Triton X100 and 8M urea
Cells from 1 litre ofBJ5465(pAMBl 1) cells, cultured and galactose induced as
described in Figure 4.5, were resuspended in buffer A (50mM NaP04 pH 8.0,
500mM NaCl) supplemented with protease inhibitors and lysed with the Bead-Beater
as before (Figure 4.5 and Chapter 2). The cell lysate was separated from the beads by
centrifugation at 6,000g for 5 min and solubilised by the addition of Triton X-100 to a
concentration of 1%. The lysate was incubated with gentle agitation for 1 hour at 4°C
then centrifiiged to yield an S20 fraction (Chapter 2) which was added to 1ml ofNi-
NTA resin that had been previously equilibrated in Buffer A plus protease inhibitors
and 1% Triton X-100. The resin was incubated on a rotating wheel for 60 min at 4°C.
The unbound material was removed from the resin by centrifugation (2,000 X g for 1
min) and the resin was washed in buffer B (8M urea, 0.1M NaP04, 0.01M Tris. HC1,
pH 8.0. and 0.1% Triton X-100) until the A28o of the wash buffer was less than 0.01.
The N(His)gSte6p was eluted by incubation with lOOpl elution buffer (lOmM Tris pH
7.5, 500mM NaCl, 0.1% Triton X-100, 300mM imidazole) for 5 min and
centrifugation at 2,000 X G for 2 min. The elution step was carried out twice.
Samples taken from each point in the purification procedure subjected to
polyacrylamide gel electrophoresis and Western blot analysis as detailed in Figure 4.5.
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Appendix to Chapter 4
Protocol for the production of a ste6::URA3 strain of BJ5465
The STE6 gene disruption strategy was based on the one-step gene replacement
method described in Kuchler et cil., 1989.
1) The plasmid pAMB4 (Table A3) would be digested with Stu 1 and SnaBl
(both ofwhich generate blunt ends) to remove a 3.4 kb fragment
representing 87% of the STE6 coding region.
2) The deleted fragment would be replaced with the URA3 containing BarnHl
fragment ofYDp-U (Berben et al., 1991) which had had its sticky ends filled
in by the action of the Klenow fragment ofDNA polymerase 1 prior to
ligation.
3) The resultant plasmid would be digested with SaR and Sad to release the
STE6 disruption cassette which would be transformed into BJ5465 (Table
A2).
4) Transformants would be screened for by their ability to grow on media
deficient in uracil.
5) Integration of the deletion construct into the genome would be confirmed by
DNA hybridisation and tetrad analysis.
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Chapter 5
The partial purification of a recombinant Ste6p tagged at
the Carboxyl terminus with eight histidine residues
5.1 Introduction
In Chapter 4 the production, expression and partial purification of an N-terminally
hexa-histidine tagged Ste6p was discussed. The failed attempts at purification of both
the recombinant and the wild-type protein left us with an interesting dilemma. It
remained of utmost importance to try and purify Ste6p from S. cerevisiae yet an
interesting question regarding the possible cleavage of the N-terminus of Ste6p had
also been posed. Although the state of the N-terminus of Ste6p could be determined
by protein sequence analysis, for this a large amount of purified protein would be
required.
In an attempt to purify Ste6p from S. cerevisiae, and in turn provide material for
protein sequence analysis, it was decided that a recombinant Ste6p would be
produced in which the C-terminus had been tagged with eight consecutive histidine
residues. This chapter describes the production, expression and partial purification of
a C-terminally octa-histidine tagged Ste6p variant. It also describes attempts made at
protein sequence analysis and how the use of a monoclonal antibody, specific for a
sequence of six or more histidine residues, was used to further substantiate the
evidence that the N-terminus of Ste6p had been removed by post-translational
modification of the protein.
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5.2 Production of a recombinant Ste6p by attaching eight consecutive histidine
residues to the carboxyl terminus to produce C(His)sSte6p
As discussed in Chapter 4 the inability to detect any binding ofN(His)gSte6p to Ni-
NTA resin may have been due to several reasons. Although the possibility of the N-
terminus being removed from mature Ste6p was of interest it led to doubt whether
conditions would ever be found which would enable N(His)gSte6p to be purified by
metal chelate chromatography. It was decided that a C-terminally octa-histidine
tagged Ste6p should be produced as an alternative to the studies on N(His)gSte6p.
Tagging the C-terminus of Ste6p contradicted the strategy of tagging the N-terminus
of the protein however it appeared to be the obvious step to take. It was expected
that a C-terminally tagged protein would be purifiable on Ni-NTA resin and would
enable the analysis of the nature of the N-terminus of Ste6p.
The addition of eight consecutive histidine residues to the extreme C-terminus of
Ste6p was carried out by the use ofPCR using the following primers:
1) 5' primer:
Start 5' end ofSTE6
5-GGC CAA OCT TAT GAA CTT TTT AAG TTT TAA GAC TAC A-3'
Hindlll
2) 3' primer:
8 consecutive histidine residues
5'-G CGG AAG CTT TTA GTG ATG GTG ATG GTG ATG GTG ATG ACT GCT TTG GTT GGA AAC AAT TTG-3'
Hindlll <—3 'end ofSTE6
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The PCR reaction was carried out using VENT polymerase with pSTE6 as the
template as detailed in Chapter 2. The PCR product was digested with Hindlll and
cloned into the Hindlll site ofYEpGAL thus placing the tagged STE6 gene under the
control of the inducible GAL promoter. The resultant plasmid was called pAMB14. In
order for DNA sequence analysis to be carried out the Hindlll fragment of pAMB14
containing the C-terminally histidine tagged STE6 gene was subcloned into the
Hindlll site of pK19 to produce pAMB15. A high quality sample of pAMB15 was
produced by the Qiagen midi-preparation kit from the E. coli strain DH5a. The DNA
was then subjected to double-stranded sequencing (method 2) with the following
primer: 5'-AGC GGA TAA CAA TTT CAC ACA GGA-3'. This enabled the DNA
corresponding to the extreme 3' end of the histidine-tagged STE6 encompassing the
octa-histidine tag to be read. The sequence was checked by two non-biased readers
and was found to contain no mistakes, so it was concluded that the DNA sequence
encoding the octa-histidine tag was correctly placed.
A cartoon ofC(His)gSte6p spanning the plasma membrane is shown below. The
boxed "His" motif at the C terminus indicates the position of the eight consecutive
histidine residues and NBD stands for Nucleotide Binding Domain.
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5.3 C(His)gSte6p complements a sie6 strain of S. cerevisiae
It was essential that C(His)gSte6p, like N(His)gSte6p, could act as a functional a-
factor transporter. The a-factor bioassay was carried out essentially as described in
4.6. This time the yeast strain WKK7 was transformed with pAMB14 to produce
WKK7(pAMB14). Samples ofWKK7, WKK7(pAMB14), BJ5465 and purified a-
factor (Chapter 2) were tested for their ability to produce a halo on a lawn ofRC757
cells grown using either glucose or galactose as a carbon source (Figure 5.1). As
expected BJ5465 and purified a-factor were capable of producing a halo effect when
grown on either carbon source. Wild-type WKK7 was unable to secrete a-factor in
the presence of either glucose or galactose and no halo was produced from
WKK7(pAMB14) grown on glucose; however a-factor secretion was apparent when
the cells were grown on galactose. The C(His)gSte6p was thus capable of
complementing a ste6 defect and was produced in the presence of galactose and not
glucose.
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The expression ofN(His)5Ste6p and C(His)gSte6pN from WKK7(pAMBl 1) and
WKK7(pAMB14) respectively were examined as detailed in Figure 5.2. It was found
that, when grown on galactose, both recombinant proteins were equally good at
complementing the ste6 mutation ofWKK7. Interestingly when cultures of both
strains were grown on galactose and then placed on an RC757 lawn grown containing
glucose as a carbon source halo production was also evident. This was an unexpected
observation when one considers that the half-life ofwild-type Ste6p is supposedly
only 13-30 min (Rolling and Hollenberg, 1994; Berkower et al., 1994). If this were
the case and if the glucose present in the RC757 lawn was sufficient to repress the
expression of the recombinant proteins, it is surprising that such an obvious halo was
produced. However it is conceivable that residual a-factor had remained associated
with the cell wall of the cells grown in the presence of glucose with subsequent
leaching resulting in the pheromone response of the RC757 tester lawn.
5.4 The expression of C(His)gSte6p in aMATct strain of S. cerevisiae
The efficient expression of recombinant Ste6p required that it should be produced in a
ste6 strain ofS cerevisiae which was preferably deficient in the vacuolar hydrolase
activities attributable to the PEP4 gene product (Ammerer et al., 1986; Woolford et
al., 1986). A strategy for the production of a WKK7 pep4 knockout strain is detailed
in the appendix to this Chapter. Suspected mutant cells were produced; however they
failed to grow on either liquid or solid media and were therefore deemed useless for
the expression of recombinant Ste6p.
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As discussed in Chapters 2 and 4, expression ofSTE6 in S. cerevisiae is a-cell type
specific, that is, it is not normally expressed in a-type cells. As it was expected that
expression ofC(His)gSte6p would be as inefficient as that observed with
N(His)gSte6p, it was decided to try and express the protein in theMATapep4 strain
BJ5464 under the control of the GAL promoter. Expression of the recombinant
protein under the control of the GAL promoter was expected to provide a high level
of protein expression which would not be subjected to transcriptional repression by
the Mata2p. If this was successful the expression of C(His)gSte6p would be stabilised
by the absence of a functional pep4 gene and detection of the recombinant protein
could be achieved without the interference from the wild-type protein. In addition the
studies ofBerkower et al., (1994) indicated that degradation ofwild-type Ste6p
occurs with identical kinetics inM47a andMATa strains of S. cerevisiae.
The expression ofC(His)gSte6p in aMA Tex ste6 strain of S. cerevisiae (BJ5464) is
shown in Figure 5.3. The expression ofwild-type Ste6p in the presence of glucose
and galactose is shown in lanes 1 and 2 respectively. The MATa strain, BJ5464, gave
no banding pattern for Ste6p when grown either in the presence of glucose or
galactose as shown in lanes 3 and 4 respectively. The expression ofC(His)gSte6p
from BJ5465(pAMB14) grown in the presence of galactose (lane 5) gave a banding
pattern comparable to that ofwild-type Ste6p (lane 1) and appeared similar to that
observed from the expression ofN(His)6Ste6p in BJ5465. No anti-Ste6p
immunoreactive material of the correct molecular weight for C(His)gSte6p was
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detected in the membrane fraction ofBJ5464(pAMB14) cells grown on glucose (lane
6). When BJ5464(pAMB14) cells were grown in the presence of galactose (lane 7) a
heavy band of approximately 145kDa corresponding to C(His)gSte6p was detected.
The results of the Western blot indicated that the expression ofC(His)gSte6p in
BJ5464 had been successful. All future experiments involving purification studies on
C(His)gSte6p were conducted on protein obtained from galactose-induced
BJ5464(pAMB14).
5.5 An anti-oligo-histidine monoclonal antibody is immunoreactive with
C(His)gSte6p but not with N(His)(;Ste6p
The practice of purifying oligo-histidine-tagged recombinant proteins by metal chelate
chromatography has stimulated the development of two different means by which the
poly-histidine "tail" can be detected. The first uses a Ni-NTA conjugate (Qiagen)
consisting ofNi-NTA coupled to either calf intestinal alkaline phosphatase (AP) or
horseradish peroxidase (HRP). These conjugates can be used for chromogenic or
chemiluminescent detection of any recombinant protein containing an accessible oligo-
histidine tag. The second method of detection involves the use of antibodies specific
for a oligo-histidine tag. Commercially-available monoclonal antibodies are available,
however they were usually directed against an oligo-His tag plus its flanking
sequence, for example the Qiagen His antibody is directed against the sequence Arg-
Gly-Ser-His-His-His-His which is the sequence contained in recombinant proteins
expressed from their commercially available expression system. Dianova GmbH
(Germany) produced the first monoclonal antibody (13/45/31) against the oligo-
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histidine tag. It was claimed to be effective in detecting oligo-histidine tagged proteins
when used in a variety of different situations including immunoblot and
immunoprecipitation analysis. Unfortunately the expense of this product prevented its
use.
A mouse monoclonal antibody directed against an oligo-Histidine residue epitope was
made available by Dr Dieter Engelcamp at the Western General Hospital, Edinburgh.
This antibody offered a means by which the presence or absence of an oligo-histidine
tag could be determined, so as to indirectly identify the N-terminus ofN(His)gSte6p.
If the antibody were immunoreactive with a protein of the correct size for
N(His)5Ste6p it would suggest that the failure to purify the protein was due to either
the experimental conditions or the inability to detect minute quantities of the protein.
On the other hand if the protein was not immunoreactive with the anti-His tag
antibody it would further confirm the idea that the N-terminus of Ste6p was cleaved
during posttranslational modifications of the protein. C(His)gSte6p would act as a
control protein being expressed under identical conditions in the same strains of S.
cerevisiae. If the C(His)gSte6p were immunoreactive with the antibody it should be
able to be purified on Ni-NTA resin.
Figure 5.4a shows a Western blot of a bacterially expressed N-terminally-deca-
Histidine-tagged protein, probed with the anti-His-tag monoclonal antibody. It
confirms that this antibody is capable of immunoreacting with a protein containing a
poly-Histidine motif attached to the N-terminus. Western blot analysis of the
membrane fractions ofBJ5464(pAMBl 1) and BJ5464(pAMB14) probed with anti-
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Ste6p antibody and anti-His-tag antibody are shown in Figure 5.4b. The Western blot
probed with the anti-Ste6p antibody demonstrates that Ste6p is being produced from
BJ5464(pAMB14) and BJ5464(pAMBl 1) cells respectively in the presence of
galactose. The Western blot probed with the anti-His-tag antibody indicates that a
protein of identical size to that detected with the anti-Ste6p antibody could be
detected in the membranes of cells expressing C(His)gSte6p, in contrast, this was not
observed in cells expressing N(His)5Ste6p. To eliminate the possibility that this was
the consequence of expressing the protein in an a-cell type the experiment was
repeated using the WKK7 strain of S. cerevisiae (Figure 5.4c). The results shown in
Figure 5.4c are identical to those shown in Figure 5.4b, the high background on the
blot being due to a longer exposure time (necessitated by the lower protein
concentrations resulting from the expression of protein in a PEP4 strain of S.
cerevisiae).
The results shown in Figure 5.4 demonstrate that the anti-His-tag monoclonal
antibody was immunoreactive with a bacterially-expressed N-terminally-deca-
Histidine tagged protein and C(His)gSte6p. This antibody was not immunoreactive
with N(His)gSte6p suggesting that there was no histidine tag accessible to the
antibody. The comparative Western blots probed with anti-Ste6p antibody indicate
that this was not due to poor expression of the protein. It is possible that this lack of
detection was due to the inability of the antibody to detect the hexa-histidine tag on
N(His)gSte6p as the proteins that were successfully detected in this study had eight
and ten histidine residues. However this explanation would seem unlikely as the
antibody had been tested against at least ten different histidine tagged proteins which
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were tagged with six to ten residues at either the N or C terminus and expressed from
different plasmid expression systems in a variety of different organisms. In each case
the protein of interest was positively identified by the antibody (D. Engelcamp
personal communication). The antibody has now been marketed commercially.
The results of the experiments carried out with the anti-His-tag antibody demonstrate
that the histidine tag of C(His)gSte6p was accessible and as a consequence it was
expected that it would be able to bind to and therefore be purifiable on Ni-NTA resin.
5.6 Studies on the binding of C(His)gSte6 solubilised with Triton X-100 from
the membranes of galactose-induced BJ5464(pAMB14) cells
The successful purification of a histidine-tagged variant of human P-glycoprotein by
its affinity to Ni-NTA was reported by Loo and Clarke (1995). This purification of
another eukaryotic ABC-transporter by nickel chelate chromatography suggested that
C(His)gSte6p could also be purified using this technique, and provided a set of
conditions on which to base the purification ofC(His)gSte6p. The P-glycoprotein
purification was based on the transient expression of a C-terminally deca-histidine
tagged P-glycoprotein variant in the mammalian cell line HEK 293. Material
solubilised by the non-ionic detergent »-dodecyl-(3-D-maltoside was bound onto a Ni-
NTA spin column (Qiagen) in the presence of 50mM imidazole. Contaminating
proteins were removed by washing the resin with 80mM imidazole. The protein was
eluted from the resin with 300mM imidazole. This protocol yielded 6-12mg of
purified P-glycoprotein which had ATPase activity in the presence of lipid.
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The initial studies on the interaction ofC(His)gSte6p with Ni-NTA resin were
concerned with finding conditions which would enable efficient binding and elution of
the protein. In order to keep the cost of these initial binding studies to a minimum the
detergent Triton X-100 was used for the solubilisation ofC(His)gSte6p from the
membranes of galactose-induced BJ5464(pAMB14) cells.
Initial attempts at binding C(His)gSte6p onto Ni-NTA resin used the protocol ofLoo
and Clarke (1995), who loaded the recombinant P-glycoprotein onto the Ni-NTA
resin spin column in the presence of 50mM imidazole in order to reduce non-specific
protein binding. An attempt at binding the C(His)gSte6p to Ni-NTA resin in the
presence of 50mM imidazole (Figure 5.5) resulted in no C(His)gSte6p binding to the
resin under these conditions. The experiment was then repeated with the omission of
imidazole from the binding buffer (Figure 5.6) and C(His)gSte6p was found to bind to
the Ni-NTA resin under these conditions. The protein was eluted from the resin by the
addition of 300mM imidazole.
Although Triton X-100 appeared to be adequate for the solubilisation of
C(His)gSte6p from the membranes ofBJ5464(pAMB14) Figures 5.5 and 5.6 indicate
that a large amount of the protein was not solubilised under these conditions. Figure
5.6 also demonstrates that although some C(His)gSte6p was bound to the Ni-NTA
resin a large proportion of the protein remained unbound under these conditions. To
overcome these problems a strong denaturant, 8M urea was used. As can be seen
from Figure 5.7 the addition of 8M urea resulted in the total solubilisation of
145
C(His)gSte6p from the membranes ofBJ5464(pAMB14). Unfortunately the addition
of urea did not decrease the proportion ofC(His)gSte6p remaining unbound. Figure
5.7, also shows that the protein remains bound to Ni-NTA when the pH was lowered
to pH6.0. This is an important consideration as contaminating proteins are usually
selectively eluted from Ni-NTA resin by the addition of a low concentration of
imidazole (c.f. Loo and Clarke, 1995). C(His)gSte6p did not bind to Ni-NTA resin in
the presence of 50mM imidazole indicating that a lower imidazole concentration,
which would allow C(His)gSte6p to bind to the resin, would have to be determined in
order that imidazole could be used as a means of removing contaminating protein
from the resin. A reduction in pH, resulting in the protonation of histidine residues
and their dissociation from the resin might provide an alternative mechanism by which
contaminating proteins could be removed. Proteins containing histidine monomers are
usually eluted at around pH 6.0 whereas proteins containing 6 or more histidine
residues are eluted at around pH 4.5 (Qiagen). The data obtained from Figure 5.7
would indicate that C(His)gSte6p remains bound to Ni-NTA when the pH is lowered
to pH 6.0. In addition the supplementation of the solubilisation buffer with 8M urea
appears to greatly increase the amount of C(FIis)gSte6p solubilised from membranes
ofBJ5464(pAMB 14) with Triton X-100.
In order to determine the imidazole concentration required to elute C(His)gSte6p
from Ni-NTA a discontinuous imidazole gradient was applied to C(His)gSte6p which
had been solubilised and bound to Ni-NTA in the presence of 1% Triton X-100 and
8M urea (Figure 5.8). As can be seen from Figure 5.8 C(His)gSte6p remained bound
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to the Ni-NTA resin in the presence of buffer at pH 6.0 and in the presence of 20mM
imidazole, but was eluted by imidazole concentrations of 40mM and greater.
Although Triton X-100 solubilised C(His)gSte6p could be purified on Ni-NTA in the
presence of 8M urea the use of the detergent «-dodecyl-/?-D-maltoside was also
explored. This was prompted by the success ofLoo and Clarke (1995) who used it in
their purification of deca-histidine tagged P-glycoprotein. They found that this
detergent solubilised around 80% of the available P-glycoprotein from mammalian cell
line membranes. In addition their purification procedure was successful without the
use of strong denaturants, e.g. 8M urea, and resulted in the recovery ofP-
glycoprotein ATPase activity.
5.7 The partial purification of C(His)gSte6p solubilised with «-dodecyl-/?-D-
maltoside
The studies conducted on Triton X-100-solubilised C(His)gSte6p indicated that the
protein remained bound to the Ni-NTA resin in the presence of 20mM imidazole.
Figure 5.9 shows an experiment in which C(His)gSte6p solubilised from the
membranes ofBJ5464(pAMB14) with A?-dodecyl-/?-D-maltoside was bound to Ni-
NTA resin in the presence of 20mM imidazole. The protein was then subjected to
elution by a discontinuous imidazole gradient using concentrations of 30mM-300mM
imidazole. As can be seen from Figure 5.9A, C(His)gSte6p bound to the resin in the
presence of 20mM imidazole and was eluted from the resin with imidazole
concentrations in excess of 40mM. There is a slight band corresponding to
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C(His)gSte6p in the 30mM imidazole wash, however, examination of the silver
stained gel (Figure 5.9B) indicates that a large amount of contaminating protein is
being eluted in the 30mM imidazole wash. A faint band corresponding to the expected
molecular weight is detectable in the silver stained gel. The inability to clearly detect
C(His)gSte6p on silver stained gel was disappointing especially when the amount of
contaminating proteins is taken into account. It was decided that subsequent attempts
at the purification ofC(His)gSte6p would be carried out with the addition of 20mM
imidazole to the binding buffer. In addition a 30mM imidazole wash would also be
included. This may result in the loss of a small amount ofC(His)gSte6p however this
loss would appear to be insignificant when one takes into account the benefits
obtained by removing such a large amount of contaminating protein. A duplicate
experiment was conducted in which the 20mM imidazole was omitted from the
binding buffer. The omission of imidazole from the binding buffer was found to have
no effect on the binding/elution pattern of C(His)gSte6p, which was found to be
identical to that indicated in Figure 5.9 (results not shown) indicating that the protein
behaves in an similar manner whether in the presence or absence of 20mM imidazole.
In an attempt to reduce the amount of contaminating proteins present in the final
eluate the resin was washed with a low pH buffer. Figure 5.10 shows an experiment in
which the Ni-NTA resin with C(His)gSte6p bound was washed with buffers of pH 6.3
and pH 5.7 before washing with buffer of pH 8.0 containing 30mM imidazole. The
Western blot (Figure 5.10A) shows that no C(His)gSte6p is lost from the resin in any
of the washing steps. It also shows that most of the C(His)gSte6p is efficiently eluted
from the resin by 300mM imidazole. The silver-stained gel (Figure 5.1OB) shows that
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contaminating protein is eluted from the resin in each of the washes. A candidate band
for C(His)gSte6p is also evident on the silver-stained gel but there was still a
considerable amount of contaminating protein present in the eluate fraction; however
the majority of these proteins appeared to be at a much lower molecular weight than
C(His)8Ste6p.
As the C(His)gSte6p appeared to be a distinct, albeit faint band on the silver stained
gel shown in 5.1 OB the purification was scaled up in an attempt to obtain enough
protein for protein analysis. The partial purification ofC(His)gSte6p from a 1 litre
culture ofBJ5464(pAMB14) is detailed in Figure 5.11. The purification was carried
out by binding the C(His)gSte6p onto the resin in the presence of 20mM imidazole
and contaminating proteins were removed by washing the resin with 30mM imidazole
at pH 8.0 and then at pH 6.3. The silver stained gel shows C(FIis)gSte6p as a clearly
identifiable band in the eluate fraction, distinct from the lower molecular weight
contaminating proteins. In addition the Western blot shows that the majority of
C(His)gSte6p was eluted from the Ni-NTA resin by of 300mM imidazole. The eluted
protein was retained for amino-acid sequence analysis as discussed in 5.8.
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5.8 Attempted sequencing of C(His)gSte6p immobilised on Polyvinylidene
Difluoride (Immobilon P) membranes
Until recently sequencing the N-terminus of a protein has required large (>nmolar)
quantities of purified protein. In recent years improvements in protein sequencing
techniques (Elizinga, 1982; Matsudaira, 1987) have resulted in the ability to directly
sequence pmol quantities of protein after spotting or electrotransfer onto
Polvinylidene Difluoride (PVDF) membranes. PVDF membranes, which are marketed
as Immobilon (Millipore), provide a mechanically strong solid phase support with a
capacity for protein adsorption similar to that of nitrocellulose (Matsudaira, 1987). In
practice it is possible to transfer proteins separated by SDS-PAGE onto Immobilon P
membranes either directly or by electrotransfer. The protein may then be detected by
staining with Coomassie Blue and the portion of Immobilon P containing the protein
excised and sequenced directly.
In an attempt to sequence the N-terminus ofC(His)gSte6p, the eluate fractions from
Figure 5.11 were concentrated and separated by SDS-PAGE according to the method
ofDunbar and Wilson, (1993) (Chapter 2) and as detailed in Figure 5.12. The gel was
electrotransferred onto Immobilon P by wet blotting and stained with Coomassie blue
as detailed in Chapter 2. The region of Immobilon corresponding to C(His)gSte6p
was cut out and sent for sequence analysis by Dr Andrew Cronshaw at the Welmet
protein sequencing facility at Edinburgh University. The material was subjected to 6
cycles of sequence analysis by the method ofHays et al., (1989) however the
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sequence analysis was unsuccessful and no information on the amino-acid sequence at
the N-terminus was obtained.
As it was possible that the blotting procedure may have blocked the N-terminus
another method for binding C(His)gSte6p to Immobilon P was attempted. The
concentrated partially purified protein from Figure 5.11 was separated by SDS-PAGE
as before and as detailed in Chapter 2 and Figure 5.12. On this occasion gel was
stained with filtered Coomassie Blue stain (Chapter 2) and the region of the gel
corresponding to C(His)gSte6p excised (Figure 5.12). The C(His)gSte6p was eluted
from the gel and bound to the Immobilon P membrane by the method of Apps as
described in Chapter 2. The Immobilon membrane was then subjected to 6 rounds of
sequence analysis as described above. The sequence analysis was unsuccessful and no
information regarding the N-terminus ofC(His)gSte6p was obtained. The failure may
have been due to insufficient quantities of protein or to the N-terminus being blocked
and therefore inaccessible to sequence analysis.
5. 9 Discussion
In this Chapter the production, expression and partial purification of a C-terminally
octa-histidine tagged Ste6p variant have been discussed. The protein (C(His)gSte6p)
was correctly expressed as an active protein as shown by its ability to complement a
ste6 null mutation.
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This protein (C(His)gSte6p) was found to be immunoreactive with a mouse
monoclonal antibody specific for a sequence of several histidine residues. In contrast
N(His)gSte6p showed no immunoreactivity with this monoclonal antibody suggesting
that the hexa-histidine tag was either inaccessible to the antibody or had been
removed during posttranslational modifications to the protein. In an attempt to
determine the amino acid sequence at the N-terminus ofmature protein the partially-
purified C(His)gSte6p was subjected to protein sequence analysis. Unfortunately the
protein sequence analysis was unsuccessful perhaps due to insufficient quantities of
protein or to the N-terminus being blocked and therefore inaccessible to sequence
analysis.
The studies conducted on the N(His)gSte6p, as detailed in Chapters 4 and 5, indicate
that the protein was correctly expressed as an active protein but was unable to interact
with Ni-NTA resin or a monoclonal antibody specific for an oligo-histidine tag. These
findings coupled with the recombinant Ste6p studies conducted by Rolling and
Hollenberg (1994b) would suggest that the N-terminus of Ste6p was removed during
posttranslational processing of the protein.
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Figure 5.1 Expression of C(His)8Ste6p in WKK7; the Halo Assay
Agar plates containing either glucose or galactose as a carbon source were seeded
with RC757 cells as detailed in Chapter 2. Single colonies ofBJ5465, WWK7 and
WKK7(pAMB14) were inoculated into 5 ml of selective medium containing mannose
as a carbon source and supplemented with the necessary amino-acids and uracil (SM).
The cultures were grown for 16 hours until they appeared turbid. The cells from a 1.5
ml aliquot of each culture were gently resuspended by pipetting until a uniform cell
suspension was obtained. A 3 pi aliquot of each cell suspension and of purified a-
factor (Chapter 2) were then pipetted on to the lawn ofRC757 cells. The plates were










Figure 5.2 Comparison of Halos produced from WKK7(pAMBll) and
WKK7(pAMB14) cells grown on either glucose or galactose as a
carbon source
Agar plates containing either glucose or galactose as a carbon source were seeded
with RC757 as detailed in Chapter 2. Single colonies ofWKK7, WKK7(pAMBll)
and WKK7(pAMB14) were inoculated into 5 ml of selective medium containing
either glucose (D) or galactose (G) as a carbon source and supplemented with
necessary amino-acids and uracil. The cultures were grown and harvested and applied
to the RC757 lawn as detailed in Figure 5.1. The plates were incubated at 25°C until









Figure 5.3 Expression of C(His)gSte6p in S. cerevisiae
Overnight cultures ofBJ5464, BJ5465, BJ5464(pAMB14) and BJ5465(pAMB14)
were inoculated into 100ml selective medium containing 2% mannose as a carbon
source supplemented with 1% casamino acids (plus tryptophan for BJ5464 and
BJ5465) and uracil (SM). The cells were then grown shaking at 30°C until an Aggo
of 0.6 had been obtained. The cells were harvested, split in half and inoculated into
50ml fresh selective medium containing either mannose (SM) or galactose (SG) as a
carbon source. The cells were incubated, shaking for 16 hours at 30°C before being
harvested, weighed and subjected to glass bead lysis and differential centrifugation to
yield S100 and P100 fractions as detailed in Chapter 2. The membrane (P100)
fractions were resuspended in lOOpl of lysis buffer, diluted in an equal volume of2X
SDS-PAGE sample buffer, heated at 37°C for 10 min, and loaded onto a 7.5%
polyacrylamide gel. The gel was blotted onto nitrocellulose and probed with a 1:100
dilution of affinity purified anti-Ste6p antibody for 16 hours. The blot was then
probed with a 1:5,000 dilution of donkey anti-rabbit HRP conjugate for 20 min and
developed by the use ofECL.
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Lane 1. BJ5465, Glucose
Lane 2. BJ5465, Galactose
Lane 3. BJ5464, Glucose
Lane 4. BJ5464, Galactose
Lane 5. BJ5465(pAMB14), Galactose
Lane 6. BJ5464(pAMB14), Glucose
Lane 7. BJ5464(pAMB14), Galactose
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Figure 5.4 Detection of C and N-terminally oligo-histidine-tagged-Ste6p
chimaeras with an anti-histidine tag monoclonal antibody
A. A 39kDa deca-histidine N-terminally tagged bacterially-expressed protein (Chapter
2) was diluted in 2X SDS-PAGE sample buffer and subjected to electrophoresis on a
12% SDS polyacryalmide gel. The electrophoresed protein was Western blotted onto
nitrocellulose and probed with a 1:50 dilution of anti-His-tag antibody for 16 hours.
The blot was then probed with a 1:1,000 dilution of anti-mouse IgG HRP conjugate
for 20 min and developed by the use ofECL.
B. Overnight cultures ofBJ5464(pAMBll) and BJ5464(pAMB14) were inoculated
into 100ml of selective medium containing either 2% glucose or galactose as a carbon
source and supplemented with 1% casamino acids and uracil. The cells were then
grown, harvested and subjected to glass bead lysis and differential centrifugation as
detailed in the legend to Figure 5.3. The membrane (PI00) fractions were
resuspended in lysis buffer and diluted with an equal volume of2X SDS-PAGE
sample buffer, heated for 10 min at 37°C and loaded in duplicate onto a 7.5%
polyacrylamide gel. The proteins were then separated by electrophoresis and blotted
onto nitrocellulose. The blot was then cut in half, half of the blot was probed with a
1:50 dilution of the anti-His-tag monoclonal antibody, the other halfwas probed with
a 1:100 dilution of affinity-purified anti-Ste6p antibody. The blots were incubated
with the primary antibody for 16 hours. Secondary antibodies were then applied as
follows; donkey anti-rabbit HRP conjugate was applied to the anti-Ste6p antibody
blot at a 1:5,000 dilution for 20 min and the anti-mouse IgG HRP conjugate was
applied at a 1:1,000 dilution to the anti-His-tag antibody for 20 min. The blots were
developed by the use ofECL.
C. WKK7 cells were transformed with pAMBl 1 and pAMB14 to produce
WKK7(pAMBl 1) and WKK7(pAMB14) respectively. These cell lines were grown
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Figure 5.5 Binding of C(His)gSte6p onto Ni-NTA resin in the presence of 50mM
imidazole
BJ5464(pAMB14) cells were grown and galactose induced as described in Figure 5.3.
The cells were harvested and subjected to glass bead lysis in 50mM NaPC>4 pH8.0
plus protease inhibitors and subjected to differential centrifugation to yield a
membrane (PI00) fraction as detailed in Chapter 2. The cells were resuspended in
buffer A (50mM NaP04 pH 8.0, 500mM NaCl, 50mM imidazole and 20% v/v
glycerol) supplemented with 1% Triton X-100, thoroughly homogenised and
incubated with gentle agitation at 4°C for 1 hour. Insoluble material (PI6) was
removed by centrifugation at 16,000 Xgfor 15 min. The soluble material (SI6) was
mixed with 150pl packed Ni-NTA resin, which had been equilibrated in buffer B
(buffer A plus 0.1% Triton X-100), and incubated with gentle agitation for 60 min at
4°C. The unbound material was removed from the resin by centrifugation (2,000 X g
for 1 min).The resin was washed in 10 bed volumes of buffer B, then incubated in
100pl of buffer C (buffer B plus 80mM imidazole) for 2 min then centrifiiged at 2,000
X g for 1 min. The supernatant (wash C) was retained for Western blot and the resin
was further washed in 10 bed volumes of buffer C. The resin was then incubated in
100gl of elution buffer (buffer B plus 300mM imidazole) and centrifuged as before.
The supernatant was retained for Western blot analysis and the elution step was
repeated. Samples taken from each point in the purification procedure were subjected
to gel electrophoresis and Western blot analysis with affinity purified anti-Ste6p
antibody as described in Figure 5.3.
161
S16 P16 Unbound 300mMImidazole 300mMImidazole Ni-NTA
Figure 5.6 Binding of C(His)gSte6p, extracted from the membranes of
BJ5464(pAMB14) with Triton X-100, onto Ni-NTA resin
The membranes from galactose-induced BJ5464(pAMB14) were collected as detailed
in Figure 5.5, resuspended in 1.5 ml buffer A (50mM NaPCX pH 8.0, 500mMNaCl
and 20% v/v glycerol) supplemented with 1% Triton X-100, thoroughly homogenised
and incubated with gentle agitation at 4°C for 30 min. Insoluble material (P16) was
removed by centrifugation at 16,000 Xgfor 15 min. The soluble material (S16) was
then mixed with 150pl packed ofNi-NTA resin which had been equilibrated in buffer
B (buffer A plus 0.1% Triton X-100). The resin was incubated on a rotating wheel for
60 min at 4°C. The unbound material was removed from the resin by centrifugation
(2,000 X g for 1 min) and the resin was washed in 20 bed volumes of buffer B.
C(His)gSte6p was eluted by incubation with 100pl lOmM Tris pH 7.5, 500mM NaCl,
0.1% Triton X-100, 20% v/v glycerol, 300mM imidazole for 5 min. The elution step
was carried out twice. Samples taken from each point in the purification procedure






Figure 5.7 Binding of C(His)j}Ste6p, extracted from the membranes of
BJ5464(pAMB14) with 1% Triton X-100 and 8M urea, onto Ni-NTA
resin
The membranes from galactose-induced BJ5464(pAMB14) were collected as detailed
in Figure 5.5, resuspended in buffer A (8M Urea, 0.1M NaP04, 0.01M Tris. HC1, and
20%v/v glycerol pH 8.0) with the addition of 1% Triton X-100 and incubated with
gentle agitation for 1 hour at 4°C. Soluble material (SI6) was separated from
insoluble material (PI6) gathered by centrifugation at 16,000 Xgfor 15 min. The S16
fraction mixed with 150pl packed ofNi-NTA resin which had been equilibrated in
buffer A plus 0.1% Triton X-100 and incubated with gentle agitation at 4°C for 1
hour. Unbound material was removed by centrifugation at 2,000 X g for 1 min. The
resin was washed with 2 X 2ml buffer A, then incubated in lOOp.1 of buffer B (8M
Urea, 0.1M NaP04, 0.01M Tris. HC1, 0.1% Triton X-100 and 20%v/v glycerol pH
6.0) for 2 min. The resin was then centrifuged at 2,000 X g for 1 min. The
supernatant (Wash B) was retained for Western blot analysis. The resin was then
washed in 10 bed volumes of buffer B. This washing process was repeated with buffer
C (buffer B plus 80mM imidazole) and buffer D (buffer B plus 300mM imidazole).
Samples taken from each point in the purification procedure were analysed by
Western blot analysis as detailed in Figure 5.3.
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Figure 5.8 Elution of C(His)8Ste6p from Ni-NTA resin with a discontinuous
imidazole gradient
C(His)gSte6p was solubilised from cell membranes from galactose induced
BJ5464(pAMB14) and bound to Ni-NTA as detailed in Figure 5.7. Protein was eluted
from the resin in a stepwise fashion using a discontinuous imidazole gradient. The
resin was washed with 2 X 2ml buffer A, then incubated in lOOpl of buffer B (8M
Urea, 0.1M NaP04, 0.01M Tris. HC1, 0.1% Triton X-100, 20%v/v glycerol pH 6.0)
for 2 min, and centrifuged at 2,000 Xg for 1 min. The supernatant (Wash B) was
retained for Western blot analysis. The resin was then washed in 10 bed volumes of
buffer B. The elution/ washing steps were carried with buffer B containing 20mM,
40mM, 60mM, 80mM and 300mM imidazole. Samples taken from each point in the
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Figure 5.9 Binding of n-dodecyl-P-D-maltoside solubilised C(His)8Ste6p to Ni-
NTA resin in the presence of 20mM imidazole
The membranes from a 100ml galactose induced BJ5464(pAMB14) culture were
collected as detailed in Figure 5.5, resuspended in 400pl buffer A (50mM NaP04 pH
8.0, 500mM NaCl, 20mM Imidazole and 20% v/v glycerol) and homogenised until a
uniform solution was obtained. The homogenate was then diluted in 1ml ofbuffer A
which had been supplemented with 1% n-dodecyl-P-D-maltoside (DDM) and
incubated with gentle agitation at 4°C for 1 hour. Insoluble material (PI00) was
removed by centrifugation at 100,000 rpm for 20 min in a Beckman TL100
centrifuge. The soluble fraction (SI00) was mixed with a 150pl packed Ni-NTA resin
which had been equilibrated in buffer A supplemented with 0.1% DDM. The resin
was incubated with gentle agitation for 1 hour at 4°C. Unbound material was
separated from the resin by centrifugation at 2000 X g for 1 min. The resin was then
washed in 10 bed volumes of buffer A supplemented with 0.1% DDM. Stepwise
elutions were then carried out in buffer B (lOmM Tris. HC1 pH 7.5, 500mM NaCl,
20% v/v glycerol and 0.1% DDM) which had been supplemented with 30mM, 50mM,
60mM, 80mM and 300mM imidazole. The elution and washing steps were carried out
by resuspending the resin in 100pl of buffer, incubating for 2 min on ice, then
separating the resin from the eluate by centrifugation for 1 min at 2000 X g. The resin
was then washed in 10 bed volumes of the same buffer. Samples taken from each
point in the purification procedure were subjected to polyacrylamide gel
electrophoresis as detailed in Figure 5.3. The gels were either silver stained according
to the method detailed in Chapter 2, or subjected to Western blot analysis with the
affinity purified anti-Ste6p antibody as detailed in Figure 5.3. The region of the silver
stained gel in which the 145kDa C(His)gSte6p protein would be expected to appear is
as indicated.
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B. Silver stained 7.5% polyacrylamide gel
C(HIs)8Ste6p I
Lane 1. S100
Lane 2. PI 00
Lane 3. Unbound
Lane 4. 30mM Imidazole
Lane 5. 40mM Imidazole
Lane 6. 50mM Imidazole
Lane 7. 80mM Imidazole
Lane 8. 300mM Imidazole
Lane 9. Ni-NTA




Figure 5.10 The effect of lowering the pH on the removal of contaminating
proteins from Ni-NTA
C(His)gSte6p was solubilised from the membranes of galactose-induced
BJ5464(pAMB14) cells and bound on to Ni-NTA resin in the presence of 20mM
imidazole as detailed in Figure 5.9. The resin was washed in 10 bed volumes ofbuffer
A (50mM NaP04 pH 8.0, 500mM NaCl, 20mM Imidazole and 20% v/v glycerol)
which had been supplemented with 0.1% DDM. The resin was then subjected to the
elution and washing steps (as described in Figure 5.9) with citrate-phosphate buffer
(50mM citrate-phosphate, 500mMNaCl, 20%v/v glycerol and 0.1% DDM) which
was at either pFI 6.3 or pH 5.7. The resin was then subjected to elution and washing
steps with buffer A which had been supplemented with either 50mM or 300mM
imidazole. Samples taken from each point in the purification procedure were
subjected to polyacrylamide gel electrophoresis as detailed in Figure 5.3. The gels
were either silver stained according to the method detailed in Chapter 2, or subjected
to Western blot analysis with the affinity purified anti-Ste6p antibody as detailed in
Figure 5.3.
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A. Western Blot ofgel shown in B.
1 2 3 4 5 6 7 8
B. Silver stained 7.5% polyacylamide gel
1 2 3 4 5 6 7 8
Lane 1. SI00 Lane 5. pH5.7 wash
Lane 2. PI00 Lane 6. 50mM Imidazole
Lane 3. Unbound Lane 7. 300mM Imidazole
Lane 4. pH6.3 wash Lane 8. Ni-NTA
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Figure 5.11 Partial purification of C(His)8Ste6p solubilised from the membranes
of BJ5464(pAMB14) cells with DDM on Ni-NTA resin
The cells from a 1 litre culture of galactose-induced BJ5464(pAMB14) were
subjected to glass bead lysis and differential centrifugation, and solubilisation with 1%
DDM as detailed in Figure 5.9. The DDM-solubilised material (S100) was collected
following centrifugation at 100,000 rpm for 20 min in a Beckman TL-100 centrifuge,
applied to a 350pil packed Ni-NTA which had been equilibrated in buffer A (50mM
NaP04 pH 8.0, 500mM NaCl and 20% v/v glycerol) supplemented with 0.1% DDM.
The resin was incubated with gentle agitation at 4°C for 16 hours then washed in 20
bed volumes of 0.1% DDM supplemented buffer A. The resin was then subjected to
elution and washing cycles (as described in Figure 5.10) with the following buffers;
buffer B (buffer A plus 30mM imidazole) and buffer C (50mM citrate-phosphate,
500mM NaCl, 20%v/v glycerol and 0.1% DDM). C(His)gSte6p was eluted from the
resin by incubation with 1ml elution buffer (buffer A plus 300mM imidazole and 0.1%
DDM) for 15 min. The eluate was harvested by centrifugation for 1 min at 2,000 Xg.
An aliquot of the eluted material was retained for further analysis and the elution
procedure was repeated with a further 9ml of elution buffer. Samples taken from each
point in the purification procedure were subjected to polyacrylamide gel
electrophoresis as detailed in Figure 5.3. The gels were either silver stained according
to the method detailed in Chapter 2, or subjected to Western blot analysis with the
affinity purified anti-Ste6p antibody as detailed in Figure 5.3.
173
A. Western blot of gel shown in B
B. Silver stained 7.5% polyacrylamide gel
kDa 1 2 3 4 5 6
Lane 1. S100
Lane 2. Unbound
Lane 3. 30mM Imidazole wash.
Lane 4. pH6.3 wash
Lane 5. 300mM Imidazole elution
Lane 6. Ni-NTA.
174
Figure 5.12 Separation of partially purified C(His)sSte6p by SDS-PAGE prior to
attachment to Immobilon P membrane and sequence analysis
The eluate from the purification experiment detailed in 5.8 was dialysed against
distilled water and concentrated by lyophilisation. The material was resuspended in
300pl IX SDS-sample buffer and subjected to gel electrophoresis according to the
method detailed in 2.25a. The gel was lightly stained with Coomassie Brilliant Blue as
detailed in 2.13a. The band corresponding to C(His)8Ste6p (as indicated) was excised





Appendix to Chapter 5
Protocol for the production of apep4::LEU2 strain ofWKK7
A vector containing the PEP4 gene, in which the majority of the open reading frame had
been replaced by the LEU2 marker gene, was made available by Carol Woolford
(Carnegie-Mellon University). This vector, known as pTS17 or BJ5783, was used in the
creation of apep4: :LEU2 strain ofWKK7. pTS17 was created by replacing a HindUl
fragment of the PEP4 open reading frame and down stream sequence with the LEU2
marker. The digestion of pTS17 with BaniHl released the 8kb disruption cassette which
was purified by agarose gel electrophoresis and transformed into the S. cerevisiae strain
WKK7 (Table A2). WKK7 transformants were selected for their ability to grow on media
deficient in leucine. A PCR strategy was designed to determine whether or not the correct
recombination event had occurred between WKK7 and the pTS17 disruption cassette and
is detailed in Figure 5.13. The genomic DNA from colonies ofWKK7 transformed with
the LEU2 disruption cassette, which were capable of growing on leucine deficient
medium, was extracted and used as a template for PCR analysis. The analysis was carried
out using the template DNA with either primers 1 and 2 or primers 1 and 3 together.
Successful integration of the LEU2 disruption cassette into the WKK7 genome resulted in
the production of a PCR product only when primers 1 and 3 were used. The production of
a PCR product when primers 1 and 2 were used together indicated that correct integration
had not occurred and that the PEP4 gene ofWKK7 remained intact. The genomic DNA
from untransformed WKK7 was used as template for control PCR reactions.
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Figure 5.13 PCR strategy to analyse the integration of a disruption cassette







The region of the WKK7 genome incorporating the PEP4 gene with and without the
integration of the LEU2 disruption cassette is shown. The PEP4 gene is indicated in
yellow and the LEU2 gene in blue. The PCR primers 1, 2 and 3 are also indicated.
Primer 1, sequence 5'-ATGTTCAGCTTGAAAGCATT-3', was directed against the 5'
end of the PEP4 gene which would be untouched if a successful disruption occurred.
Primer 2, sequence 5'-TATCGATGGCGGCACC-3', was directed against a region in the
centre of the PEP4 gene which is present in wild-type WKK7 but would be absent if the
successful disruption ofPEP4 by the LEU2 disruption cassette occurred. Primer 3,




A genetic approach to studying the interaction between
Ste6p and a-factor
6.1 Introduction
In addition to the biochemical approach to studying the interaction between a-factor
and Ste6p a genetic study involving the random mutagenesis of theMFal gene was
attempted. It was hoped that random mutagenesis of theMFal gene would result in
the production ofmutant a-factor molecules which, when expressed in a wild-type
MATu strain, were capable of interacting with and blocking the Ste6p pump. This
mutagenic strategy was expected to provide some insight as to which residues of the
mature a-factor molecule were involved in the interaction with Ste6p.
The mature form of a-factor consists of three parts (Figure 1.5), the C-terminal
farnesyl and methyl groups and the N-terminal amino-acid backbone. The structural
requirements of a-factor that are required for transport by Ste6p and detection by
Ste3p are not well defined. Previous studies (Marcus et al., 1990; He et al., 1991)
have demonstrated that both the farnesylation and methyl-esterification of a-factor are
essential for its export and biological activity. For the purpose of this project we were
interested in determining which residues of the amino-acid backbone of the mature
molecule play an essential role in mediating the interaction between Ste6p and a-
factor.
Region-directed oligonucleotide mutagenesis is a technique which allows random
mutagenesis of a defined region ofDNA. Vails et al., (1990) successfully employed
oligonucelotide-directed mutagenesis to determine which amino-acids were essential
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for targeting yeast carboxypeptidase Y to the vacuole. It was hoped that this
technique could be used as a means of producing a-factor molecules which were able
to interact with and block the Ste6p pump. It was proposed that a library ofmutant
MFal genes could be produced following mutagenesis with primers directed against
all residues of the mature a-factor molecule with the exception of the C-terminal
sequence, CVIA. This sequence is known to be required for a-factor modifications
(farnesylation and methylation) which are essential for a-factor secretion and
bioactivity (Marcus et al., 1990; He et al., 1991). Mutant a-factor molecules which
were able to interact with and block the Ste6p pump could, in theory, be detected by
transforming the mutated a-factor libraries carried at one copy per cell on a yeast
centromere-based plasmid, into aMATn strain of yeast containing intact MFal and
MFa2 genes. Transformants would then be screened for their ability to secrete a-
factor using a growth inhibition (halo) assay in which colonies of a-type cells
secreting a-factor can be detected by the ability of a-factor to inhibit the growth ofa-
type cells plated in a lawn. As the mutated a-factor molecules would be expressed in
the presence ofwild-type a-factor it could be rationalised that only those mutant a-
factor molecules capable of interacting with and blocking the pump would prevent the
secretion of a-factor. Such a-factor mutants would exert a dominant negative effect
and could be described as dominant negative mutations (DNM) of the a-factor gene.
The plasmid DNA from transformed cells displaying such a phenotype could be
rescued and retransformed into yeast to ensure that any observed inhibition of a-
factor secretion was due to the presence of the mutated a-factor. The plasmids of
interest could then be subjected to DNA sequence analysis to detect which mutations
in the MFal gene product conferred the dominant trait.
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It is conceivable that such a-factor mutants could exert their effects by blocking some
part of the a-factor maturation machinery for example those enzymes involved in C-
terminal modification or N-terminal proteolysis. To eliminate this doubt it was
intended that extracts of cells synthesising a confirmed DNM would be assayed for
their ability to modify a chemically synthesised a-factor precursor molecule (Marcus
et al., 1990).
It was hoped that this genetic screen would allow the isolation of a-factor DNMs
which were capable of interacting with and blocking the Ste6p-a-factor pump. Such
mutants would then be chemically synthesised and tested for their ability to block
Ste6p pump which had been purified and reconstituted into phospholipid vesicles. It
was hoped that kinetic studies on the interaction ofmutant a-factor and Ste6p along
with cross-linking studies would help identify which amino-acid residues, if any, were
essential for a-factor-Ste6p interaction.
The following Chapter describes the attempts made to produce a library ofmutant a-
factor genes. It also discusses the results of others' recent studies conducted on the
N-terminal region of a-factor.
6.2 Cloning MFal
The nucleotide sequences of the genes encoding the a-factor precursor molecules,
MFal andMFa2, were originally reported by Brake et al., (1985). For the purpose of
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this study it was decided that thtMFal gene would be cloned and subjected to
mutagenesis. A fragment ofDNA encoding the entire MFal structural gene was
amplified by PCR using VENT DNA polymerase, genomic DNA isolated from the S.
cerevisiae strain BJ5465 (as detailed in Chapter 2) and the following primers:
1) 5' primer 05127")
5'-GCC CCA AGC TTC TTT GTT CTT GTT ACA AAC GAG TGT GT-3'
Hindlll
2) 3' primer (El26)
5'-CGG GAT CCG TGC ATG GAT GTA CAA CGA TAA CC-3'
BamHl
The 560bp PCR product was digested with Hindlll and BamHl and cloned into the
Hindlll/BamHl site of the yeast phagemid vector pVT103-U (Vernet et al1987) to
produce pAMB8. The cloned material was subjected to double stranded DNA
sequencing (method 1) as detailed in Chapter 2 using primer "53" (Vernet et al.,
1987) as detailed below:
Primer "53"
5'-CTG CAC AAT ATT TCA AGC-3'
The region of the cloned material containing the a-factor structural gene was found to
contain no mistakes.
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6.3 Design and production of oligonucleotide primers for the random
mutagenesis ofmutagenesis ofMFal
The clonedMFal gene was used as a template for oligonucleotide-targeted
mutagenesis by the method ofKunkel (1987) and in Sambrook et al., (1989). The
mutagenic primers were designed so that a library ofmutant a-factor molecules that
contained amino acid substitutions at any position in the mature a-factor, with the
exception of the C-terminal CVIA, would be produced as discussed above. Mutagenic
oligonucleotides directed against the remaining 11 amino-acid residues of the mature
a-factor were produced according to the strategy detailed in Figure 6.1. Two
oligonucleotides were produced: a 30-mer (G1192) corresponding to the region
encoding [DN]YIIKGV[FW] and a 27-mer (G1191) corresponding to
[GV]FWDPA[CV], For each oligonucleotide the first and last six residues
(corresponding to the bracketed amino-acids) were synthesised according to the
MFal sequence. The intervening 18 (or 15) residues were "doped" (contaminated)
during synthesis with 0.22% of each of the incorrect nucleotides as described in Vails
et al., (1990). This strategy was calculated to yield single mutational frequencies of
20% (that is one in five oligonucleotides within the synthesised population will have a
single base change) and 4% and 0.8% for double and triple mutations respectively.
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6.4 Attempted mutagenesis ofMFal with random "doped" primers.
To increase the efficiency of oligonucleotide directed mutagenesis the Kunkel method
(Sambrook et al., (1989) taken from Kunkel, 1987) was used, in which the single-
stranded template DNA is produced in a strain ofE. coli which has a duf ung'
genotype. The duf ung' genotype results in the production of uracil-containing single-
stranded template DNA due to a deficiency in the dUTPase and uracil-N-glycosylase
activities respectively. Oligonucleotide directed-mutagenesis relies on the
semiconservative nature ofDNA replication resulting in half of the progeny carrying
the desired mutation. The Kunkel method increases the chances of the progeny
carrying a mutation to 80% due to the instability of the parent, uracil-containing,
strand ofDNA.
Uracil-containing single-stranded template DNA was produced in the E. coli strain
BW313 transformed with pAMB8 as described in Chapter 2. The single-stranded
DNA was purified from the culture supernatant with the QiagenMl3 kit and used as
a template for oligonucleotide-directed mutagenesis with either primer G1191 or
G1192 as described in Sambrook et al., (1989). The extension reactions were carried
out using Sequenase 2 (Amersham). The resultant DNA was transformed into the E.
coli strain NM522.
Initial attempts at mutagenesis failed due to the small number (<100) of transformants
per reaction carried out. Transformation efficiency was increased by the use of
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commercial competent E. coli strain DH5a (GIBCO BRL). Transformants were
picked and subjected to DNA sequence analysis (Chapter 2) following extraction of
plasmid DNA with Qiagen spin-column mini-preparation kits. In the first instance
six transformants, from a mutagenesis reaction carried out with the G1191 primer,
were characterised and none contained mutations. Colonies picked from subsequent
mutagenesis reactions were screened by DNA sequence analysis and in all cases
failed to show any sequence alteration. It was thought that this apparent lack of
mutagenesis might be due to the quality of the single stranded DNA; in addition it
was possible that the BW313 strain was failing to produce uracil-containing DNA.
Figure 6.1




target region for random mutagenesis
Asp Asn Tyr lie lie Lys Gly Val Plie Trp Asp Pro Ala Cys Val
GAG AAC TAT ATT ATC AAA GGT GTC TTC TGG GAC CCA GCA TGT GTT
Primer
G1192 GAC AAC TAT ATT ATC AAA GGT GTC TTC TGG
G1191 GGT GTC TTC TGG GAC CCA GCA TGT GTT
Representation of the primary gene product of the a-factor gene, MFa\. The yellow
region represents the portion of the precursor molecule present in mature a-factor
with the boxed area representing the target region for random mutagenesis. The
mutagenic oligonucleotides, G1191 and G1192, are shown with the emboldened
residues representing those which were doped during synthesis.
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In order to rule out any doubt regarding the uracil content of the template DNA
another duf ung strain ofE. coli, CJ236 (Table Al), was employed. Single-stranded
DNA produced from CJ236 harbouring pAMB8 and purified using the Qiagen kit was
used in a mutagenesis reaction with G1191 as the mutagenic primer. Transformants
were characterised by DNA sequence analysis and once again failed to show any
sequence alteration over the region supposedly mutagenised by G1191.
In all, approximately 50 transformants, recovered from mutagenesis with G1191,
were sequenced. The Kunkel method of mutagenesis is thought to be about 80%
efficient (Sambrook et al., 1982) therefore out of the 50 colonies screened some 40
would be expected to carry the mutagenised strand ofDNA. The oligonucleotides
were doped to the extent that 20% of oligonucleotides would carry a single base
change. If this were the case then 8 out of the 40 supposedly mutagenised
transformants would be expected to carry a single base change. If the E. coli strains
BW313 and CJ236 had been efficient at producing uracil-containing single-stranded
template DNA then 5 transformants would have been expected to carry a single base
change.
In an attempt to determine why the mutagenesis was unsuccessful the decision was
taken to clone and sequence the primers to determine the exact level of doping. The
primer G1191 was cloned following the PCR reaction detailed in Figure 6.2 where
pAMB8 was used as a template ofMFal with primers El26 (MFal V primer) and
G1191 (mutagenic primer). The PCR reaction was carried out in duplicate using Taq
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polymerase and the pooled product was cloned using the p-GEMT vector (Chapter
2).
The PCR reaction was carried out under low stringency conditions to ensure that the
reaction was non-biased against G1191 oligonucleotides which contained mutations.
Transformants were screened for the presence of PCR product by restriction digestion
and sequence analysis. 15 transformants were sequenced, but none were found to
contain any sequence alteration. If 20% of the oligonucleotide primers produced had
had a single base change then we would have expected to see 3 mutant forms of the
MFal gene over the G1191 priming region. This estimate assumes that the PCR
reaction was un-biased and accurate.
In all, approximately 50 transformants, recovered from mutagenesis with G1191,
were sequenced. This taken with the results of the studies on the cloned primer
G1191 would suggest that the primers were not doped to a sufficiently high level to
allow efficient screening ofmutant forms of theMFal gene.
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Figure 6.2











The template, pAMB8, is shown with the region ofDNA corresponding toMFal
highlighted. The PCR product produced by reactions carried out with primers E126
and G1191 is also shown.
Information obtained in discussions at the Yeast Genetics and Molecular Biology
Meeting (Seattle, 1994) indicated that analysis of the amino-acid determinants for a-
factor-Ste6p interaction had already been attempted with little success. This
information taken with the apparent difficulty we were having with the creation of a
library ofmutant a-factor molecules prompted us to drop this side of the project. The
decision was taken to concentrate on the biochemical approach to studying a-factor-
Ste6p interaction by focusing on the purification and reconstitution of Ste6p.
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6.5 Discussion
In recent years several studies have concentrated on the molecular determinants of a-
factor bioactivity and Ste6p interaction. Caldwell et al., (1994) examined the role of
the N-terminal amino-acid residues on the bioactivity of a-factor. Their analysis of
truncated a-factor molecules showed that sequential removal of the N-terminal amino-
acids resulted in a progressive loss of potency. To further examine the importance of
N-terminal residues for the bioactivity of a-factor they used doped oligonucleotide
mutagenesis to create a library of mutagenised a-factor molecules. As their study was
concerned with the bioactivity ofmutant a-factor molecules they expressed the
mutagenic a-factor library in an mfal mfa2 null mutant and screened for colonies
which secreted biologically inactive a-factor. The identification ofmutant a-factor
molecules which were biologically inactive (or less active than wild-type) but secreted
could act as a reverse screen for amino-acids involved in a-factor secretion. Their
analysis showed that the mutant a-factor molecules were present at a lesser
concentration than wild-type molecules and they suggested that this was due to their
inability to immunoprecipitate mutant variants as efficiently as wild-type molecules.
This could also have been due to less efficient secretion by the Ste6p pump. The data
presented in this paper is too limited to draw any precise conclusions regarding which
residues might be important for bioactivity and secretion. In general they showed that
only extreme changes in the peptidyl structure affect the biological activity suggesting
that Ste6p may be a promiscuous peptide transporter. This is in marked contrast to
the effects of removal of either the methyl or farnesyl moieties.
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Studies on the importance the carboxyl methyl esterification of a-factor by the STE14-
encoded protein (Sapperstein et al., 1994) suggest that is essential for the export of a-
factor by the Ste6p pump. These studies (of Sapperstein et al., 1994) indicate that
although a-factor is correctly synthesised and membrane associated in a steJ4 null
mutant, the (stel4 null) mutant exhibits a block in a-factor export which is as severe
as that seen in a ste6 mutant strain. They suggest that the carboxyl methyl
esterification of a-factor is likely to be an essential determinant in the recognition of
the peptide by Ste6p. In addition they refer to unpublished data (Kistler, et al) that
states that most amino-acid alterations in mature a-factor do not cause an a-factor
export defect.
To date the precise structural requirements for the recognition of a-factor by Ste6p
remain unknown. The studies by Sapperstein et al., (1994) suggest that C-terminal
methyl esterification of a-factor is necessary for its interaction with Ste6p. In addition
attempts made at elucidating which N-terminal amino-acid residues are important for
the recognition of a-factor both by Ste6p and Ste3p have shown that neither protein is
able to discriminate against a variety of amino-acid changes within the N-terminal
portion of the peptide (Caldwell et al., 1994, Kistler et al., unpublished data).
Recent studies (Quinby and Deschenes, 1997) have shown that processing of the
CVIA sequence is not sufficient for the generation of a-factor competent for export.
Experiments conducted on truncated a-factor precursor molecules and GST-(pro)-a-
factor fusion molecules implicated the amino terminal prosequence in a-factor
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biogenesis. Deletion of the a-factor prosequence was found to lead to a dramatic
decrease in the level of intracellular a-factor resulting in sterility. They proposed that
the amino terminal prosequence may play a role in directing the a-factor precursor
through a transport pathway that culminated in Ste6p.
In order to ascertain which components of the a-factor molecule are involved with the
interaction of Ste6p it will be necessary carry out kinetic studies on purified,





The STE6 gene product of the yeast Saccharomyces cerevisiae encodes a
transmembrane ATPase which is essential for the export of the a-factor mating
pheromone. Ste6p is a member of the ATP binding cassette superfamily of transport
proteins which includes many human proteins of medical significance, as discussed in
Chapter 1. The identification of the Ste6p substrate, a-factor, coupled with the power
of yeast genetics made this an ideal candidate protein with which to study this family
of transport proteins.
During the course of this project I set out to purify Ste6p from the membranes of
yeast cells which were overexpressing the protein. The Ste6p was detected by use of a
rabbit polyclonal antibody directed against the C-terminal 400 amino-acids of Ste6p.
The antibody was raised and affinity-purified from the rabbit serum by use of two
bacterially-expressed recombinant Ste6p proteins which contained the C-terminal 400
amino acids of Ste6p fused to Protein A or P-galactosidase respectively. The affinity-
purified antibody was shown to be specific for Ste6p and was capable of detecting the
protein in yeast cell membranes by Western blot analysis (Chapter 3).
Initial purification studies were centred on the purification ofwild-type Ste6p from
the membranes of yeast which were constitutively overexpressing the protein from a
yeast episomal vector (Chapter 4). Although conditions were found in which the
protein could be solubilised from the membranes, it was soon realised that the
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purification ofwild-type Ste6p, by conventional means, could be extremely difficult,
the main reason for this being the poor level of Ste6p expression. This could possibly
have been overcome by greatly increasing the culture volume, or by placing the STE6
gene under the control of a powerful inducible promoter such as GAL. However the
decision was taken to tag the extreme N-terminus of Ste6p with six consecutive
histidine residues in order to allow its affinity purification on Ni-NTA resin (Chapter
4). The N-terminally histidine tagged version of Ste6p (N(His)eSte6p) was fully
functional, as shown by its ability to complement a Aste6 mutation and its expression
under the control of the GAL promoter was detectable when expressed in BJ5465.
However attempts made at purifying the N(His)6Ste6p by its supposed affinity for Ni-
NTA resin failed. It was proposed that the N-terminus was being proteolytically
removed during the post translational processing of the protein thus preventing it
from binding to the Ni-NTA resin. This proposal was supported by the observations
ofRolling and Hollenberg (1994b) who suggested that the N-terminus of Ste6p is
removed by signal peptidases on transit to the ER (as discussed in Chapter 4).
A functional octa-histidine-C-terminally tagged variant of Ste6p (C(His)gSte6p) was
then produced and conditions were found by which it could be partially purified from
yeast cell membranes (Chapter 5). A monoclonal antibody specific for a poly histidine
tag failed to detect the N(His)6Ste6p in Western blots analysis whereas the
C(His)sSte6p was readily detected under identical conditions. These observations also
supported the suggestion that the N-terminus of Ste6p was indeed being removed
during maturation of the protein.
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Recent studies in which the metabolic stability of Ste6p tagged with an HA tag at
either the N-terminus (between amino acids 7 and 8) or at its C-terminus have
indicated that the N-terminus of Ste6p is intact in the mature protein (Geller et al.,
1996). In this study the metabolic stability of the N and C-tagged variants of Ste6p
were compared by pulse-chase analysis and detection by SDS-PAGE following
immunoprecipitation with anti-HA antibodies. Geller et al., (1996) reasoned that a
cleavage event involving the N-terminus of Ste6p would occur very shortly if not
immediately after synthesis. Therefore, if the N-terminus were being removed, the
pulse-chase experiment would show a more rapid disappearance of the radioactive
label from the N-terminally tagged molecule that from Ste6p tagged at the C-
terminus. Their results indicated that there was no difference in the stability of the N
and C-terminally tagged Ste6p suggesting that no cleavage event was taking place.
The findings of Geller et al., (1996) conflict with those detailed in this thesis. The
discrepancy in the findings might be explained by differences in tagging strategies.
Their N-terminally tagged Ste6p variant was labelled between amino acids 7 and 8
whereas the hexa-histidine tag was added to the extreme N-terminus ofN(His)6Ste6p.
It is conceivable therefore that the addition of the HA tag at this position in some way
disrupted the proteolysis of the N-terminus. The definitive answer regarding the
nature of the N-terminus of Ste6p will require protein sequence analysis to be carried
out. Attempts made at sequencing the N-terminus of the partially purified
C(His)gSte6p proved unsuccessful probably as a result of the small quantity and low
purity of the material used (Chapter 5).
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Further aims:
This thesis details the expression and partial purification of C(His)gSte6p from yeast
cell membranes. The initial aims of the project were concerned with the isolation and
reconstitution of Ste6p into phospholipid vesicles to allow kinetic analysis to be
carried out. The reconstitution ofC(His)8Ste6p into phospholipid vesicles will first
require that improvements be made to the purification procedure in order that large
quantities of purified protein can be obtained. In addition protein sequence analysis of
C(His)gSte6p is more likely to be successful if large amounts of pure protein were
used. The C(His)gSte6p might be further purified by eluting it from the resin in the
presence of a continuous imidazole gradient. However this may prove difficult as
C(His)gSte6p is competed off the Ni-NTA resin by relatively low concentrations of
imidazole. Alternatively it may be possible to further enrich the crude cell membrane
extract for C(His)gSte6p prior to its incubation with Ni-NTA. This could be achieved,
for example, by passing crude cell extract through a lectin column to remove
contaminating glycoproteins. The quantity of crude material will most likely have to
be greatly increased to overcome losses encountered by the introduction of an extra
purification step.
The successful reconstitution ofC(His)gSte6p into phospholipid vesicles and the
development of a suitable assay with which to measure the transportation of a-factor,
will provide a mechanism in which the kinetics of Ste6p-a-factor interaction may be
studied (as discussed in Chapter 6). Ste6p-substrate specificity could be studied by
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measuring the kinetics of the interaction between C(His)gSte6p and a-factor
molecules lacking, for example, the methyl moiety, the farnesyl moiety or which have
been truncated at the N-terminus.
The studies discussed in 1.10 suggest that Ste6p may function in the accumulation of
a-factor into intracellular vesicles prior to reaching the plasma membrane. It would be
interesting to determine whether Ste6p and proteins involved in the modification of a-
factor were co-localised within any intracellular compartment. Indirect
immunofluorescence and cellular fractionation may be used to determine if this were
the case. An alternative approach might lie in the isolation of the Ste6p containing
intracellular membranes. This might be achieved by the use of techniques developed in
this laboratory for the immunoisolation of the Kex2-containing compartment of yeast
Golgi (Bryant, 1992). The isolation of the hypothetical Ste6p containing compartment
would enable the identification of other compartmental components, for example the
a-factor maturation machinery. It can be envisioned that, if such a compartment were
isolated, that it could be used in the development of a cell free assay system for the
maturation and export of a-factor.
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Table A2 Saccharomyces cerevisiae strains used in this study.
S. cerevisiae strain Genotype Remarks














































Table A3 Plasmids used in this study.
PLASMID CONSTRUCTION/ COMMENTS SOURCE
pAX12 Used in the production of protein A fusion
protein. Discussed in Chapter 3.
Zueco and Boyd
(1992).
pEX12 Used in the production of (3-galactosidase Kusters et al.,
fusion proteins. Discussed in Chapter 3. (1989).
pkl9 Small, high copy number E. coli plasmid
cloning vector.
NEB.
pVT-103U Yeast/if. coli shuttle phagemid vector used Vernet et al.,
for the production of single-stranded DNA in (1987)
mutagenesis studies.
YDp-U Yeast integrating vector carrying a URA3 Berben et al.,
disruption cassette. (1991).




YEpGAL GAL promoter cloned into the
EcoKHBamYil site ofYeplacl 12.
Boyd lab.
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